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1.1. Cancer 
Cancer is a disease that is rapidly becoming the leading cause of death worldwide (Witte 
and Witte, 1999). Although many types of cancer do exist, they all result from of out-of-
control growth of abnormal cells. In normal tissues there is a fine balance between cell 
growth (proliferation), cell differentiation (specification), and cell death (apoptosis). To 
maintain a normal tissue architecture, it is important to ensure that the number of cells 
produced through division is approximately equal to the number of cells that dies through 
apoptosis. To tightly control this cellular turnover, sophisticated and effective growth control 
mechanisms are required. Whenever these growth control mechanisms are disrupted, a 
tumor may be formed. Basically, three stages of tumor development can be distinguished: 
initiation, promotion and progression. These different stages cannot be discerned in most 
human cancers as they are diagnosed at relatively late stages. In some cancers, however, 
among which colorectal cancer and cancer of the uterine cervix, these different stages in 
tumor development can be distinguished histologically (Ioachim, 1999). The first step 
(initiation) in the development of tumors from normal epithelia is usually defined by the onset 
of dysplasia. Through dysplasia epithelial cells change into hyperproliferative cells in which 
the normal process of differentiation is disregulated. Morphologically, these cells are distinct 
from normal cells in size and shape. Dysplastic cells may develop (promotion) into a non-
invasive lesion or benign tumor, i.e., a papilloma or carcinoma in situ. At this stage the cell 
division and differentiation processes are more severely disrupted. Both lesions, dysplasia 
and papilloma/carcinoma in situ, are in principle harmless and can regress spontaneously. 
Complete cure can be achieved by destroying or removing the abnormal tissue components. 
However, when not removed, proliferating cells can invade the surrounding connective 
tissue and the tumor is than called a carcinoma (progression). When finally the tumor cells 
have gained the ability to enter blood or lymph vessels, they can spread to other organs of 
the body and form ‘secondary’ tumors or metastases. At these stages the tumor is said to be 
malignant. It is the ability of tumor cells to destroy other tissues through invasion that 
ultimately makes them lethal. 
Based on the tissue and cell type from which they originate, cancers can be divided into two 
main groups: hematopoietic tumors and solid tumors. Leukemias and lymphomas are both 
hematopoietic tumors and develop from abnormal blood-forming and lymphoid cells, 
respectively. Among the solid tumors, two major subtypes can be discerned: carcinomas 
that develop from epithelial cells and sarcomas that develop from connective tissue or 
muscle cells (mesenchymal cells). Four tumor types do not fit within these main categories, 
i.e., melanomas, retinoblastomas, neuroblastomas and glioblastomas, originating from 
melanocytes, stem cells from the retina, neurons, and glia cells, respectively. 
 
1.1.1. Cancer as a genetic disease 
Initially, cancer was hypothesized to result from defective immunity, viruses and/or 
deregulated differentiation processes (Vogelstein and Kinzler, 1998). Nowadays, however, 
cancer is assumed to be caused by heritable factors. This assumption is based on the 
observation that a single abnormal cell gives rise to a tumor and that, therefore, the 
causative abnormality should be passed on to its progeny. The identification of genes that, 
when damaged (mutated), lead to cancer led to the suggestion that the heritable factor must 
be a genetic change (Boveri, 1914; Sandberg, 1990). These changes or mutations can be 
brought about by environmental factors such as chemical carcinogens (smoking), ionizing 
radiation (x-rays) and viruses, but also by inaccuracy of the DNA replication mechanism of 
the cell itself. The DNA changes may vary from single base pair substitutions, deletions and 
insertions of one or more base pairs to gross chromosomal abnormalities such as 
translocations, inversions and amplifications. Normal cells are able to overcome the harmful 
effects of these changes through different defence systems such as cellular DNA repair 
mechanisms. When a cell is not able to repair its DNA damages, this cell may go into 
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apoptosis. If a mutated gene is directly involved in the regulation of cellular proliferation or 
cell death, this change could lead to an imbalance between these two processes and result 
in net growth and, thus, in tumor formation. Genes that play critical roles in these growth 
control processes and, when mutated, to tumorigenesis have been categorized into two 
major classes: the proto-oncogenes and the tumor suppressor genes.  
 
Oncogenes 
Oncogenes are like the accelerators of the cell (Park, 1998). They are the altered forms of 
normal cellular genes called proto-oncogenes and were originally identified as the 
transforming genes in retroviruses (Blair et al., 1981; Bishop, 1982). Proto-oncogenes 
encode growth-stimulating proteins that can become constitutively activated, and thus 
oncogenic, through overexpression of the unrearranged gene or through structural changes. 
Overexpression can be caused by amplification or chromosomal translocations/inversions. 
Structural changes can be caused by subtle point mutations and, again, by chromosomal 
translocations/inversions (Rabbitts, 1994; Cooper, 1996; Dos Santos and Geurts van 
Kessel, 1999).  
 
Tumor suppressor genes 
Tumor suppressor genes are like the brakes of the cell (Park, 1998). They encode growth 
inhibiting proteins that, when inactivated, can no longer suppress tumor growth. They act in 
a recessive way at the cellular level, which means that a single active allele is able to 
suppress tumor development (Knudson, 1971). Kinzler and Vogelstein (1997) divided the 
growth controlling genes into ‘gatekeepers’ and ‘caretakers’. Gatekeeper genes were 
defined as genes that directly regulate the growth of tumors by inhibiting growth control or 
cell death. They may fulfil different criteria: (i) loss-of-function mutation accompanied by loss 
of heterozygosity (LOH; or gene inactivation by epigenetic mechanisms such as 
methylation), (ii) mutation in inherited syndromes that predispose to cancer, (iii) somatic 
mutation in spontaneous tumors and (iv) the ability to rescue the tumor phenotype of 
transformed cells in vitro by reintroducing a wild type allele. By these criteria, each cell type 
has only one (or a few) gatekeepers. Inactivation of such a gatekeeper leads to a specific 
type of cancer. The caretaker genes were defined as genes involved in DNA repair and 
genome integrity which, when mutated, cause an increased mutation rate in all genes, 
including proto-oncogenes and tumor suppressor genes. Therefore, these genes have a 
more indirect and general role in regulating cell growth.  
 
1.1.2. Inherited predisposition to cancer  
Several familial cancer syndromes have been associated with defective tumor suppressor 
genes, and only a few with affected oncogenes. This difference was explained by the fact 
that oncogenes act in a dominant way and that excessive growth during embryologic 
development is incompatible with life. Instead, tumor suppressor genes act in a recessive 
way and, therefore, a second somatic mutation is needed before excessive growth can take 
place. Usually this second mutation occurs during life after birth. This two-hit mechanism 
was first proposed by Knudson (1971) on the basis of population studies. He noticed that the 
differences between hereditary and non-hereditary cancers of the same type were the age 
of onset, which was earlier in hereditary cases than in non-hereditary cases, and the 
multifocal and/or bilateral character of tumor development among the hereditary cases. He 
explained these differences by assuming that two mutations were necessary for tumors to 
develop, of which the first mutation could be either germline or somatic and of which the 
second mutation was always somatic (Figure 1.1). This hypothesis was first confirmed by 
Cavanee et al. (1983). They demonstrated loss of function of both alleles of the RB gene in 
retinoblastomas (Lee et al., 1987). Their results were further substantiated by biochemical 
and molecular studies on retinoblastomas, in which a cloned normal RB gene was 
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reintroduced and expressed in retinoblastoma cells resulting in suppression of the malignant 
phenotype (Huang et al, 1988). This two-hit model was also validated in several other 
familial cancer syndromes, including Wilms’ tumor, neuroblastoma, and pheochromocytoma 
(Knudson and Strong, 1972a and b; Knudson, 1973), and has been held true for most tumor 
suppressor genes in explaining cancer predisposition in inherited cancer syndromes and 
their sporadic counterparts.  
 
Tumor suppressor related familial cancer 
Familial cancer syndromes have been instrumental in the search for tumor suppressor 
genes. As such genes conform to Knudson’s two-hit hypothesis, they often also play a role 
in the more common sporadic form of the same tumor. Moreover, subsequent studies on 
familial cancer syndromes and their sporadic counterparts have resulted in pathogenic 
models requiring broader interpretations and, thus, modifications of the original two-hit 
hypothesis of Knudson (Figure 1.1). 
One of these modifications came from molecular analyses of sporadic tumors that revealed 
high frequencies of loss of heterozygosity (LOH). LOH has long been associated with the 
loss of tumor suppressor genes. This notion is based on the observation that in many 
tumors the second mutagenic event represents a gross chromosomal change (deletion, 
unbalanced translocation, mitotic recombination or nondisjunctional loss with reduplication of 
the chromosome carrying the mutated gene). Such changes may occur at relatively high 
rates in somatic cells, thus leading to loss of the chromosomal region containing the wild 
type allele of the mutated tumor suppressor gene (Cavanee, 1983; Figure 1.1). However, in 
many sporadic tumors no concomitant somatic mutations were found in candidate tumor 
suppressor genes in the regions exhibiting LOH (Brown, 1997). It was, therefore, suggested 
that besides LOH, silencing mechanisms different form inactivating mutations might cause 
loss of expression of these genes. One such mechanism turned out to be DNA methylation, 
a covalent chemical modification of cytosine residues within CpG islands at the 5’ ends of 
actively transcribed genes. In general, these regions act as the regulatory domains for 
transcriptional control of these genes. Hypermethylation can thus silence tumor suppressor 
genes. In breast cancer, for example, two genes, BRCA1 and BRCA2, have been identified 
that underlie a substantial proportion of high-risk inherited cases (Ford et al., 1998; OMIM 
114480). As such, these genes may be classified as ‘classical’ tumor suppressor genes 
(Miki et al., 1994; Futreal et al., 1994; Wooster et al., 1995; Lancaster et al., 1996). 
However, despite frequent LOH at the BRCA1 locus and absence of BRCA1 protein, no 
somatic mutations in this gene have been found in sporadic breast cancers and only a few in 
sporadic ovarian cancers (Futreal et al., 1992; Merajver et al., 1995; Thompson et al., 1995; 
Berchuck et al., 1998). Recent investigations have suggested an alternative ‘LOH-plus-
hypermethylation’ model for BRCA1 in sporadic breast and ovarian carcinomas and thus, 
through this model, a tumor suppressor role for this gene in breast and ovarian cancer 
development (Esteller et al., 2000). At present, inactivation by hypermethylation has been 
observed in several tumor suppressor genes, such as VHL and APC, and has led to the 
inclusion of epigenetic events in Knudson’s two-hit model (Herman et al., 1994; Hiltunen et 
al., 1997; Baylin and Herman, 2000; Figure 1.1). 
Haplo-insufficiency is another modification of Knudson’s two-hit model and has been 
demonstrated in a mouse tumorigenesis model for the tumor suppressor gene p53 
(Donehower et al., 1992). Inherited mutations in this gene have been implicated in the Li-
Fraumeni syndrome, a familial cancer syndrome predisposing to multiple childhood- and 
adult-onset neoplasms (Srivastava et al., 1990; OMIM 151623). In addition, in almost half of 
all sporadic tumors examined to date p53 mutations have been observed. However, in a 
subset of sporadic and inherited tumors with p53 mutations, the second wild type allele 
remains intact (Nigro et al., 1989; Mulligan et al., 1990). This feature was also observed in 
tumors that developed in p53+/- mice (Donehower et al., 1992). Further analysis showed that 
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most tumors that developed in the heterozygous mice did not lose the wild type allele and 
expressed functional p53 protein, indicating that tumor suppression by p53 may occur in a 
dose-dependent manner (Venkatachalam et al., 1998). Further studies in other mutant 
mouse models suggest that also other tumor suppressor genes, such as p27 and APC, may 
show haplo-insufficiency effects (Komuro et al., 1999; Wu and Pandolfi, 2001).  
 
Multiple hits instead of two hits 
Various studies in recent years have demonstrated that more than two hits may be required 
for full blown cancer formation and, as a consequence, the somatic mutation theory was 
proposed (Amitage and Doll, 1954; Nowell, 1976; Harwood et al, 1991; Wittenkeller et al, 
1997). This theory maintains that most cancers arise from a single cell and that tumor 
development is a multistep process in which a series of sequential gene mutations needs to 
take place (Foulds, 1958; Farber, 1988; Vogelstein and Kinzler, 1993). This multistep 
process is nicely illustrated in hereditary nonpolyposis colorectal cancer (HNPCC), an 
autosomal dominant cancer syndrome characterized by an increased incidence of cancers, 
most notably of the colon, endometrium, ovary and stomach (Lynch et al., 1993; Boland, 
1998; OMIM 114500). The genetic cause underlying this disease is a germline mutation in 
one of the DNA mismatch repair genes, hMSH2, hMLH1, hPMS2, or hPMS1, which are 
categorized as caretaker genes (see above; Leach et al., 1993; Bronner et al., 1994; 
Papadopoulos et al., 1994; Nicolaides et al., 1994). Mutations in these genes are only rarely 
found in sporadic tumors (Ilyas, 1999; Peltomaki, 2001). Kinzler and Vogelstein (1996) 
Figure 1.1 Adaptation of Knudson’s model for the inactivation of tumor suppressor genes. Loss of the first allele (first
hit) usually results from a rare mutation in a tumor suppressor gene (TSG) (a: marked by an asterisk) that can be either
germline or somatic, or from LOH caused by an acquired somatic deletion (b) or unbalanced translocation (c). The
second hit may be loss of a chromosomal region containing the wild type tumor suppressor allele (TSG+; d-g) or a
somatic mutation (h). LOH may result from nondisjunctional loss and reduplication of the chromosome carrying the
mutated gene (d), chromosomal deletion (e), mitotic recombination (f), or an unbalanced translocation (g). Inactivation
of the wild type allele may also be achieved through hypermethylation (M) of the gene promoter (i). This latter
phenomenon is mostly observed after LOH as a first hit. Also, a subclass of tumor suppressor genes has been
identified that does not require a second hit (haplo-insufficiency effect). 
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explained this feature by a requirement after the first initiating mutation of at least two or 
three sequential mutations, in which one of these mutations occurs in the second allele of 
the caretaker gene. The subsequent mutations may take place in proto-oncogenes and/or 
tumor suppressor genes (Kinzler and Vogelstein, 1996; Russo et al., 2000). Extensive 
molecular studies have validated this multi-step model for different types of cancer among 
which another inherited form of colorectal cancer, familial adenomatous polyposis (FAP). 
FAP is characterized by the presence of adenomatous polyps in the colon and rectum, with 
an inevitable development of colorectal cancer if left untreated (OMIM 175100). Germline 
mutations in the APC gene are responsible for this disease (Groden et al., 1991; Cotrell et 
al., 1992; Powell et al., 1992). Somatic mutations in APC occur in ∼80% of sporadic 
colorectal tumors (Cotrell et al., 1992; Rowan et al., 2000). This gene is, therefore, 
categorized as a ‘classical’ tumor suppressor gene. FAP tumors have been very useful for 
the study of multistep tumorigenesis (Kinzler and Vogelstein, 1996 and 1998; Ilyas et al., 
1999; Russo et al., 2000). Mutations in the APC gene can already be identified during the 
development of small adenomas and are, therefore, thought to be associated with the 
initiation of tumor development (Powell et al., 1992; Ichii et al., 1992). Mutations activating 
the K-RAS proto-oncogene occur slightly later and are rarely found in these small adenomas 
but frequently in the larger ones which show alterations in cell differentiation and tissue 
organization (Miyaki et al., 1990; Ichii et al., 1993). Mutations of the p53 gene have been 
shown to occur in the adenoma to carcinoma developmental stages and, most probably, 
before metastasis (Kikuchi-Yanoshita et al., 1992; Ichii et al., 1993) 
Based on this pathogenic model it was suggested that, although mutations occur at random 
throughout the genome, only those that impose growth advantage to the cell would be 
selected for. This selection will change as the tumor evolves, depending on the different 
stages and growth limiting factors present during tumor development (Ilyas et al., 1999). For 
example, mutations affecting proliferation, differentiation and cell death, causing cells to 
proliferate and form a tumor, may be selected during the early steps in tumorigenesis, 
whereas at later stages mutations stimulating the vascularization of the tumor and the 
invasion of tumor cells into the neighbouring tissues provide a more selective advantage. In 
cancer genetics these various mutations have been categorized into ‘primary’ and 
‘secondary’ changes, of which the primary occur early during tumorigenesis being present in 
all tumor cells and the secondary occur later and, thus, being present in tumor cell 
subpopulations (Nowell, 1976). Till now it remains unclear whether the initiating mutation 
remains essential for tumor survival at all later stages including metastasis. If so, than the 
primary changes are critical throughout cancer development and may, therefore, serve as 
targets for therapy (Ilyas et al., 1999, Druker et al., 2001). 
 
Penetrance of inherited predisposition  
The cardinal feature by which inherited predisposition is recognized clinically is family 
history. Only a small fraction of inherited predisposition cases can be characterized by a 
simple Mendelian inheritance pattern, i.e., passage to 50% of the offspring of an affected 
person (Ponder, 2001). This type of inherited predisposition is categorized as ‘hereditary 
cancer syndrome’, and includes the above mentioned retinoblastoma, breast cancer, FAP, 
and HNPCC. However, the largest category of inherited predisposition cases shows a non-
Mendelian inheritance pattern and shows predisposition without evident family histories 
(Peto, 1980; Ponder, 1990; Ponder, 2001). 
In hereditary cancer syndromes incomplete penetrance and phenotypic differences in 
clinical presentation and age of onset have been noticed between families and even within 
the same family. These variations have been studied in more detail and revealed different 
causes. Some of these variations could be explained by ‘low penetrance’ alleles of a ‘high 
penetrance’ tumor suppressor gene. This phenomenon was observed for e.g. the APC 
gene. Different mutations in this gene turned out to be associated with different forms of 
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FAP. A particular aggressive early onset form of FAP appears to be associated with 
truncating mutations between the codons 1250 and 1464, whereas a milder form of this 
disease (attenuated APC or AAPC; a variant of FAP which presents a lower polyp 
multiplicity and a delayed age of onset) is associated with mutations at the extreme 5’ or 3’ 
ends of the gene (Nagase et al., 1992; Fodde and Khan, 1995; Soravia et al., 1998). The 
exact mechanism underlying these genotype-phenotype correlations is not clear yet but, 
most likely, the mild mutations affect APC function to a lesser extent, thus allowing residual 
activity of the gene (Teh et al., 1999). 
However, wide clinical variability has also been observed among carriers of the same APC 
mutation and could only be explained by interference of environmental and/or genetic 
modifying factors. One such modifying factor has been demonstrated in a mouse model for 
colon cancer, the multiple intestinal neoplasia (Min) mouse (Su et al., 1992). A variation of 
polyp multiplicity and tumor size was observed in Min mice with different strain backgrounds. 
Min mice with a C57BL/6 background developed a larger number of tumors than Min mice 
with an AKR background. The difference between these strains was identified as Mom-1 
(modifier of Min), a locus that is present in the resistant strain and absent in the sensitive 
strain (Dietrich et al.,, 1993). Subsequent studies identified Mom-1 as a gene encoding 
secreted phospholipase 2a (Pla2g2a). A mutation in this gene is present in the sensitive 
strain. Rescue of the tumor phenotype of the sensitive strain after reintroduction of a 
functional Pla2g2a gene supported its modifying effect on tumor development (Cormier et 
al., 1997). Such a modifying effect has also been observed in other inherited cancer 
syndromes. The variable penetrance of BRCA1 in breast cancer, for example, has been 
demonstrated to be caused by the modifying effect of rare variable number of tandem repeat 
(VNTR) polymorphisms located directly downstream of the HRAS1 proto-oncogene (Phelan 
et al., 1996). Genetic modifiers are part of a broad concept and are defined as features that 
influence the chance of tumor initiation or the rate of tumor progression (Ilyas et al., 1999). 
As such, modifiers may affect DNA mutation rates or the selective values of these 
mutations. At another level, modifier genes may affect tumor development by direct or 
indirect interaction with proteins that play a role in the cancer pathway. 
Finally, little is known about the genetic causes of non-Mendelian familial cancers, but from 
recent studies it is becoming clear that more subtle genetic changes may play important 
roles in these forms of cancer. As such, a missense germline mutation of APC (I130K7) 
confers an increased risk for colorectal cancer, but this risk is not transmitted in a classical 
Mendelian fashion (Laken et al., 1997). The exact mechanism by which this mutation acts in 
not clear yet. One option that has been put forward is that this polymorphism gives rise to a 
mild dominant negative effect by a slight change in APC function or by hypermutability of the 
APC gene (Bodmer, 1999; Teh et al., 1999). Similar missense germline variants have also 
been observed for other ‘classical’ tumor suppressor genes such as BRCA1 and CDH1 
(Fearnhead et al., 2001). Another option for the low penetrance phenotype is that genes, 
when mutated, contribute to tumor development via indirect effects on the cancer pathway, 
i.e., through detoxifying metabolisms, the regulation of epigenetic effects, and the production 
and destruction of endogenous mutagens including free radicals (Ponder, 2001).  
 
1.2. Renal cell carcinomas 
Renal cell carcinomas (RCCs) represent 85% of all renal neoplasms and the overall 
incidence increases significantly between the ages of 50 and 70 (Linehan and Klausner, 
1998). The development of RCC is unpredictable: tumors can grow silently for years with no 
symptoms as hematuria or abdominal pain, until they attain a large size or grow explosively 
with widespread metastases (especially in lung, bones, brain and liver) (Cotran et al., 1989; 
Motzer et al., 1996). Only 3% of the tumors are bilateral, i.e., they metastasize across the 
midline to the opposite kidney (Motzer et al., 1996). RCC is usually resistant to radiotherapy 
and chemotherapy and is nowadays treated with radical or partial nephrectomy, the latter to 
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preserve renal function. New treatment modalities, including immunotherapeutic approaches 
involving interleukine 2 and interferon-α, -β, and -γ, are being investigated intensively and 
appear to be promising (Rosenberg, 1990; Mulders et al., 1997). The prognosis relates to 
the pathologic stage of the tumor (Weiss et al., 1995). Also tumor spread (the Robson’s 
system) and TNM classification (Tumor, Nodes and Metastases stages) serve as prognostic 
tools but, as yet, microscopic features have the most profound prognostic value. (Linehan et 
al., 1989; Hermanek and Schrott, 1990; Störkel et al., 1990). Renal tumors are graded (G1, 
G2 and G3/4) according to nuclear morphology, size of nucleoli and cytoplasmic features. 
The five year survival decreases from G1 to G4. 
RCCs comprise a heterogeneous group of tumors. Based on their location within the 
nephron and the cell type from which the tumors originate, Thoenes and Störkel (1986) 
introduced one of the first detailed classification systems. They recognized five different 
subtypes of RCC. Clear cell carcinomas (also called non-papillary RCC) and chromohilic 
RCC (also called papillary RCC) develop from epithelial cells of the proximal part of the 
renal tubule. The collecting tubule of the nephron gives rise to chromophobe RCCs, renal 
oncocytomas and Duct Bellini carcinomas. Recently, another classification system for RCCs 
was proposed by Kovacs et al., (1997) and has been denoted the ‘Heidelberg’ classification. 
Through this classification system renal cell tumors are subdivided into benign and 
malignant parenchymal neoplasms and, where possible, each subcategory is linked to the 
most commonly documented genetic abnormalities. This system is primarily based on 
studies of recent years in which several genetic alterations have been identified in different 
RCC subtypes related to stage and subtype (Van den Berg et al., 1993; Kovacs, 1993; Van 
den Berg et al., 1997a). Thus, benign tumors have been subclassified into metanephric 
adenoma and adenofibroma, papillary renal cell adenoma (RCA), and renal oncocytoma. 
The malignant tumors are subclassified into common or conventional RCC, papillary RCC, 
chromophobe RCC, collecting duct carcinoma, and unclassified RCC (Figure 1.2). All 
different subtypes and stages of tumor development (adenoma to carcinoma) are now 
characterized by genetic alterations, with exception of the metanephric adenomas and 
adenofibromas. The category of unclassified RCCs includes all renal carcinomas that do not 
fit into one of the other categories. The common or conventional RCCs are identical to the 
clear cell carcinomas of the ‘Thoenes and Störkel’ classification and comprehend the major 
subgroup of RCCs.  
 
1.2.1. Genetic aspects of renal cell carcinomas 
As discussed above, (cyto)genetic studies have revealed that most subtypes and stages of 
RCC are characterized by specific chromosomal abnormalities (Figure 1.2). As such, 
trisomy of the chromosomes 7 and 17 and loss of the Y chromosome have predominantly 
been observed in papillary RCAs and RCCs and are, thus, associated with the 
adenomatous stages of these tumors (Kovacs et al., 1991). The development from adenoma 
to carcinoma is associated with trisomies of the chromosomes 3q, 8, 12, 16, and 20 and, 
thus, account for the promotion and progression stages of RCC. Another subgroup of 
papillary RCCs is characterized by a translocation between the chromosomes X and 1, 
t(X;1)(p11;q21), which is sometimes present as sole cytogenetic anomaly (Meloni et al., 
1993). Variants of this translocation have also been described with different breakpoints on 
chromosome 1 and other partner chromosomes than chromosome 1, among which the 
chromosomes 10 and 17 (Dijkhuizen et al., 1995; Heimann et al., 2001). Also in renal 
oncocytomas, which are essentially benign neoplasms although cases with local or distant 
metastasis have been described, two genetic subtypes have been distinguished. The first 
subtype is characterized by loss of chromosome arms 1p, 14q and the Y chromosome, 
whereas the second subgroup exhibits a translocation between the chromosomes 5 and 11 
or variants thereof (Walter et al., 1989; Weiss et al., 1995; Van den Berg et al., 1995a; Presti 
et al., 1996; Sinke et al., 1997; Dijkhuizen et al., 1997). In the common RCCs, collecting 
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duct carcinomas, and chromophobe RCCs genetic changes related to tumor initiation, 
promotion, or progression could not be discerned yet as the morphologic differences 
between the adenoma and carcinoma stages are difficult to establish in these tumors. 
Chromophobe RCCs and collecting duct carcinomas are relatively rare (2-5% and 1% of all 
RCCs, respectively) and these tumors await further (cyto)genetic investigation.  
 
As mentioned before, conventional RCCs constitute the most common from of RCC. Loss of 
sequences of the short arm of chromosome 3 is a characteristic finding in this type of tumors 
and was observed as the sole karyotype change in about 10% of the cases (Wang et al., 
1983; Kovacs et al., 1987; Kovacs, 1993). Therefore, it has been suggested that such 
changes may be related to the early stages of tumor development. In addition to these 
genetic changes, duplication of chromosome band 5q22 and deletion of chromosome arms 
6q, 8p, 9p, and 14q are characteristic alterations. A significant association has been found 
between loss of chromosome 14q and RCC progression (Kovacs, 1993; Wu et al., 1996). In 
addition, chromosome 5 frequently serves as a translocation partner to chromosome 3 
(Kovacs et al., 1987; Mitelman Database of Chromosome Aberrations in Cancer at 
http://cgap.nci.nih.gov/Chromosomes/CytList). 
The frequently noted loss of 3p sequences suggested the presence of one of more tumor 
suppressor gene(s) on this chromosomal arm relevant for RCC development. In order to 
identify such a gene(s), LOH studies were performed in sporadic RCCs to define the 
smallest region of overlap (SRO) of the heterozygous deletions. By doing so, three common 
regions of allelic loss could be defined: 3p12-14, 3p21, and 3p25 (Van den Berg and Buys, 
1997b). Additionally, it was found that allelic losses in adenomas occurred in either 3p25 or 
3p12-14, whereas those in carcinomas occurred in 3p21 together with losses in 3p25 or 
3p12-14, or both (Van den Berg et al., 1996). These results indicated that loss of 3p21 might 
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are classified on basis of both genetic and morphologic criteria. The genetic changes that characterize the different
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be related to malignant transformation. Chromosome transfer studies revealed that 3p12-14 
derived sequences could suppress tumorigenic properties of RCC cell lines, thus implying 
the presence in this region of a gene(s) involved in early stages of tumor development 
(Sanchez et al., 1994). Similar results were obtained for the 3p21 region (Killary et al., 
1992). Recent data, in which LOH studies were performed on renal tumors with allele 
titration assay (ATA) and comparative genome hybridization (CGH) techniques, indicated 
that this region can be divided into two separate subregions, 3p21.3-3p22 and 3p21.2, of 
which the first is most frequently deleted (Alimov et al., 2000). This same region was also 
implicated in several other histologically distinct cancers and coincides with homozygous 
deletions detected in lung and breast tumors (Braga et al., 1999; Lerman and Minna, 2000). 
Several candidate genes in this region are currently under investigation, including a new 
RAS effector homologous gene RASSF1A. So far, no candidate tumor suppressor genes 
have been identified in the 3p21.2 region. The third tumor suppressor region on 3p is 3p25. 
The most relevant RCC-related gene within this region is the Von Hippel Lindau (VHL) gene.  
 
VHL 
The VHL gene is an example of a ‘classical’ tumor suppressor gene and was identified after 
linkage analysis and comparison of constitutional deletions identified in patients with the 
VHL syndrome. These patients can develop different types or cancers among which 
conventional RCCs (Hosoe et al., 1990; Latif et al., 1993; OMIM 193300). In agreement to 
Knudsons two-hit model, inactivation of the VHL gene was observed in 100% of the tumors 
analysed in VHL families and in a significant proportion of sporadic conventional RCCs 
(Gnarra et al., 1994; Shuin et al., 1994; Foster et al., 1994; Prowse et al., 1996). Moreover, 
transfection studies with the wild type VHL gene revealed suppression of growth in both 
VHL-deficient RCC cell lines and in Vhl-null RCC cells in nude mice, thus supporting the 
tumor suppressor function of this gene (Chen et al., 1995; Iliopoulos et al., 1995). 
Inactivation of the gene may occur through mutation or genomic deletion, but silencing by 
promoter hypermethylation has also been observed in about 20% of the tumors (Herman et 
al., 1994). However, in several hereditary RCCs and in 30-50% of sporadic conventional 
RCCs VHL was not affected. Therefore, it was suggested that RCC development may be 
associated with VHL-dependent and VHL-independent pathways (Teh et al., 1997; 
Woodward et al., 2000). To evaluate whether VHL gene inactivation is essential for tumor 
formation, the patterns and extent of allelic losses on 3p were compared in a set of 
conventional RCCs both with and without VHL mutations. This study revealed that, although 
the frequency of 3p12-22 LOH was similar in both tumor types, LOH at 3p25 was 
significantly less than LOH at 3p12-22 in tumors without VHL mutation, whereas LOH at 
3p25 and 3p12-22 was similar in tumors with VHL mutation (Clifford et al., 1998; Martinez et 
al., 2000). These results supported the presence of both VHL-dependent and VHL-
independent tumorigenic pathways and also that inactivation of a tumor suppressor gene at 
3p12-22 appears to play an important role in both these tumorigenic pathways. As no 
differences in stage and grade were observed between VHL-positive and VHL-negative 
RCCs, it was suggested that in the VHL-independent pathway most likely a gene is 
inactivated that is biologically related to the VHL gene (Martinez et al., 2000). 
The VHL protein forms a complex with elongin B, elongin C, CUL2, NEDD8 and RBX1 
(Pause et al., 1997; Lonergan et al., 1998; Kamura et al., 1999; Liakopoulos et al., 1999). 
This complex closely resembles the so called SCF complex that is known to be involved in 
ubiquitin mediated proteolysis in yeast (Kaelin Jr, 1999; Ivan and Kealin Jr, 2001). Recent 
studies revealed that the VHL protein can also bind to one of the subunits of the hypoxia 
inducible factor (HIF) and targets this factor for destruction in the presence of oxygen 
(Maxwell et al., 1999). The HIF protein controls the expression of several target genes, 
including two surface transmembrane carbonic anhydrases (CA9 and CA12) and genes 
involved in angiogenesis (i.e., vascular endothelial growth factor (VEGF) and erythropoietin), 
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via oxygen dependent ubiquitination (Ivanov et al., 1998; Semenza, 2001). The two CA 
genes were first identified in VHL-defective tumors. As they were overexpressed not only in 
these tumors, but also in other tumor types, a general role for these genes in tumorigenesis 
was suggested. It has been hypothesized that CA enzymes may be involved in maintaining 
an extracellular low pH in tumors, which appears to be essential for tumor growth and 
spread (Ivanov et al., 2001). An increased concentration of VEGF and erythropoietin in VHL-
defective cancer cells, irrespective of ambient oxygen concentrations, has implicated the 
indirect involvement of VHL via HIF in tumor angiogenesis (Weizigmann-Voos et al., 1995; 
Iliopoulos et al., 1996; Krieg et al., 1998). In addition, VHL-associated neoplasms are 
typically hypervascular and, on occasion, associated with excessive production of red blood 
cells. Also other functions of the VHL protein have been reported, including a role in cell 
cycle exit control, fibronectin and extracellular matrix binding, and posttranscriptional 
regulation of target genes through mRNA stability effects (Gnarra et al., 1996; Pause et al., 
1998; Knebelmann et al., 1998; Ohh et al., 1998).  
The exact role of VHL in the development of conventional RCCs is still unclear. The indirect 
effect on angiogenesis and microenvironment of the tumor via HIF and a possible role in the 
regulation of the extracellular matrix by VHL incline a role for this gene rather in the 
progression stage of tumor development than in the initiation stage. On the contrary, the 
observation that inactivation of the VHL gene causes the development of benign renal cysts 
in the kidney and that a wide spectrum of benign tumors is observed in VHL-affected 
individuals, suggest a role for VHL in tumor initiation (Neumann and Zbar, 1997; Linehan 
and Klausner, 1998). One explanation for the development of these cysts might be a 
localized increase in vessel leakiness regulated by VEGF or alterations in epithelial cell-
matrix interactions via the interaction of VHL with fibronectin (Ivan and Kaelin, 2001). A local 
increase of epithelial mitogens that are normally under VHL control, such as TGFα, might 
induce abnormal epithelial cell proliferation and localized disruption in tissue architecture 
(Knebelmann et al., 1998). Consequently, a defect in the VHL gene may be associated with 
all stages of tumor development: (i) tumor initiation (cyst formation) via vessel leakiness or 
(de)regulation of the extracellular matrix, (ii) tumor promotion via transcription (de)regulation 
of genes encoding epithelial mitogens and (iii) tumor progression via HIF induced 
angiogenesis, microenvironmental changes and the acquisition of invasiveness. 
 
NRC-1 and NRC-2 
The 3p12-14 region is, as mentioned above, one of the chromosomal regions that may 
harbour (a) tumor suppressor gene(s) relevant for RCC. Using a functional genetic assay, 
tumor suppressive activity could be demonstrated for this chromosomal region and, 
additionally, that this suppressive activity results from rapid cell death (Sanchez et al., 1994). 
Physical mapping of suppressing and non-suppressing DNA fragments divided this tumor 
suppressor region into two parts: 3p12 and 3p14.2, designated NRC-1 and NRC-2 
(nonpapillary renal carcinoma-1 and –2; Lott et al., 1998; Jülicher et al., 1999), respectively. 
Within NRC-2, the tumor suppressive region was further narrowed down to a single YAC 
which contains both exons 9 and 10 of the FHIT (Fragile histidine triad) gene (Jülicher et al., 
1999). 
Tumor suppressive activity of NRC-1 was also observed in VHL-defective RCC cell lines 
and it was hypothesized that NRC-1 may act either downstream from VHL in the same 
pathway or in a pathway completely unrelated to VHL (Lovell et al., 1999). Also a function in 
apoptosis was suggested, but the exact role that NRC-1 plays in kidney cancer awaits the 
identification of (a) candidate gene(s) in this region. Finally, NRC-1 coincides with a 
homozygous deletion observed in a lung cancer cell line (Lott et al., 1998). Thus, it was 
proposed that this region may either contain multiple genes, each involved in different tumor 
types, or a single broadly acting tumor suppressor gene.  
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FHIT 
The FHIT gene is located in 3p14.2 and was first identified as a breakpoint-spanning gene in 
a RCC-related constitutional translocation between the chromosomes 3 and 8 (Ohta et al., 
1996). The gene co-localizes with the most common inducible fragile site within the human 
genome, FRA3B (Smeets et al., 1984; Ong et al., 1997). Several reports support a tumor 
suppressor function for this gene by demonstrating hemi- or homozygous loss in a variety of 
tumors, mostly as a result of intragenic deletions or through absence or reduced expression 
of FHIT protein in these tumors (Ohta et al., 1996; Sozzi et al., 1996; Druck et al., 1997; 
Hadaczek et al., 1998; Eysaguirre et al., 1999). Alterations of the FHIT gene have been 
observed in many types of cancer originating from different tissues, among which kidney, 
lung, cervix, esophagus, colon, stomach and pancreas. Therefore, a general role in tumor 
development was suggested (Virgilio et al., 1996; Sozzi et al., 1996). Transfection studies 
revealed that FHIT expression indeed reduced tumorigenicity of FHIT-defective cancer cells 
in nude mice. These assays also demonstrated that mutant FHIT, lacking enzyme activity, 
could suppress tumorigenicity, indicating that also another function of this protein may be 
related to tumor development (Siprashvili et al., 1997). However, several other reports 
suggested that the fragility of the locus alone could account for the occurrence of FHIT 
alterations (Le Beau et al., 1998a). For one, Panagopoulos et al. (1997) revealed the 
presence of altered FHIT transcripts in normal non-neoplastic cells and explained this 
observation by alternative splicing or artefacts of the amplification method. In addition, 
breakage in the FRA3B chromosomal region may occur as a consequence of physical, 
chemical, or biological agents and thus lead to intragenic deletions of the FHIT gene (Sozzi 
et al., 1996; Inoue et al., 1997). This latter option was supported by the finding of an 
increased frequency of carcinogen-induced tumors in heterozygous and homozygous Fhit-
deficient mice as compared to the wild type mice (Fong et al., 2000). Further analysis of 
these tumors showed complete absence of FHIT protein, indicating that the intact FHIT 
allele must be inactivated in the heterozygous Fhit-defective mouse cells. Interestingly, 
inhibition of tumor development in carcinogen-induced heterozygous mice was 
demonstrated by oral gene transfer, using adenoviral or adeno-associated viral vectors 
expressing the wild type human FHIT gene (Dumon et al., 2001). The observed difference in 
susceptibility between carcinogen-induced wild type and heterozygous mice is in agreement 
with Knudson’s two-hit hypothesis and supports a tumor suppressor function for FHIT. The 
spectrum of tumors that developed in these mice was similar to those characteristic of the 
Muir-Torre familial cancer syndrome, which is caused by a deficiency in one of the DNA 
mismatch repair genes (Schwarz and Torre, 1995; Krusse et al., 1998). The investigators 
implied that in this model the carcinogen fulfils a role similar to mismatch repair deficiency. It 
would, therefore, be interesting to see if the frequency of inactivation of the FHIT gene in 
human mismatch repair deficiency syndromes is increased. Several lines of evidence 
suggest that fragile sites are located in regions that are subject to late replication. This was 
also demonstrated for FRA3B (Le Beau et al., 1998b). Wang et al (1999) showed that a 
delay in replication coincides with FRA3B breaks/gaps and it was hypothesized that a further 
replication delay may be caused by mismatch repair or carcinogens and result in incomplete 
replication and, thus, in deletion.  
The exact function of FHIT, however, is still unclear. FHIT is a member of the histidine triad 
(HIT) family of nucleotide-binding proteins and encodes a protein similar to the diadenosine 
5’,5”’-P1,P4-tetraphosphate (Ap4A) hydrolase of the fission yeast Schizosaccharomyces 
pombe (Ohta et al., 1996; Barnes et al., 1996). The gene product indeed possesses 
hydrolase activity with Ap3A as the preferred substrate (Barnes et al., 1996). Site-directed 
mutagenesis demonstrated that the conserved histidines encoded by exon 8 are required for 
full activity (Barnes et al., 1996). However, as mentioned before, this hydrolase activity is not 
needed for its tumor suppressive activity. The binding to Ap3A or other proteins may be 
more important for this function (Siprashvili et al., 1997). Ap3A has been proposed to be 
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involved in the regulation of DNA replication and intracellular signaling in response to stress 
but, as yet, this hypothesis has not been supported by strong experimental evidence 
(Plateau and Blanquet, 1994). Nevertheless, the latter notion can be translated into FHIT 
being a ‘sensor’ that senses cell defects or damaging carcinogen exposure via the FRA3B 
site, and that inactivation by deletions or increased rates of alternative splicing induces a 
stress signal pathway. Interesting in this respect is the demonstration that FHIT is involved 
in the regulation of p53-independent apoptosis and cell cycle arrest. Concomitantly, a pro-
apoptotic function was suggested for FHIT or the FHIT-Ap3A complex (Sard et al., 1999). In 
conclusion, it may be hypothesized that inactivation of FHIT triggers a signaling pathway 
that results in cell cycle arrest or apoptosis, depending on the rate of inactivation of FHIT 
(one or two alleles inactivated) which, in turn, may be a reflection of the damaging effect of 
the stress inducing factor(s).  
 
RASSF1A 
RASSF1A was first identified as a candidate tumor suppressor gene for lung and breast 
cancer located in the 3p21.3 region (Dammann et al., 2000; Dammann et al., 2001; Burbee 
et al., 2001). Recently, silencing by hypermethylation of RASSF1A was also demonstrated 
in 90% of primary clear cell renal tumors and, thus, a role in RCC development was 
suggested (Dreijerink et al., 2001). This suggestion was supported by growth suppression of 
several RCC cell lines after exogenous RASSF1A expression (Burbee et al., 2001; 
Dreijerink et al., 2001). Moreover, mutants of this gene exhibited a significantly reduced 
growth suppressive activity (Drijerinink et al., 2001). Other researchers reported silencing of 
RASSF1A by hypermethylation in 20% of RCCs showing 3p21 allelic loss (Morrissey et al., 
2001). It was therefore suggested that this gene may act in an haplo-insufficient manner or 
that inactivation of (an)other tumor suppressor gene(s) precede(s) RASSF1A insufficiency.  
RASSF1A shows significant homology (55% identity) to the mouse RAS effector protein 
Nore1 and to the rat orthologous protein Maxp1, of which Nore1 interacts with Ras in a 
GTP-dependent manner (Dammann et al., 2000). The presence of conserved domains in 
the RASSF1A protein, known to play important roles in several signal transduction 
pathways, support a role for RASSF1A in RAS signaling (Dammann et al., 2001; Burbee et 
al., 2001). RAS proto-oncogenes have been found mutated in a high percentage of colon 
cancers (Kinzler and Vogelstein, 1996 and 1998). The lack of mutations in smaller colon 
adenomas and the presence of these mutations before loss or mutation of the p53 gene in 
colon carcinomas suggested that RAS mutations might be acquired during adenoma 
progression. As such, they may have a promoter function in the development of colon 
cancers (Kinzler and Vogelstein, 1996 and 1998; Ilyas et al., 1999). It has been suggested 
that RASSF1A is an effector of RAS signaling and that inactivation of this gene may have 
the same effect as oncogenic RAS mutations, namely the activation of the RAS signaling 
pathway and, thus, cell proliferation (Burbee et al., 2001). This would indicate that RASSF1A 
most likely contributes to tumor development as a promoter. Further investigations are 
needed to substantiate such a role. 
 
TβR-II 
The gene for the transforming growth factor-β (TGF-β) type II receptor (TβR-II) has been 
mapped to chromosome 3p22 (Mathew et al., 1994). This receptor forms a complex with the 
TGF-β type I receptor to which TGF-β binds. In general, TGF-β is a potent inhibitor of 
epithelial cell growth and plays a central role in cell cycle control (Fynan and Reiss, 1993). 
By binding to the TGF-β receptor complex its biological activity is exerted (Wrana et al., 
1992). The majority of epithelial tumors, however, are insensitive to the inhibitory effects of 
TGF-β and it was demonstrated that this insensitivity is often correlated with malignant 
progression of the tumor (Manning et al., 1991; Engel et al., 1999). In addition, it has 
become clear that this TGF-β insensitivity in cancer cells is most commonly due to 
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alterations in the TβR-II gene. Rescue of wild type TβR-II activity by gene transfection 
restored TGF-β responsiveness and reduced the growth rate of cancer cell lines (Inagaki et 
al., 1993; Park et al., 1994). The same observation was made in different subtypes of 
human RCC and in a mouse RCC cell line (Ramp et al., 1997; Kundu et al., 1998). 
Transfection of TβR-II in a TGF-β insensitive mouse RCC cell line restored TGF-β sensitivity 
and reduced tumorigenicity, strongly suggesting a role for TβR-II and the TGF-β regulated 
pathway in RCC development (Engel et al., 1999). Further support for such a role was 
obtained through altered expression of proteins downstream in the TGF-β signaling 
pathway, such as SMAD2 and SMAD4 (Cardillo et al., 2001). Remarkable is also the 
elevated TGF-β plasma level in peripheral blood of RCC patients (Wunderlich et al., 1998; 
Junker et al., 2000). In this context it is of interest to note that an elevated level of another 
transforming growth factor, TGF-α, has been observed in VHL-deficient cancer cells (De 
Paulsen et al., 2001). TGF-α shows no homology to TGF-β and acts, in contrast to TGF-β, 
as a growth-stimulating factor (Paulsen et al., 2001). Despite these differences they act 
synergistically in inducing transformation and, as such, they may both be involved in RCC-
related pathways.  
 
Other candidate genes in RCC development 
Besides the genes discussed above, also other RCC candidate genes were identified on the 
short arm of chromosome 3. Until now, however, no substantial evidence has been gathered 
for their actual involvement in RCC development. Recently the DRR1 (downregulated in 
renal cell carcinoma) gene was identified in the chromosomal 3p21.1 region. A reduced 
expression of this gene in different tumor types, among which conventional RCC, and 
growth suppression after transfection of DRR1-negative cell lines with wild type DRR1 
supported a role for this gene in RCC development (Wang et al., 2000). Another candidate 
gene is OGG1 (8-oxoguanine DNA glycosylase), located on 3p26.2. One study 
demonstrated LOH for this gene in about 85% of the conventional RCCs analysed and the 
presence of an inactivating mutation in one RCC. As this gene is involved in DNA repair, a 
role in tumor development warrants further investigation (Audebert et al., 2000). Other 
candidate genes on 3p shown to be involved in cancers from other organs than the kidney 
are, MLH1, β-catenin, WNT5, and RON (Lerman and Minna, 2000). The identification of 
‘classical’ tumor suppressor genes on 3p has been hampered by the fact that no inactivating 
mutations could be detected. It is now understood that these genes may be silenced through 
promoter hypermethylation or, alternatively, that these genes may act in an haplo-insufficient 
way. Another option is that genes located on 3p may have modifying effects on RCC 
tumorigenesis and that heterozygous loss of these genes confers an indirect selective 
growth advantage onto renal cells. Thus, gene transfer studies in cancer cell lines and gene 
disruption analyses in mice are now necessary to identify additional tumor suppressor genes 
on chromosome 3.  
Based on the frequent loss of chromosome 3 sequences in conventional RCCs, the 
chromosome 3 candidate genes discussed above are suggested to be specific for this 
subtype of RCC. However, silencing of the RASSF1A gene by promoter hypermethylation 
was also observed in papillary RCCs and genetic alterations in the TβR-II gene were also 
detected in other RCC subtypes (Ramp et al., 2000; Morrissey et al., 2001). An overlap in 
tumorigenic pathways between the different RCC subtypes is thus possible. In contrast, 
FHIT expression is only reduced in conventional RCCs, with the exception of collecting duct 
carcinomas. This gene may thus act in a RCC subtype-specific fashion (Hadaczek et al., 
1999). 
Up till now, little attention has been paid to the identification of putative candidate genes on 
the duplicated 5q arm and other chromosomal regions that are associated with promotion 
and/or progression of the conventional RCC subtype. One gene located on chromosome 
5q35.3, TCF17, was identified as the human homologue of the rat Kid1 (kidney ischemia 
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and developmentally regulated) gene (Omori et al., 1997). Kid1 is directly involved in the 
transcription regulation of renal genes and, therefore, suggested to be involved in the 
regulation of cell growth and differentiation in this tissue. However, as yet no oncogenic 
mutations or abnormal expression patterns were observed for this gene in conventional 
RCCs  (Bugert et al., 2000).  
For papillary RCC, several candidate genes were identified. Germline oncogenic mutations 
in the MET gene on chromosome 7 were identified in a rare hereditary form of papillary RCC 
and in a subset of sporadic papillary RCCs (Zbar et al., 1995; Schmidt et al., 1997; Fischer 
et al., 1998). Cytogenetic studies revealed that papillary RCCs from patients with germline 
mutations in the MET gene commonly showed trisomy of chromosome 7 (Zhuang et al., 
1998; Fischer et al., 1998). Transfection studies in combination with biological assays 
showed that the identified MET mutants were indeed tumorigenic and that this tumorigenicity 
is related to its enzymatic activation (Jeffers et al., 1998). MET belongs to the tyrosine 
kinase family, of which the members play important roles in transmitting signals from the 
cellular surface to the nucleus (Dean et al., 1985). The MET gene encodes a 
transmembrane tyrosine kinase receptor for the hepatocyte growth factor (HGF) and binding 
of this growth factor induces a growth stimulating signaling cascade via RAS (Park et al., 
1987). Most mutations were observed in the cytoplasmic domain of the MET gene. It was 
suggested that these mutations might lead to constitutive kinase activation without ligand 
binding and, thus, to a continued activation of the signaling cascade and in an out of control 
cell proliferation. Another member of the MET family, designated RON, was identified in one 
of the candidate tumor suppressor regions on 3p (Ronsin et al., 1993). RON encodes a 
tyrosine kinase receptor for the macrophage stimulating protein (MSP) which is structurally 
related to HGF (Wang et al., 1994). As the MET and HGF genes are both located on 7q, and 
the RON and MSP genes both on 3p, a subtype specific role was suggested for the MET-
HGF signaling pathway in papillary RCC development and the RON-MSP signaling pathway 
in conventional RCC development. Recently, it was reported that point mutations in the RON 
gene analogous to those found in the MET gene, and overexpression of RON induce 
malignant transformation, tumor formation, and metastases (Peace et al., 2001). Till now, no 
mutations and/or overexpression of this gene have been observed in conventional RCCs or 
other RCC subtypes. Another recurrent cytogenetic finding in a subset of sporadic cases of 
papillary RCC is t(X;1)(p11;q21) (de Jong et al., 1986). Positional cloning of the genes 
involved in this translocation revealed that the TFE3 gene on chromosome X is fused to the 
PRCC gene on chromosome 1 (Weterman et al., 1996a; Weterman et al., 1996b; Weterman 
et al., 1996c; Sidhar et al., 1996). Consequently, two reciprocal fusion genes are formed, 
TFE3PRCC and PRCCTFE3, encoding two putative fusion proteins of which PRCCTFE3 
has most transforming capacities. Thus, PRCCTFE3 may be most critical for papillary RCC 
development (Weterman et al., 2001). Cytogenetic studies revealed variant translocations in 
which TFE3 is fused to other genes such as RCC17 on chromosome 17, PSF on 
chromosome 1, and NonO (p54nrb) on the X chromosome (Clark et al., 1997; Heimann et al., 
2001). TFE3 is a member of the helix-loop-helix family of transcription factors that can bind 
to the mu-E3 motif of the immunoglobulin heavy-chain enhancer. Interestingly, recent 
studies demonstrated that TFE3 and the SMAD proteins cooperate to mediate TGF-β-
induced transcription (Hua et al., 1998; Hua et al., 2000). Unfortunately, little is known about 
the target genes that are regulated by this signaling pathway. PRCC does not show 
significant homology to any other known gene. As PSF and NonO (p54nrb) encode both pre-
mRNA splicing factors, a similar role was suggested for PRCC. This was supported by 
studies showing that PRCC colocalizes with the cellular splicing machinery and by 
coimmunoprecipitation of endogenous PRCC with antibodies that recognize a variety of pre-
mRNA splicing factors (Skalsky et al., 2001). A notable feature frequently observed in tumor-
associated translocations in which one of the breakpoint genes is a transcription factor, is 
that the resulting fusion gene often entails the reshuffling of domains of both breakpoint 
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genes (Rabbitts, 1994; Dos Santos and Geurts van Kessel, 1999). The resultant fusion 
protein functions in a different way in transcription regulation than the wild type proteins. The 
fusion between PRCC and TFE3 in the X;1 translocation seems to be in agreement to this 
pattern. In the PRCCTFE3 fusion protein the proline rich N-terminal region of the PRCC 
protein (which is found in many transcriptional activators) is fused to all known domains for 
DNA binding, dimerization, and transactivation of the TFE3 protein. Significant differences 
were indeed noted between the transactivating capacities of the fusion protein PRCCTFE3 
and the wild type protein TFE3 (Weterman et al., 2001).  
Finally, two candidate genes were identified in a rat model for hereditary RCC, the EKER rat 
(Eker et al., 1981). These rats develop bilateral tumors from the proximal tubule of the 
nephron with an early age of onset. Linkage analysis revealed a high LOD score for a 
chromosomal region containing the tuberous sclerosis 2 gene (TSC2; Hino et al., 1994). 
Subsequent mutation analysis indeed revealed a germline mutation in this gene in the EKER 
rat (Yeung et al., 1994; Kobayashi et al., 1995). Human tuberous sclerosis patients develop 
many lesions in different tissues and organs, but only at a low frequency in the kidney. 
Renal tumors in these patients were both of the conventional and the oncocytic subtype. 
Two human genes were identified for tuberous sclerosis: TSC1 on chromosome 9q34 and 
TSC2 on chromosome 16p13.3. However, no inactivating mutations or reduced gene 
expression levels were observed in sporadic RCCs. A possible role for these genes in 
human RCC development, therefore, awaits further analysis (Parry et al., 2001).  
 
1.2.2. Inherited renal cell carcinomas 
Although RCC mostly occurs in a sporadic form, several inherited RCC cancer syndromes 
and familial RCC cancer cases have been described. Some of them have been mentioned 
earlier in this chapter, as they have been instrumental in the identification of RCC candidate 
genes and the establishment of pathogenic models. At present, five types of inherited renal 
neoplasms have been described: (i) conventional RCC in the VHL cancer syndrome, (ii) 
conventional RCC in families with a constitutional chromosome 3 translocation, (iii) 
hereditary papillary RCC caused by germline mutations in the MET proto-oncogene, (iv) 
familial renal oncocytoma and (v) familial oncocytoma and papillary RCC in the Birt-Hogg-
Dubé syndrome. A high RCC incidence was also reported for patients with end-stage renal 
disease, acquired cystic kidney disease, and tuberous sclerosis (Hughson et al., 1996; 
Bjornsson et al., 1996). 
The VHL cancer syndrome is a dominantly inherited disease characterized by the 
development of vascular tumors (haemangioblastomas) in the retina and central nervous 
system, conventional RCC, and phaeochromocytomas (Linehan and Klausner, 1998). The 
risk of RCC in VHL disease is >70% by the age of 60 years. However, not all germline VHL 
mutations are associated with such a risk of RCC development (Maher et al., 1990). There 
is a marked genotype/phenotype correlation between VHL gene mutations and 
manifestations of the different phenotypes. Based on these differences, VHL families were 
divided into two major subgroups: VHL type 1 and 2. The first represents the most common 
group and is characterized by a predisposition to develop retinal angiomas, central nervous 
hemangioblastomas, and conventional RCCs. The second group was subdivided into 2A 
and 2B. VHL type 2A is the next most common form and is characterized by a predisposition 
to develop pheochromocytomas in addition to the manifestations of VHL type 1. The rarest 
form is the VHL type 2B and is characterized by a predisposition to develop 
pheochromocytomas with little or no tendency to develop RCCs (Zbar and Lerman, 1998). 
Genetic alterations in the VHL gene in VHL type 1 families mostly constitute deletions, 
nonsense- or frameshift mutations, whereas 90% of VHL mutations found in the VHL type 2 
families are missense mutations. A few missense mutations have been described that 
specifically lead to VHL type 2A. Further investigation is needed to explain these 
phenotype/genotype relationships. 
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Until recently, two RCC families were identified in which an association was found between 
a constitutional chromosome 3 translocation and a predisposition to conventional RCC 
development (Cohen et al., 1979; Kovacs et al., 1989). In the first family a constitutional 
t(3;8)(p14;q24) was found in all affected family members. In the second family a 
constitutional t(3;6)(p13;q25) was found in three consecutive generations. As yet, only the 
oldest member developed multiple RCCs in both kidneys. In addition, a single sporadic RCC 
case has been reported, carrying a constitutional t(3;12)(q13;q24) (Kovacs and Hoene, 
1988). Subsequent studies showed that all tumors analysed from these cases had lost the 
translocation derivative chromosome containing the short arm of chromosome 3. In some of 
these tumors the VHL gene was completely inactivated by mutations in the remaining allele 
on chromosome 3 (Kovacs et al., 1989; Li et al., 1993; Gnarra et al., 1994; Schmidt et al., 
1995). Positional cloning of the 3;8 translocation breakpoints revealed FHIT as breakpoint-
spanning gene on chromosome 3 (see above; Ohta et al., 1996) and TRC8 as breakpoint-
spanning gene on chromosome 8 (Gemmill et al., 1998). TRC8 showed similarity to the 
Drosophila ‘patched’ (PTC) gene, which is a segment polarity gene. This similarity involves a 
putative sterol-sensing domain and a second extracellular loop that participates in the 
binding of sonic hedgehog. PTC plays an important role in embryonic development by 
inhibiting the hedgehog pathway that, in turn, targets the expression of proteins involved in 
the Wingless-Wnt and TGF-β pathways (Teh et al., 1999). Inactivation of the human 
homologue of this patched gene (PTCH) leads to growth stimulation, indicating that this 
gene may function as a tumor suppressor gene (Teh et al., 1999). In the 3;8 translocation, 
TRC8 was found to be fused to FHIT and disrupted within the sterol-sensing domain 
(Gemmill et al., 1998). In contrast, the FHIT coding region remained intact and, thus, was 
expressed normally (Ohta et al., 1996). The identification of a TRC8 mutation in one 
sporadic RCC supported a role for TRC8 in tumor development. However, further 
investigation is needed to reveal the exact functions of these genes and their respective 
fusion products in familial RCC development. Molecular analysis of the 3;6 translocation 
showed that its chromosome 3 breakpoint is different from that of the 3;8 translocation (van 
den Berg et al., 1995b). No genes were identified yet at this breakpoint. 
Hereditary papillary RCC caused by a germline mutation in the proto-oncogene MET shows, 
like the VHL cancer syndrome, an autosomal dominant inheritance pattern with reduced 
penetrance (Zbar and Linehan, 1998). Most identified MET mutations turned out to be 
missense mutations and all of them were located within exons 17, 18, and 19, encoding the 
tyrosine kinase domain of MET (Schmidt et al., 1997). Germline missense mutations were 
also detected in patients without a clear family history of papillary RCC and it was, therefore, 
suggested that the MET proto-oncogene may be a low-penetrance cancer-causing gene 
with RCC onset at relatively late ages (Zbar and Lerman, 1998).  
Only a few familial cases of renal oncocytomas have been described. Affected members in 
these families often develop multiple and/or bilateral oncocytomas. No metastases were 
observed (Weirich et al., 1998). Little is known about their genetic background. In one 
patient with bilateral multifocal renal oncocytomas and cysts a constitutional reciprocal 
translocation was observed, t(8;9)(q24.1;q34.3), in conjunction with a rare constitutional VHL 
missense mutation (Teh et al., 1998). Remarkably, the chromosome 8 breakpoint occurs in 
the same region as found in the earlier described t(3;8)(p14;q24). The chromosome 9 
breakpoint occurs in the region containing the TSC1 locus. FISH analysis with cosmids 
flanking the TSC1 region demonstrated that the breakpoint maps telomeric to the TSC1 
locus and, therefore, that this gene most likely is not involved. The involvement of TRC8 on 
the chromosome 8 breakpoint was not tested and can, as yet, not be excluded.  
The Birt-Hogg-Dubé (BHD) syndrome represents an inherited autosomal genodermatosis 
characterized by benign tumors in the hair follicles and has been associated with renal and 
other types of neoplasia (Weirich et al., 1998; Toro et al., 1999). Linkage analysis in several 
of these families indicated that BHD is genetically heterogeneous and that one locus for 
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BDH lies within chromosomal band 17p11.2 (Khoo et al., 2001; Schmidt et al., 2001). 
Several candidate genes within this region are currently being tested for their putative 
involvement in this familial disease. 
 
1.3. Outline of the thesis 
At the start of this work, only two familial RCC cases and one sporadic RCC case with 
constitutional chromosome 3 translocations were described. Little was known about the role 
of these translocations in RCC development. In this thesis, the identification and 
characterization of two additional familial RCC cases with constitutional t(2;3)(q35;q21) and 
t(3;6)(q12;q15) translocations, respectively, are described (Chapter 2 and Chapter 5). We 
observed loss of the derivative chromosome carrying the short arm of chromosome 3 and 
different somatic VHL mutations in a subset of the tumors that we analysed (Chapter 3 and 
Chapter 5). The finding of different VHL mutations in different tumors, even from the same 
patient, indicates that these tumors developed independently. In addition, we suggest that 
3p loss precedes the somatic VHL mutations. Based on these findings, an alternative 
tumorigenesis model was proposed in which the chromosome 3 translocation may act as a 
primary oncogenetic event leading to (nondisjunctional) loss of the derivative chromosome 
harbouring the 3p arm. Inactivation of (a) tumor suppressor gene(s) on the remaining 3p 
arm, such as VHL, acts as a secondary event involved in tumor progression (Chapter 3). No 
loss of 3p was found in one small early stage tumor in the family with the 2;3 translocation 
and in a few tumor biopsies analysed in the family with the 3;6 translocation (Chapter 4 and 
Chapter 5). Positional breakpoint cloning revealed that a gene on chromosome 3, DIRC2, is 
disrupted by the 2;3 translocation (Chapter 6). DIRC2 encodes a novel well-conserved 
member of the major facilitator superfamily (MFS) of transporters. Isolation of the 
chromosome 2 breakpoint revealed that another novel gene, DIRC3, is disrupted by the 
translocation (Chapter 7). A fusion transcript is formed between the first two exons of 
DIRC3 and the exons 2-9 of the PASS1 gene, which is located proximal to the breakpoint on 
chromosome 3 (Chapter 7). To evaluate whether the DIRC2 gene and/or its neighbouring 
genes are also targeted in sporadic RCCs with cytogenetically defined breakpoints in the 
3q21 region, we set out to analyse 12 such tumors (Chapter 8). We found that, although the 
breakpoints are clustered at the cytogenetic level, they are not clustered at the molecular 
level and, thus, unlikely disrupt or deregulate the same gene(s). In the last chapter (Chapter 
9) the results of the molecular genetic studies described in this thesis are discussed in the 
context of general mechanisms underlying familial renal cell cancer development. In 
addition, some suggestions for future studies are provided.  
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Abstract 
 
Cytogenetic analysis was performed on peripheral blood lymphocytes of members of a 
family with inherited renal cell cancer (RCC). Four family members in three generations 
developed multiple/bilateral RCCs of the clear cell type. In one additional case a bladder 
carcinoma was diagnosed. In two of the RCC patients a constitutional t(2;3)(q35;q21) was 
encountered, whereas in the two other (deceased) patients the presence of this 
translocation could be deduced. Also, the bladder cancer patient was found to be positive for 
t(2;3)(q35;q21). This is the third familial RCC-associated chromosomal translocation ever 
described. The previously reported cases also involved chromosome 3, thereby supporting 
the notion that this chromosome may play a crucial role in the development of RCCs. 
Interestingly, the translocation breakpoints in these three families map at different locations, 
suggesting that multiple genes on chromosome 3 may be involved. 
 
Introduction 
 
Renal cell carcinomas (RCCs) represent 85% of all primary renal tumors and have, together 
with nephroblastoma (Wilms' tumor), been studied frequently both at the cytogenetic and the 
molecular level (Meloni et al., 1992; Zhao et al., 1995; Van den Berg et al., 1997a). In recent 
years the incidence of RCCs has been steadily rising. This increase was accompanied by a 
minor improvement of the five-year survival rate (Motzer et al., 1996). In general, RCCs are 
sporadic tumors but familial cases have also been reported. These familial cases have the 
presence of abnormalities involving chromosome 3 in common, suggesting a primary role for 
this chromosome in renal cancer causation, particularly the clear cell type (Cohen et al., 
1997; Kovacs et al., 1989). The involvement of chromosome 3 in (sporadic and familial) 
RCCs has also been established by molecular (loss of heterozygosity) investigation of tumor 
material (Van den Berg et al., 1997b). Functional loss of both alleles of a tumor suppressor 
gene on chromosome 3 may be an essential step in the development of these tumors. 
Familial cases carrying constitutional (3;6) (Kovacs et al., 1989) or (3;8) (Cohen et al., 1979) 
translocations have been used to define such putative tumor suppressor genes (Van den 
Berg et al., 1995; Ohta et al., 1996). Another inherited disorder that predisposes to a variety 
of cancers, including those of the kidney, is the Von Hippel-Lindau (VHL) syndrome. 
Recently the VHL gene, located on chromosome 3, was identified using positional cloning 
strategies (Latif et al., 1993; Krumm et al., 1995). Somatic mutations and loss of 
heterozygosity of the VHL gene were also observed in various primary clear cell and non-
clear cell renal carcinomas (Shuin et al., 1994; Gnarra et al., 1994; Duan et al., 1995). Here 
we report a familial case of RCC with a constitutional (2;3) chromosome translocation. This 
novel case may be of help in the identification of additional gene(s) that predispose to the 
development of RCCs. 
 
Patients, methods and results  
 
Case reports of four related renal cell carcinoma patients 
In 1984 patient II:7 (Figure 2.1; age 54 years) presented with hematuria. At that time a 
unilateral (right sided) RCC was diagnosed and radical nephrectomy was performed. 
Histological evaluation of the kidney revealed a single 7 cm tumor of the clear cell type in the 
lower pole. The tumor was classified as T3b (with renal vein involvement). During eleven 
years of follow-up no signs of local recurrence and/or metastasis were noted. In 1995 the 
patient again presented with hematuria. Renal echoscopy, followed by a CT scan, revealed 
a 3.5 cm tumor in the remaining left kidney. This tumor could be removed by partial 
nephrectomy. After pathologic examination the diagnosis of clear cell carcinoma confined to 
the kidney capsula (stage 1) was made. No signs of recurrence and a fair renal function 
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(plasma creatinine value of 160 µmol/liter and creatinine clearance of 60 ml/min) were noted 
after subsequent follow-up of the patient until January 1997. 
 
After the second tumor was detected (1995) the patient (II:7) informed us that his mother 
(patient I:2) and sister (patient II:1) both died from RCC, and that his nephew (patient III:6) 
also had been operated for RCC. Patient I:2 died in 1946, one year after the diagnosis RCC 
was made from a metastasis at the age of 53. Patient II:1 presented in 1987 at the age of 68 
with a metastasis in the thoracic spine from a RCC (clear cell type) of the right kidney. A 
nephrectomy was performed and three tumors were encountered, extending outside the 
capsula. The patient developed pulmonary liver- and bone-metastases and died one year 
later. Patient III:6 was referred to the urologist by his general practitioner in 1994 (age 40 
years) because of loin pain. An enlarged left kidney was noted and echoscopy and CT 
scans revealed a tumor of 6.5 cm in diameter. Radical nephrectomy was performed and a 
clear cell carcinoma, confined to the capsula without renal vein and/or lymph node 
involvement (stage 1), was found. Three years of follow-up of this patient revealed no signs 
of recurrence and only a slight decrease in renal function. The clinical data of these four 
patients are summarized in Table 2.1. 
In 1991 a bladder cancer (squamous cell carcinoma) was diagnosed in patient II:5 (age 66 
years) which, after treatment, recurred in 1992 without signs of invasive growth. 
 
Table 2.1 Clinical data of the four RCC patients.  
 
Patient Gender Age at diagnosis Histology Cancer site    No. of lesions 
 
I:2  F 53 no data 
II:1  F 68 clear cell right 3 
II:7  M 54 clear cell right and left 2 
III:6  M 40 clear cell left 1 
 
F, female; M, male 
 
Cytogenetic analysis and the occurrence of t(2;3)(q35;q21) 
Cytogenetic analyses were carried out on metaphase spreads derived from cultured periph-
eral blood lymphocytes using routine procedures. Carriership of a constitutional chromo-
some translocation (2;3)(q35;q21) was detected in the two index renal cancer patients (II:7 
and III:6) (Figure 2.2). Based on these findings, cytogenetic investigations were extended to 
Figure 2.1 Pedegree of the renal cancer family. The presence of the translocation in patients I:2 and II:1 could be
deduced. 
I:2I:1
II:1 II:2 II:3 II:4 II:5 II:6 II:7 II:8
III:1 III:2 III:3 III:4 III:5 III:6 III:7 III:8 III:9 III:10 III:11 III:12 III:13
T T T T
T T T T T T T
T 2;3 Translocation
Renal cell carcinoma
Bladder cell carcinoma
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the other family members (Figure 2.1). Several additional t(2;3)(q35;q21) carriers could be 
detected, i.e. II:3, II:5 (bladder cancer patient), III:1, III:2, III:3, III:5, III:8 and III:13. All other 
living members tested were found to be negative. Since sibs III:1, III:2 and III:3 are all 
translocation carriers, it can be deduced that their mother (renal cancer patient II:1) also 
must have been a carrier. Through genealogic investigation, two additional family branches 
could be identified (first and second degree relatives of both I:1 and I:2). In total, 23 persons 
were karyotyped within these two branches but no additional translocation carriers were 
detected. One further case of RCC was reported in this extended family (nephew of patient 
I:2). Cytogenetic analysis of this patient's lymphocytes did not show t(2;3)(q35;q21). These 
observations indicate that the translocation most likely has occurred de novo, presumably in 
patient I:2. At present, echoscopy has been carried out on the family members II:5, III:1, 
III:2, III:4, III:8, III:9, III:10, III:11, III:12 and III:13. So far, all of them were found to be 
negative for renal neoplasms. All family members undergo urinary examination and 
echoscopy of the kidneys every two years. 
 
Discussion 
 
The observed presence of a constitutional t(2;3)(q35;q21) in two of the RCC patients (II:7, 
III:6) and its deduced presence in two other patients (I:2, II:1) is highly suggestive for a 
causal relationship between this translocation and the occurrence of RCCs within this family. 
Rearrangements and/or loss of heterozygosity (LOH) of chromosome 3 loci are nearly 
universal features of clear cell carcinomas of the kidney (Meloni et al., 1992; Zhao et al., 
1995; Van den Berg et al., 1997a; Van den Berg., 1997b). In 1979 Cohen et al., (1979) 
described, for the first time, a family with hereditary RCC and a reciprocal translocation 
(3;8)(p14;q24). In this family the tumors were frequently bilateral and occurred at an earlier 
age than sporadic renal cancers usually do. Another family carrying a constitutional 
translocation (3;6)(p13;q25) in three consecutive generations was reported by Kovacs et al., 
(1989). At least one of the translocation carriers developed RCC. More detailed analysis 
revealed that in this case the breakpoint maps proximal to the one encountered in the above 
Figure 2.2 Lymphocyte-derived karyotype of index patient II:7 exhibiting t(2;3)(q35;q21). The translocation derivatives
are marked by arrows. 
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t(3;8) family, indicating that distinct loci (genes) on chromosome 3 may be involved in 
different cases (Van den Berg., 1995; Zhuang et al., 1996). In addition, a single non-familial 
case has been reported (Kovacs and Hoene, 1988) of a patient with RCC and a 
constitutional chromosomal translocation (3;12)(q13;q24), which indicates that cytogenetic 
anomalies involving either the short arm or the long arm of chromosome 3 may predispose 
to renal tumor formation. Recently, positional cloning of the familial (3;8) translocation 
breakpoint led to the identification of a novel gene, designated FHIT (Ohta et al., 1996). This 
gene appears to be rearranged in a high percentage of renal cancers and some other 
neoplasms (Virgilio et al., 1996). The novel familial case of RCC and t(2;3)(q35;q21) 
reported here may be instrumental in the identification of yet another gene(s) on chromo-
some 3 that plays a key role in the development of both familial and sporadic RCCs. 
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Abstract 
 
Through allele-segregation and loss of heterozygosity analyses, we demonstrated loss of 
the translocation-derivative chromosome 3 in five independent renal cell tumors of the clear 
cell type, obtained from three members of a family in which a constitutional t(2;3)(q35;q21) 
was encountered. In addition, analysis of the Von Hippel Lindau gene, VHL, revealed 
distinct insertion, deletion, and substitution mutations in four of the five tumors tested. On 
the basis of these results, we conclude that, in this familial case, an alternative route for 
renal cell carcinoma development is implied. In contrast to the first hit in the generally 
accepted two-hit tumor suppressor model proposed by Knudson, the familial translocation in 
this case may act as a primary oncogenic event leading to (nondisjuntional) loss of the 
der(3) chromosome harbouring the VHL tumor suppressor gene. The risk of developing 
renal cell cancer may be correlated directly with the extent of somatic (kidney) mosaicism 
resulting from this loss 
 
Introduction 
 
Renal cell carcinomas (RCCs) represent 85% of all primary renal neoplasms and, together 
with nephroblastoma, have been studied frequently at both cytogenetic and molecular level 
(Meloni et al., 1992; Van den Berg and Buys, 1997). They constitute a heterogeneous group 
of tumors that can be divided into different subtypes, including the papillary and the 
nonpapillary types (Meloni et al., 1992; Motzer et al., 1996; Van den Berg et al., 1997a). 
Papillary RCCs are characterized by a combination of gains of chromosomes 7 and 17 and 
loss of the Y chromosome. In addition, t(X;1)(p11;q21) has repeatedly been encountered in 
a subset of these tumors (Meloni et al., 1992). We and others recently found that this 
translocation results in a fusion of the transcription factor TFE3 gene, on the X chromosome, 
to a novel gene, designated PRCC, on chromosome 1 (Sidhar et al., 1996; Weterman et al., 
1996a, 1996b). In addition, mutations in the MET proto-oncogene on chromosome 7 were 
detected in the germline of affected members of papillary RCC families and in a subset of 
sporadic papillary RCCs (Schmidt et al., 1997). 
Nonpapillary RCCs are found mostly in the sporadic form. Loss of heterozygosity (LOH) 
analysis of these RCCs revealed that allelic losses predominantly occur in the chromosome 
3p21 region, together with losses in either 3p25, 3p13-14, or both (Van den Berg and Buys, 
1997). These results indicated that the corresponding regions on 3p may harbour tumor 
suppressor genes. One of these putative tumor suppressor genes is the Von Hippel Lindau 
(VHL) gene, located on 3p25. Hereditary nonpapillary RCC is rare, is often bilateral and/or 
multifocal in nature, and has a relatively early onset (Meloni et al., 1992; Stein and Stein, 
1995; Motzer et al., 1996). These hereditary RCCs may develop as a consequence of VHL 
disease, in which the VHL gene is inactivated by mutation and/or hypermethylation (Gnarra 
et al., 1994; Herman et al., 1994). Somatic mutations and LOH of the VHL gene were also 
found in primary sporadic RCCs (Foster et al., 1994; Gnarra et al., 1994; Shuin et al., 1994; 
Gnarra et al., 1995; Zhuang et al., 1996).  
Until recently, only two familial RCC cases with balanced chromosomal translocations had 
been encountered. In the first family, a constitutional t(3;8)(p14;q24) was found in several 
family members, including 10 RCC patients, over four generations (Cohen et al., 1979; Li et 
al., 1993). In the second family, a constitutional t(3;6)(p13;q25) was found in three 
consecutive generations. As yet, only the oldest member of this latter family developed 
multiple bilateral RCCs (Kovacs et al., 1989a). In addition, a single sporadic RCC case has 
been reported, carrying a constitutional t(3;12)(q13;q24) (Kovacs and Hoene, 1988). In both 
these familial and sporadic RCC cases, the translocation-derived chromosome containing 
the distal 3p segment was found to be lost in the tumor tissues (Kovacs and Hoene, 1988; 
Kovacs et al., 1989a; Li et al., 1993; Kok et al., 1997), which supports a pivotal role for this 
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chromosomal segment in nonpapillary RCC causation. The chromosome 3 breakpoints are 
different in all three cases. If these translocations disrupt genes, they will thus involve 
different genes. At present, only one of these genes, FHIT, which is involved in the (3;8) 
translocation and maps to 3p14, has been identified (Ohta et al., 1996). However, the exact 
role of this gene in cancer causation remains to be resolved (Van den Berg et al., 1996, 
1997b). 
Recently, we identified a new familial case of RCC (Koolen et al., 1998). Four patients over 
three generations developed nonpapillary RCCs and one patient was diagnosed with a 
squamous bladder carcinoma. Cytogenetic analysis revealed that all these patients (and 
several unaffected members) carried a balanced (2;3)(q35;q21) translocation. To elucidate 
the role of this novel chromosome 3 translocation in RCC development, we performed allele- 
segregation, LOH and mutation analyses on various normal tissues and primary tumor 
samples. 
 
Material and methods  
 
Patient material and somatic cell hybrids 
Paraffin-embedded tumor samples were available (with informed consent) from patients II:1, 
II:7 and III:6 (Figure 3.1). From patient II:7, three different samples were obtained. One of 
these samples was isolated from a tumor in the right kidney, which was removed after RCC 
had been diagnosed in 1984, and two were isolated from the left kidney after partial 
nephrectomy and multifocal RCC diagnosis in 1995 (Koolen et al., 1998). Before DNA 
extraction, tumor-containing areas were selected via microscopic inspection. Wherever 
possible, adjacent normal renal tissues were included as controls. 
 
 
Blood samples from all living members of the RCC family (except III:7) were used (with 
informed consent) to generate lymphocytic cell lines after in vitro Epstein-Barr virus (EBV) 
transformation. Somatic cell hybrids were isolated after fusion of thymidine kinase- deficient 
Chinese hamster A3 cells with t(2;3)-positive lymphocytes of patient II:7, following 
hypoxanthine-aminopterine-thymidine (HAT) selection as described elsewhere (Geurts van 
Kessel et al., 1983). Approximately 80 independent clones were isolated, and their human 
chromosomal constitution was established through karyotyping and polymerase chain 
I:2I:1
II:1 II:2 II:3 II:4 II:5 II:6 II:7 II:8
III:1 III:2 III:3 III:4 III:5 III:6 III:7 III:8 III:9 III:10 III:11 III:12 III:13
T T T T
T T T T T T T
T 2;3 Translocation
Renal cell carcinoma
Bladder cell carcinoma
Figure 3.1 Pedigree of the renal cancer family. 
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reaction (PCR)-screening with chromosome 2- and 3-specific primer sets (see below). 
A3KE-11C was chosen as a derivative chromosome 2 (der(2)) hybrid, A3KE-1D as a der(3) 
hybrid, and A3KE-34B and A3KE-1A as normal chromosome 2- and 3-containing hybrids, 
respectively. No other chromosome 2 or chromosome 3 material was found to be present in 
these selected hybrid lines. 
 
DNA isolation and PCR analysis 
Cell line-derived genomic DNA were isolated by means of proteinase K/SDS treatment 
followed by phenol/chloroform extraction and ethanol precipitation. DNA extractions from 
selected parts of paraffin-embedded tumor samples were performed with a lysis buffer and 
protein-precipitation solution (Puregene, Gentra Systems). 
PCR was performed in a volume of 25 µl containing 10 mM Tris-HCL, pH 9.0; 50 mM KCl; 
1.5 mM MgCl2; 200 µM each nucleotide; 50 ng each primer; 0.25 U Taq-polymerase 
(Thermoperfect Integro); approximately 100 ng genomic DNA; and 0.1 µl fluorescent-
labelled dUTP R110 or R6G (PE Biosystems). Samples were covered with mineral oil and 
were amplified for 35 cycles. Each cycle included denaturation at 94°C for 30 sec, annealing 
at 5-10°C below the melting temperature of the primers for 45 sec, and elongation at 72°C 
for 1 min. In the first cycle, an extra denaturation step of 2 min was included, and in the last 
cycle elongation was extended for 5 min. The fluorescently-labelled PCR products were 
analysed by use of 6% polyacrylamide gels (Sequagel-6, National Diagnostics), an ABI 
373A apparatus (PE Biosystems) and the Genescan Analysis software package (PE 
Biosystems).  
The microsatellite markers used in this study were D2S162 (Genome Database (GDB) ID 
188450), D2S144 (GDB ID 188238), D2S139 (GDB ID 188182), D2S156 (GDB ID 188377) 
and D2S172 (GDB ID188529) from chromosome 2, and D3S1038 (GDB ID 188715), 
D3S1481 (GDB ID 197992), D3S1303 (GDB ID 188447) and D3S1290 (GDB ID 188268) 
from chromosome 3 (Smith et al., 1995; Van den Berg et al., 1996; Spurr et al., 1996). 
These markers were selected from the consensus map generated at the 5th International 
Chromosome 3 Workshop (Smith et al., 1995). 
 
Sequence analysis 
For sequence analysis of the VHL gene, five different primer sets were used as depicted in 
Figure 3.4: K54 (5' GAA ATA CAG TAA CGA GTT GGC CTA GC 3')/G7R72 (5' ACC TCG 
GCC TCG TCC CAG T 3'), G7F27 (5' CCC GGG TGG TCT GGA TCG 3')/G7R297 (5' ATA 
CGG GCA GCA CGA CGC 3'), VHL-22-1/VHL-7 (GDB ID 375133), G712F2 (5' CCT TTG 
CTT GTC CCG ATA GGT CA 3')/G713R1 (5' ACA TCA GGC AAA AAT TGA GAA CTG G 
3'), and G713FX4 (5' CCT TGT ACT GAG ACC CTA GTC TGC CAC T 3')/ G7R727(5' CAA 
GAC TCA TCA GTA CCA TCA AAA GGT 3'). DNA sequences were analysed using the 
Ready Reaction Dye Terminator Cycle Sequencing kit (PE Biosystems) and the automated 
DNA sequencer ABI 373A (PE Biosystems). 
 
Results 
 
Renal cell cancer family and t(2;3)(q35;q21) 
A family in which four different patients over three generations had developed RCC of the 
clear cell type (Figure 3.1) was referred to our clinic. Cytogenetic analysis revealed that two 
of the patients (II:7, and III:6) carried a constitutional balanced t(2;3)(q35;q21) translocation 
(Figure 3.2A). In the two other RCC cases (I:2 and II:1), carriership of the translocation could 
be deduced through cytogenetic analysis of the patients' children (Koolen et al., 1998). 
Furthermore, one squamous bladder cell carcinoma was diagnosed in the t(2;3)(q35;q21)-
positive patient II:5. The (2;3) translocation was also observed in eight other family members 
tested (Koolen et al., 1998). Through genealogic investigation, two additional family 
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branches (27 first- and second-degree relatives of both I:1 and I:2) could be identified, but 
no translocation carriers were detected. This finding suggested that the t(2;3)(q35;q21) most 
likely occurred de novo in patient I:2. In this branch of the family, the tumors developed at an 
earlier age than that at which sporadic renal cancers normally develop and, in some cases, 
they were bilateral and/or multifocal in nature (Koolen et al., 1998). 
 
Segregation of chromosome 2 and 3 markers 
The microsatellite markers that were used in this study and their relative positions on 
chromosomes 2 and 3 are shown in Figure 3.2B. The chromosome 3 markers D3S1038 and 
D3S1481 are located near two of the putative RCC-associated tumor suppressor loci in the 
regions 3p25 (VHL) and 3p14 (FHIT), respectively (Van den Berg et al., 1997c). Somatic cell 
hybrid analysis using the II:7-derived lines A3KE-34B, A3KE-11C, A3KE-1A and A3KE-1D 
revealed that D3S1303 is located proximal to the t(2;3)(q35;q21) breakpoint on chromosome 
3 and that D3S1290 maps distal to it (Figures 3.2B and 3.3). Similarly, on chromosome 2 the 
marker D2S172 could be positioned distal to the breakpoint whereas the other markers 
(D2S162, D2S144, D2S139, and D2S156) were mapped proximal to it. 
 
In addition, using the same hybrid-cell panel, the maternal or paternal origin of the different 
microsatellite alleles on the normal chromosomes 2 and 3 and their respective translocation 
derivatives could be deduced from patient II:7, assuming that RCC patient I:2 was also a 
translocation carrier (Figure 3.3). This microsatellite analysis was extended to all other 
family members using EBV-transformed lymphocytic cell lines and/or patient-derived normal 
kidney tissues (data not shown). This information was subsequently used for interpretation 
of the LOH data obtained from the different tumor samples. 
 
Tumor-associated loss of the der(3) chromosome 
For LOH analysis, tumor areas were selected by microscopy and were subsequently 
isolated from paraffin sections by microdissection. After DNA extraction, the chromosome 2 
and chromosome 3 microsatellite patterns of the tumor samples were compared with those 
of the normal control kidney tissues and/or corresponding lymphocytic cell lines. In Figure 
A B
2 der(2) 3 der(3)Chromosome 2          
markers
D2S162
D2S144
D2S139
D2S156
D2S172
Chromosome 3 
markers
D3S1038(VHL)
D3S1481 (FHIT)
D3S1303
D3S1290
3q212q35
2 der(2) 3 der(3)
Figure 3.2 (A) Lymphocyte-derived partial karyotype of patient II:7, showing the normal chromosomes 2 and 3 and the
translocation derivative chromosomes der(2) and der(3). The chromosomal breakpoints are located within bands 2q35
and 3q21, respectively. (B) Schematic overview of both normal and derivative chromosomes 2 and 3 and the relative
positions of the different microsatellite markers that were used in this study. The positions of the translocation
breakpoints are marked by arrows. 
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3.3, some examples of such LOH analyses are shown. One of the tumors isolated from 
patient II:7 (T95.1) was assayed for chromosome 2 markers D2S139 and D2S172 and 
chromosome 3 markers D3S1303 and D3S1290, located proximal and distal to the 
t(2;3)(q35;q21) breakpoints on chromosomes 2 and 3, respectively (Figure 3.2B). 
Microsatellite profiles from tumor tissue, normal tissue and II:7-derived somatic cell hybrids 
were compared. The alleles located on der(3) (D2S172:279 and D3S1303:209) exhibited a 
significant loss in the tumor tissue as compared to the normal tissue and/or the somatic cell 
hybrids (marked by LOH in Figure 3.3). Such losses can best be explained by a loss of the 
der(3) chromosome in the original tumor. No complete LOH was observed in the tumor 
DNA, suggesting that the tumor sample was still contaminated with normal cells in spite of 
microdissection prior to DNA extraction. No LOH was observed for the microsatellite 
markers D2S139 and D3S1290, located proximal to the breakpoint on chromosome 2 and 
distal to the breakpoint on chromosome 3, respectively (Figure 3.3). This result may indicate 
that both the normal copies of chromosomes 2 and 3 and the translocation-derived der(2) 
chromosome were retained in the original tumor sample. Similar results were obtained with 
all other (informative) markers and tumors included in this study. A summary of these data is 
provided in Table 3.1. After combining the chromosome 2 and 3 segregation data (above) 
Figure 3.3 Tumor T95.1 (patient II:7)-derived allele plots of four different markers located on chromosomes 2 and 3.
Allele patterns of the tumor tissue were compared with those of normal tissue and II:7-derived somatic cell hybrids
containing chromosome 2, chromosome 3, and the respective translocation derivatives. (A) Marker D2S139, located
proximal to the breakpoint on chromosome 2. (B) Marker D2S172, located distal to the breakpoint on chromosome 2.
(C) Marker D3S1303, located proximal to the breakpoint on chromosome 3. (D) Marker D3S1290, located distal to the
breakpoint on chromosome 3. LOH: loss of heterozygosity. 
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with the LOH data from patients II:1 and III:6 (Table 3.1), we conclude that in these cases, 
too, the der(3) chromosome must be lost in the tumors. 
 
Table 3.1 Summary of chromosome 2 and 3 LOH results in five RCCs from patient II:1, II:7 and 
III:6. 
 
Polymorphic markers Renal cell carcinomas 
 
Chromosome 2 II:1 II:7 T84 II:7 T95.1 II:7 T95.2 III:6 
D2S162 - - - - - 
D2S144 - - - - - 
D2S139 - - - - - 
D2S156 - - - - - 
D2S172 + + + + + 
Chromosome 3 
D3S1038 + + + + + 
D3S1481 + + + + + 
D3S1303 + + + + + 
D3S1290 - - - - - 
 
-: LOH negative  
+: LOH positive 
 
VHL gene mutations in the renal cell carcinomas 
Based on the observed loss of the der(3) and, as a consequence, the loss of one copy of the 
VHL gene in the different tumor samples examined within this family, we performed mutation 
analysis on the remaining VHL gene in the tumor-derived DNA by direct sequencing, using 
exon 1-, exon 2- and exon 3-specific primer sets. Again, normal kidney-derived and/or 
lymphocytic cell line-derived DNA were included as controls (Figure 3.4). In one of the 
tumors (T95.1) of patient II:7, isolated from the right kidney in 1995, sequence analysis 
revealed a single basepair (bp) insertion at position 535 (535insC) of exon 1. In the second 
tumor (T95.2) isolated from the same kidney at the same time, a deletion of 10 bp at position 
373 (373del10) was observed, again in the first exon of the gene. In the tumor (T84) isolated 
from the left kidney in 1984 of this same patient, no mutations were detected in either of the 
exons tested. In the RCC of patient II:1, a 19 bp deletion (722del19) was found in the third 
exon, and in the tumor of patient III:6, a single basepair substitution, P86H(C->A), was 
observed in, again, the first exon. All the observed VHL mutations are located in the 
mutation hotspot regions described in the literature, and lead to frameshifts and/or 
substitutions that result in a loss of function of the encoded proteins. The numbering of the 
nucleotide positions mentioned corresponds to the GenBank accession number L15409 
sequence and to the nomenclature described by Beaudet and Tsui (1993). 
 
Discussion 
 
We have detected a novel familial case of renal cell cancer with a t(2;3)(q35;q21) 
chromosome translocation. Patient II:7 was of particular interest, since three tumors could 
be obtained independently from different anatomical locations at two different occasions, 
with a time lapse of 11 years (1984-1995). Lymphocyte-derived somatic cell hybrid and 
microsatellite marker analyses unambiguously demonstrated that in all three tumors the 
translocation-derived der(3) chromosome was lost. Subsequent segregation and LOH 
analyses revealed that the der(3) was also lost in two additional tumors derived from 
patients II:1 and III:6. Sequence analysis of the VHL gene revealed distinct mutations in 4 of 
the 5 tumors tested. All these mutations resulted in a loss of function. These data indicate 
that the different tumors that were studied developed independently (and not as metastases 
of a primary tumor, in particular the three tumors of patient II:7) and that, most likely, in all 
cases loss of the der(3) has occurred as a primary event. As a consequence of this 
scenario, the different VHL gene mutations should be considered as secondary events. 
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Figure 3.4 (A) Schematic representation of the VHL gene including the nucleotide and codon (in parenthesis) numbers
(above) and the primer sets that were used for mutation analysis (below). The regions underlined with solid bars are
known mutation hot spots. (B) VHL gene mutations found in four tumor DNA of three RCC patients (II:1, II:7, and III:6).
Since the tumor samples were contaminated with normal cells, double sequence patterns are seen after the
insertion/deletion mutations. 
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Translocations involving chromosome 3 have frequently been encountered in sporadic 
RCCs and in some (three to date) familial RCC cases (Cohen et al., 1979; Kovacs and 
Hoene, 1988; Kovacs et al., 1989a; Li et al., 1993). Kovacs and Kung (1991) developed an 
alternative model for RCC development in which, in contrast to the generally accepted two-
hit tumor suppressor model put forward by Knudson (Knudson, 1993, 1996), familial 
translocations may act as primary oncogenic events. They proposed that reciprocal 
translocations involving chromosome 3 could, somatically, result in random nondisjunctional 
loss of the derivative chromosome carrying the 3p segment harbouring putative tumor 
suppressor loci such as VHL (Kovacs and Frisch, 1989b; Kovacs and Kung, 1991; Kovacs, 
1993). Subsequent tumor formation would result from mutation of the remaining tumor 
suppressor allele. Our results are in full support of this model and provide experimental 
evidence for it. Nondisjunctional loss may occur in any cell at any stage of (embryonic 
kidney) development. Accordingly, the chance to develop RCC may be correlated directly to 
the extend of somatic mosaicism resulting from this (random) loss. This latter notion nicely 
explains the relatively wide range in age of RCC onset as observed in this family (e.g., 
patients II:3 and III:6; Koolen et al., 1998). 
The proposed nondisjunctional loss may be due to an increased genetic instability, possibly 
caused by t(2;3)(q35;q21) itself. Therefore, we also searched for microsatellite and/or mitotic 
anomalies. Microsatellite instability in tumor tissues was not observed for any of the markers 
tested in this work. Mitotic errors were evaluated in 300 lymphocyte-derived methaphase 
spreads of three different translocation carrriers, but no significant increases in abnormalities 
could be observed. Other tissues were not investigated. 
VHL gene mutations have been reported to occur frequently (in 33%-57% of cases) in 
sporadic RCCs and in 2 of the 4 familial t(3;8)-associated RCCs (Gnarra et al., 1994; 
Schmidt et al., 1995). All these mutations were found to be located within known VHL 
'mutation hotspots' (Foster et al., 1994; Gnarra et al., 1994; Zbar et al., 1996; Decker et al., 
1997). In one of the current tumors (T84), no mutations could be detected in either of the 
exons tested. In this case, mutations may still be present in the VHL promotor-region, or 
alternatively, the VHL gene may be inactivated in the tumor via hypermethylation (Herman et 
al., 1994). Obviously, mutations in other putative tumor suppressor gene(s) on 3p may also 
be present (Van den berg and Buys, 1997). These latter possibilities remain to be tested. 
Taken together, our results support the RCC development model of Kovacs and Kung 
(1991) as an alternative route for multi-step tumorigenesis. Currently, we are isolating the 
t(2;3)(q35;q21) breakpoint to find out whether, analogous to FHIT, a gene can be identified 
at or near the breakpoint in either chromosome 2 or chromosome 3. 
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Abstract 
 
Previously, we described a family with renal cell cancer and a constitutional balanced 
t(2;3)(q35;q21). Based on loss of heterozygosity (LOH) and Von Hippel Lindau (VHL) gene 
mutation analyses in five tumor biopsies from three patients in this family, we proposed a 
multistep model for RCC development in which the familial translocation may act as a 
primary oncogenic event leading to (nondisjunctional) loss of the translocation derived 
chromosome 3, and somatic mutation of the VHL gene as a secondary event related to 
tumor progression. Here, we describe the cytogenetic and molecular analysis of three novel 
tumors at early stages of development in two members of this family. Again, loss of the 
derivative chromosome 3 was found in two of these tumors and a VHL mutation in one of 
them. In the third tumor, however, none of these abnormalities could be detected. These 
results underline our previous notion that loss of the derivative chromosome 3 and VHL 
gene mutation play critical roles in these familial RCCs. In addition, they show that both 
anomalies may occur at relatively early stages of tumor development.  
 
Introduction 
 
Renal cell carcinomas (RCC) mostly occur as sporadic tumors (Motzer et al., 1996). 
However, familial cases have also been encountered and recent observations even suggest 
that these may be far more prevalent than was previously imagined. Hereditary RCCs may 
represent different histological subtypes including the papillary subtype, the clear cell or 
nonpapillary subtype, and the oncocytic subtype. In at least a subset of hereditary papillary 
RCCs the MET proto-oncogene is affected (Schmidt et al., 1997). Among the clear cell 
RCCs, three modes of inheritance can be distinguished. The first type constitutes an 
inherited tumor susceptibility syndrome in which the patients carry a germline mutation in the 
Von Hippel Lindau (VHL) tumor suppressor gene (Zbar and Lerman, 1998). The second 
type is associated with constitutional chromosome 3 translocations (Cohen et al., 1979; 
Kovacs and Hoene, 1988; Kovacs et al., 1989; Koolen et al., 1998; Geurts van Kessel et al., 
1999; Zajaczek et al., 1999; Kanayama et al., 2001). The third type encompasses families in 
which no constitutional chromosomal abnormalities or VHL gene mutations have been 
observed (Teh et al., 1997). The average age of onset in the latter type of familial RCC is 
later than that in the first two types. Another difference is that the first two types of familial 
RCC are characterised by multifocal and/or bilateral features (Zbar and Lerman, 1998), 
whereas in the third type only unilateral solitary tumors are encountered (Teh et al., 1997).  
Cytogenetic and molecular studies have demonstrated that chromosome 3 abnormalities 
occur frequently in RCCs of the clear cell type (Meloni et al., 1992; Van den Berg et al., 
1997). Loss of heterozygosity (LOH) of one or more 3p markers has been reported to occur 
in 45-90% of sporadic RCCs (Zbar and Lerman, 1998; Kovacs et al., 1991; Gnarra et al., 
1994). Karyotypic evolution analyses in this type of RCCs revealed that loss of a 3p 
segment may act as an early chromosomal change (Kovacs et al., 1991). This notion was 
supported by the finding that 3p anomalies can be observed with the same frequency in 
carcinomas with and without metastatic growth (Kovacs, 1993). Three regions on 3p were 
identified as sites where putative tumor suppressor genes may be located (van den Berg et 
al., 1997). Completely in line with these results was the finding that reintroduction of 
genomic fragments derived from these 3p regions into RCC cell lines resulted in 
suppression of tumorigenicity (Killary et al., 1992; Sanchez et al., 1994; Chen et al., 1994). 
Thus, a hypothesis was formulated that inactivation of one or more tumor suppressor 
gene(s) on 3p appears to be critical to the pathogenesis of clear cell RCCs. One such gene 
is located at 3p25, i.e., the VHL tumor suppressor gene. This gene was found to be mutated 
in 60% [(Gnarra et al., 1994) and inactivated by methylation in 19% (Herman et al., 1994) of 
sporadic RCCs. Nevertheless, in a substantial proportion of sporadic RCCs no VHL gene 
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mutation and/or methylation could be observed (Clifford et al., 1998). It was therefore 
suggested that VHL inactivation may represent an important but not a critical step in RCC 
tumorigenesis. Inactivation of other, not yet identified, tumor suppressor gene(s) on 3p may 
equally well be related to RCC development (Van den Berg et al., 1997; Van den Berg and 
Buys, 1997; Clifford et al., 1998; Alimov et al., 2000). 
In 1998 we identified a family with RCC and a constitutional translocation between the 
chromosomes 2 and 3, t(2;3)(q35;q21) (Koolen et al., 1998). In this family the translocation 
chromosome containing the 3p-arm was lost in the tumors. In addition, different VHL gene 
mutations were found in four of five familial t(2;3)(q35;q21)-associated RCCs (Bodmer et al., 
1998). Similar observations were made by others in familial RCC cases with constitutional 
chromosome 3 translocations (Kovacs and Hoene, 1988; Kovacs et al., 1989; Li et al., 1995; 
Schmidt et al., 1995). Based on these observations, a tumorigenesis model was suggested 
in which the constitutional translocation may act as a primary oncogenic event leading to 
(nondisjunctional) loss of the 3p arm (Bodmer et al., 1998; Schmidt et al., 1995). Somatic 
mutation of the VHL gene, or another tumor suppressor gene(s) on 3p, may act as a 
secondary hit resulting in tumor progression. Through a periodic screening program that has 
been initiated in the t(2;3)-family, three novel renal neoplasms at early stages of 
development were detected. Here we report the cytogenetic and molecular analysis of these 
early-stage tumors and discuss its implications for familial RCC development. 
Material and methods 
 
Patient material 
Previously we described a family with renal cell cancer (RCC) and t(2;3)(q35;q21) (Koolen et 
al., 1998). In a subsequent study, five tumor biopsies from three patients in this family 
(Figure 4.1) were analysed (Bodmer et al., 1998). Via periodic screening in this family, three 
novel early stage tumors were detected among which one in family member II:7 (remaining 
left kidney after previous surgery; age 69) and two in family member III:13 (left and right 
kidney; age 30). After surgery, tumor samples and adjacent normal kidney tissue samples 
were processed for (i) short term cell culture and preparation of metaphase spreads for 
cytogenetic analysis, (ii) histologic examination and (iii) the extraction of DNAs and 
subsequent molecular analyses.  
Figure 4.1 Pedigree of the renal cancer family with a constitutional t(2;3)(q35;q21). The RCC patients are represented
by black symbols. The translocation carriers are marked by a capital letter T. 
I:1 I:2
II:1 II:2 II:3 II:4 II:5 II:6 II:7 II:8
4 3
III:3
2
III:13
T
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T
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Cytogenetic and histologic analysis 
Tumor and normal kidney tissue samples were disaggregated overnight with collagenase 
(200 U/ml) and subsequently cultured for 4-7 days in RPMI-1640 medium supplemented 
with 10% fetal calf serum and antibiotics. Metaphase spreads were prepared according to 
standard procedures. After trypsin-Giemsa staining, cytogenetic analysis was carried out 
and karyotypes were described according to the ISCN (1995). For histologic examination 
frozen tissue sections and paraffin-embedded tissue sections were routinely stained with 
hematoxylin-eosin. 
 
LOH and VHL gene mutation analysis 
DNA extraction from frozen tissue samples was performed as described before (Bodmer et 
al., 1998), using a lysis buffer and a protein-precipitation solution (Puregene Gentra 
Systems). Prior to DNA extraction, tumor and normal tissue areas were selected via 
microscopic inspection. For LOH analysis the markers D2S162, D2S144, D2S139, D2S156, 
D2S172 from chromosome 2, and D3S1038, D3S1481, D3S1303, D3S1290 from 
chromosome 3 were used (Bodmer et al., 1998). PCRs were performed using standard 
buffers and R110 fluorescently labelled dUTP (PE Biosystems). PCR conditions were 
optimised for each primer set. Unincorporated fluorescent dUTP was removed from the PCR 
mixtures using the QIAquick PCR purification kit (QIAgen). The PCR products were run on 
6% polyacrylamide gels (Sequagel-6, National Diagnostics), and analysed using an 
ABI373A apparatus and the Genescan analyses software (PE Biosystems). VHL gene 
mutation analysis was performed by direct sequencing using exon 1-  (K54/G7R72, 
G7F27/G7R297, and VHL-22-1/VHL-7), exon 2- (G712F2/G713R1), and exon 3- 
(G713FX4/G7R757) specific primer sets as described before (Bodmer et al., 1998). DNA 
sequences were analysed using the ABI PRISM BigDye Terminator Cycle Sequencing Kit 
(PE-Biosystems), QIAquick PCR purification kit (QIAgen) and an ABI PRISM 3700 DNA 
analyser (PE-Biosystems). The numbering of the nucleotide position of the VHL gene 
corresponds to the GenBank accession number L15409 sequence.  
 
Results 
 
Identification and histologic classification of three early stage renal cell carcinomas 
Through a periodic screening 
program in the t(2;3)(q35;q21)-
positive RCC family (Koolen et 
al., 1998), three novel renal 
neoplasms were detected at 
early stages of development in 
family member  II:7 and his son 
III:13 (Figure 4.1). From II:7 
several renal tumors were 
removed on previous occasions 
(Bodmer et al., 1998). A recent 
CT scan again revealed the 
presence of a tumor in the 
remaining kidney tissue of this 
patient (diameter 1 cm). Total 
nephrectomy had to be carried 
out, making this patient anephric. 
Microscopic examination of 
paraffin-embedded tumor tissue 
Figure 4.2 RCC histology from the left kidney of patient III:13 showing
clear cells with little atypia and a compact to alveolar growth pattern
(nuclear grade 1; HE x 25 objective). 
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revealed a compact or tubulo-alveolar growth pattern. The tumor cells showed an epithelial 
morphology with a clear cytoplasm, prominent cytoplasmic membranes, and small oval 
hyperchromatic nuclei with limited polymorphia and inconspicious nucleoli. These 
characteristics are in accordance with a diagnosis of clear cell RCC, nuclear grade 1 (Figure 
4.2). In the same period a CT scan revealed abnormalities in both kidneys of the son (III:13) 
of this patient. During surgery, small cystic/solid tumors were detected in both kidneys. Two 
tumor samples, one from the left and one from the right kidney, with average sizes of 0.8 to 
1.6 cm respectively, were again microscopically classified as clear cell RCCs of nuclear 
grade 1 (Figure 4.2). 
 
Loss of the derivative chromosome 3 in two renal cell carcinomas 
Previous cytogenetic analysis of peripheral blood lymphocytes revealed that patients II:7 
and III:13 are both t(2;3)(q35;q21) carriers (Bodmer et al., 1998). Cytogenetic analysis of 
normal kidney samples from these patients again revealed a diploid karyotype with a 
balanced t(2;3)(q35;q21) translocation in all cells examined (not shown). In the tumor 
sample isolated from the right kidney of patient III:13 loss of the derivative chromosome 3 
was encountered as the sole abnormality in 5 out of 10 cells examined. Hence, the 
karyotype of this tumor sample reads: 45, XY, der(2)t(2;3)(q35;q21), -3 [5] (Figure 4.3). Due 
to the rapid overgrowth by normal cells of the cultures, no conclusions could be drawn from 
the other tumor biopsies of patients II:7 and III:13. 
Tumor areas from frozen primary tumor samples of both patients were selected 
microscopically for DNA extraction. These DNAs were subjected to loss of heterozygosity 
(LOH) analysis. Therefore, five informative markers from chromosome 2 and four 
informative markers from chromosome 3 were used (Bodmer et al., 1998). Their relative 
positions on both chromosomes are depicted in Figure 4.4A. Allele patterns of normal and 
Figure 4.3 Karyotype observed in 50% of the cultured renal cell carcinoma cells from the right kidney sample of patient
III:13. The sole abnormality is loss of the derivative chromosome 3 (asterisk). The derivative chromosome 2 is retained
(arrow). The karyotype of this tumor sample reads: 45,XY,der(2)t(2;3)(q35;q21),-3[5]. 
*
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tumor samples were compared for all the markers. The tumor from patient II:7 (90% tumor 
cells) showed LOH for all the markers located above the breakpoint on chromosome 3 
(D3S1038,  D3S1481, and D3S1303) and marker D2S172 below the breakpoint on 
chromosome 2. Representative allele patterns for D3S1303 and D2S172 are shown in 
Figure 4.4B. In contrast, no loss was observed for any of the markers above the breakpoint 
on chromosome 2 (D2S162, D2S144, D2S139, and D2S156) and below the breakpoint on 
chromosome 3 (D3S1290) (not shown). This LOH pattern is consistent with loss of the 
derivative chromosome 3 (Bodmer et al., 1998). In contrast, no allelic losses were observed 
in the tumor sample from the left kidney of patient III:13 (70% tumor cells). LOH analysis of 
the tumor sample from the right kidney of this patient could not be performed due to lack of 
suitable tumor material.  
 
A novel VHL mutation in one renal cell carcinoma  
In analogy to our previous study in this family (Bodmer et al., 1998), we performed VHL 
gene mutation analyses in the tumor-derived DNAs by direct sequencing. In the tumor of 
patient II:7 this analysis revealed a single basepair substitution in exon 2, L128P (T>C) 
(Figure 4.5). This mutation is distinct from any of the mutations observed in the other tumors 
in this patient and from those observed in tumors of the other family members in our 
previous study (Bodmer et al., 1998). In the tumor isolated from the left kidney of patient 
III:13, no mutations could be detected. Again, no suitable tumor material from the right 
kidney of this patient was available for VHL gene mutation analysis. 
Figure 4.4 (A) Diagram showing the different markers located on chromosomes 2 and 3 and their positions relative to
the breakpoints (arrowheads). (B) Allele plots of chromosome 2 marker D2S172 and chromosome 3 marker D3S1303
derived from tumor and normal kidney tissue of the patients II:7 and III:13 (left kidney). Loss of heterozygosity (LOH)
was observed for both markers in the tumor sample of patient II:7 and is indicated by arrows (D2S172:279 and
D3S1303:209). Allele sizes are indicated (265, 279 and 285 for marker D2S172; 202, 208, and 217 for marker
D3S1303). 
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Discussion 
 
We have detected three novel early stage RCCs of the clear cell subtype in two members of 
a family with a constitutional t(2;3)(q35;q21) translocation. Previous molecular studies on 
five independent RCCs isolated from three different members in this family revealed loss of 
the derivative chromosome 3 in all of them (Bodmer et al., 1998). Additionally, different VHL 
gene mutations were observed in four of these tumors. In this study, one additional tumor 
was isolated from patient II:7 (diameter 1 cm; grade 1; 90% tumor cells). LOH analysis of 
this tumor again revealed loss of the derivative chromosome 3. In addition, a novel single 
basepair VHL gene mutation was detected in this tumor. Furthermore, two RCCs were 
collected from both kidneys of patient III:13. Cytogenetic analysis revealed loss of the 
derivative chromosome 3 in 50% of the cells from the right kidney biopsy (diameter 1.6 cm). 
No LOH and/or VHL gene mutation analyses could be performed on this tumor due to lack 
of further suitable tumor material. Remarkably, no loss of the derivative chromosome 3 
and/or VHL gene mutation could be observed in the tumor biopsy isolated from the left 
kidney of this patient (diameter 0.8 cm; grade 1-2; 70% tumor cells). The percentage of 
tumor cells in this frozen sample, however, may be at the limit of LOH detection. In contrast, 
sequence analysis is not influenced by such a percentage of contaminating normal cells. It 
has been found that VHL gene inactivation may also result from hypermethylation (Herman 
et al., 1994). This latter option, however, remains to be tested.  
 Similar results were recently obtained in a newly identified RCC family with a constitutional 
translocation between the chromosomes 3 and 6, t(3;6)(q12;q15). In this family two tumors 
were analysed from two different family members. In one of these tumors again loss of the 
derivative chromosome 3 and a VHL gene mutation were observed, consistent with our 
observations in the t(2;3)(q35;q21) family. From the second tumor four individual samples 
were analysed, and in only one of them loss of the derivative chromosome 3 could be 
detected. In none of these samples VHL gene mutations were found (Eleveld et al., 2001). 
Figure 4.5 VHL gene sequence analysis of the tumor sample from patient II:7. A T to C substitution in the VHL gene is
observed in this tumor. Sequences of the mutation detected by the forward primer G712F2 (A) and by the reverse
primer G713R1 (B) are shown. The mutation is marked by an arrow. 
A→G
T→C
A.
B.
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Thus, RCCs without loss of 3p and/or VHL mutations were detected in both t(2;3)(q35;q21)- 
and t(3;6)(q12;q15)-positive family members. Based on our previous observations in the 
t(2;3)(q35;q21) family and similar observations made by others, a tumorigenesis model was 
proposed in which loss of the 3p-containing translocation chromosome and somatic 
mutation of the VHL gene act as sequential events, ultimately leading to malignancy 
(Bodmer et al., 1998). Our present results and those reported by Eleveld et al., (2001) are in 
support of this model. In addition, they indicate that these two genetic events show a 
heterogeneous pattern and may be preceded by other (epi) genetic event(s).  
Mitotic instability leading to nondisjunctional loss may act as a predisposing factor in 
translocation-positive RCC families. However, no increase in numerical chromosomal 
abnormalities was observed in cultured lymphocytic or normal kidney cells in translocation 
carriers in these families (Bodmer et al., 1998; Eleveld et al., 2001; this report), which 
excludes mitotic instability. Increased genetic instability due to a deficient mismatch repair 
system was also ruled out earlier in the t(2;3)-positive family, as no overt microsatellite 
instability was observed in the renal tumors analysed (Bodmer et al., 1998). Additionally, we 
tested whether a cell cycle defect in the G2-phase may be present in members of this family 
using a bleomycin sensitivity test (Hsu et al., 1989). EBV immortalised lymphoblastoid cell 
lines derived from both translocation carriers and non-carriers in the t(2;3) family were used 
for this test, but no obvious differences were observed (data not shown). A similar test was 
performed by others on cultured peripheral blood lymphocytes collected from different 
members of a RCC family with a constitutional t(3;6)(p13;q25). Also here no obvious 
differences were found (Kovacs et al., 1989).  
Taken together, our results indicate that loss of the derivative chromosome 3 and VHL gene 
mutation represent important steps in various stages of RCC development in carriers of 
(familial) chromosome 3 translocations. In addition it is suggested, based on these results 
and those reported by Eleveld et al., (2001), that another (epi) genetic event may be 
associated with tumor initiation. Currently, we are in the process of positional cloning the 
t(2;3)(q35;q21) breakpoint in search for a gene(s) that, through disruption or gene fusion, 
may be involved in RCC initiation. 
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Abstract 
 
We identified a novel familial case of clear cell renal cancer and a t(3;6)(q12;q15). 
Subsequent cytogenetic and molecular analyses showed the presence of several 
abnormalities within tumor samples obtained from different patients. Loss of the der(3) 
chromosome was noted in some, but not all, of the samples. A concomitant VHL gene 
mutation was found in one of the samples. In addition, cytogenetic and molecular evidence 
for heterogeneity was obtained through analysis of several biopsy samples from one of the 
tumors. Based on these results and those reported in the literature, we conclude that loss of 
der(3) and subsequent VHL gene mutation may represent critical steps in the development 
of renal cell cancers in individuals carrying the chromosome 3 translocation. Moreover, 
preliminary data suggest that other (epi)genetic changes may be related to tumor initiation. 
  
Introduction 
 
The heterogeneous group of kidney tumors constitutes 2-3% of all cancers in human adults 
(Dayal et al., 1983; Boring et al., 1994). From this group, 80-85% are classified as non-
papillary or clear cell renal cell carcinoma (RCC) (Störkel and Van den Berg, 1995). Clear 
cell RCC mostly occurs in a sporadic form, with a higher incidence in males (Dayal and 
Kinman, 1983; Kovacs, 1994). Approximately 1-2 % of the cases are familial (Griffin et al., 
1967). Familial clear cell RCC is characterized by an early onset and is frequently bilateral 
and/or multifocal (Yao and Shain, 1995; Zbar and Lerman, 1998). Most of these familial 
tumors occur as a consequence of the Von Hippel Lindau (VHL) disease (Yao and Shain, 
1995; Van den Berg and Buys, 1997). This disease constitutes an inherited tumor 
susceptibility syndrome that causes a wide variety of tumors to develop in patients (Decker 
et al., 1997). The gene for this disease has been isolated and is localized on chromosome 
bands 3p25-26 (Latif et al., 1993). In a limited number of non-VHL RCC families, 
constitutional chromosome translocations have been found. Until recently, only four families 
had been described: a family with a t(3;8)(p14;q24) with 10 patients in four generations 
(Cohen et al., 1979), a family with a t(3;6)(p13;q25.1) with one patient in the first generation 
(Kovacs et al., 1989), a family with a t(2;3)(q35;q21) with 4 patients over three generations 
(Koolen et al., 1998), and a family with a t(2;3)(q33;q21) with 7 patients in three generations 
(Zajaczek et al., 1999). Also, a single RCC case with a constitutional t(3;12)(q13;q24) 
translocation has been described (Kovacs and Hoene, 1988).  
In concordance with the finding that the most common genetic aberration in sporadic clear 
cell RCCs is loss of heterozygosity (LOH) of the chromosomal regions 3p25, 3p21 and 3p14 
(Kovacs, 1993; Hugson et al., 1996, 1998; Van den Berg and Buys, 1997; Alimov et al., 
2000), it was found that in all the tumors successfully analysed in these familial cases the 
derivative chromosome 3, including the 3p arm, was lost (Kovacs and Hoene, 1988; Decker 
et al., 1992; Li et al., 1993; Schmidt et al., 1995; Bodmer et al., 1998). The 3p arm, and 
more specifically the previously mentioned regions, is thought to harbour several tumor 
suppressor genes (Kovacs and Hoene, 1988; Kok et al., 1997; Van den Berg and Buys, 
1997). The VHL gene is located in 3p25. Based on its involvement in VHL disease and the 
frequent occurrence of somatic mutations in both sporadic and familial RCCs, this gene 
generally is considered a tumor suppressor (Gnarra et al., 1994; Shuin et al., 1994, 1995; 
Gallou et al., 1999). In the t(3;8) family, the breakpoint in chromosome 3 is located in 3p14. 
Through positional cloning it was found that the translocation results in disruption of the 
FHIT gene (Ohta et al., 1996). Although loss of FHIT protein has been observed in clear cell 
RCCs (Eyzaguirre et al., 1999; Hadaczek et al., 1999), the exact role of this gene in the 
development of RCC is as yet unclear (Van den Berg and Buys, 1997; Le Beau et al., 1998). 
Recently, a candidate tumor suppressor gene, DLC1, was identified in the 3p21 region. This 
gene shows aberrant splicing patterns in different tumors, including RCCs. In addition, 
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transfection of its corresponding cDNA in four different DLC1-negative cancer cell lines 
exerted in vitro growth-suppressive activity, which is indicative of a tumor suppressor gene 
(Daigo et al., 1999).  
We and others have provided evidence for an alternative route for multistep tumorigenesis in 
which a familial chromosome 3 translocation may act as a primary oncogenic event leading 
to (nondisjunctional) loss of the derivative chromosome 3 (der(3)) harbouring the 3p arm 
(Gnarra et al., 1994; Schmidt et al., 1995; Bodmer et al., 1998). Subsequently, cells lacking 
this chromosome may suffer a second hit, resulting in full-blown tumor development. Indeed, 
different mutations in the remaining VHL allele were encountered frequently (Bodmer et al., 
1998). As a corollary of these findings, a follow-up study was done to investigate the overall 
risk of RCC development in families with chromosome 3 translocations. This study yielded 
two more families (of 10 investigated) with RCC: a t(3;4)(p13;p16)-positive family with one 
patient and a t(3;6)(q12;q15)-positive family with 3 patients (Geurts van Kessel et al., 1999). 
These and other published data strongly indicate a substantial risk for RCC in families with 
chromosome 3 translocations, particularly when the breakpoints on chromosome 3 are 
located pericentromerically (Geurts van Kessel et al., 1999). After this study was completed, 
yet another patient was diagnosed with RCC in the latter family. Here we present a detailed 
study of the t(3;6)(q12;q15) family including cytogenetics, fluorescence in situ hybridization 
(FISH), LOH, comparative genomic hybridization (CGH), and VHL gene mutation analyses. 
 
Material and methods 
 
Patient material 
Paraffin-embedded material from tumors of patients III:2, III:3 and III:13 (see Figure 5.1) was 
available for histologic analysis and DNA extraction (with informed consent). From these 
RCC patients, peripheral blood cells were collected for isolation of normal DNA. From 
patient III:25, peripheral blood cells, fresh tumor, and normal kidney tissue samples were 
collected (with informed consent). Two tumor samples (tumor 1 and 2) as well as a normal 
kidney sample (normal 1) were used for cell culture and the preparation of metaphase 
spreads for cytogenetic analysis. Cells were cultured for 6 days in RPMI-1640 medium 
supplemented with 10% foetal calf serum and antibiotics after tissue disaggregation using 
collagenase. Two other tumor samples (tumor 3 and 4) and another normal kidney sample 
(normal 2) were frozen in liquid nitrogen for DNA extraction and histologic examination. 
Macroscopically and microscopically, no well-separated tumor foci could be distinguished 
within the kidney of patient III:25. All tumor samples showed clear cell morphologic features. 
Cytogenetic analysis also was performed on peripheral blood cells of family members using 
standard procedures. Karyotypes were described according to the ISCN (Mitelman, 1995). 
 
Figure 5.1 Pedigree of the t(3;6)(q12;q15)-positive clear cell RCC family. Black symbols represent affected members.
Symbols with a dot represent translocation carriers. Symbols with a cross represent translocation-negative family
members. The remaining persons were not examined. The carrier status of  II:1, II:4 and II:6 were deduced. RCC
patients III:2, III:3, III:13 and III:25 are translocation carriers. Symbols with slash represent deceased family members. 
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DNA isolation from blood cells 
DNA was extracted from frozen peripheral blood cells using a protocol adapted from Miller et 
al., (1988). Briefly, after thawing, the erythrocytes were lysed using a lysis buffer. The 
remaining mononuclear cells were recovered, washed, and lysed to isolate the DNA through 
salt extraction and ethanol precipitation. 
 
DNA isolation from paraffin embedded and frozen tissues 
DNA was extracted from paraffin-embedded kidney tissues as described previously (Bodmer 
et al., 1998) and purified by phenol/chloroform extraction. From the frozen normal and tumor 
material of patient III:25, DNA was extracted using the same protocol as for the paraffin-
embedded material. In all cases, tumor areas were selected and microdissected after 
histologic examination. 
 
FISH analysis 
FISH analysis was carried out using routine procedures, as described by Suijkerbuijk et al., 
(1994). Briefly, cultured cells from tumor samples 1 and 2 and normal sample 1 were used 
to prepare metaphase spreads. The 3p painting probe was labelled with digoxigenin-11-
dUTP (Roche), the whole chromosome 6 painting probe was labelled with biotin-14-dATP 
(Jackson Immunoresearch Laboratories), and the centromere 3 probe was labelled with 
Cy3-dCTP (Amersham Pharmacia Biotech) using a nick translation kit (Roche). 
Hybridizations were carried out in a Hybaid hybridization station (Hybaid). Detection of the 
3p and whole chromosome 6 painting probes was achieved using the following fluorochrome 
conjugates and antibodies: for paint 3p, sheep-anti-digoxigenin-rhodamine (Roche) and 
donkey-anti-sheep-Texas Red (Jackson Immunoresearch Laboratories) and, for paint 6, 
avidin-fluorescein isothiocyanate (FITC) (Vector Laboratories) and goat-anti-avidin-FITC 
(Vector Laboratories). Finally, slides were mounted, pseudo-coloured with DAPI (Serva), 
and analysed using the Oncor Imaging software package (Oncor Imaging). 
 
LOH 
For LOH analyses, the markers D3S1560, D3S1286, D3S966, D3S1303, D3S1290, and 
D3S1614 from chromosome 3 and D6S344, D6S260, D6S271, D6S300, D6S262 and 
D6S305 from chromosome 6 were selected. Polymerase chain reactions (PCRs) were done 
on DNA extracted from paraffin-embedded tissues, using a touchdown PCR protocol 
adapted from Jouquand et al., (1999). Standard PCR mixtures were used (Bodmer et al., 
1998) with either 6-FAM or HEX fluorescently labelled primers or R110 fluorescently labelled 
dUTP (PE Biosystems). The PCR cycles included: denaturation for 2 min at 94°C; 10 cycles 
of  30 sec at 94°C, 30 sec at 59°C (decreasing 1°C per cycle to 49°C) and 45 sec at 72°C; 
20 cycles of 30 sec at 94°C, 30 sec at 49°C, and 45 sec at 72°C; a final step of 72°C for 30 
min. For PCR analysis of DNA extracted from frozen tissue samples, the PCR cycles 
included: 2 min at 94°C; 35 cycles of 30 sec at 94°C, 30 sec at the appropriate annealing 
temperature, and 45 sec at 72°C; a final step of 5 min at 72°C. To remove unincorporated 
fluorescent dUTP, the PCR products were purified using the QIAquick PCR purification kit 
(QIAgen). The PCR products were analysed as previously described (Bodmer et al., 1998). 
 
VHL gene mutation analysis 
VHL gene mutation analysis was done by direct sequencing, as described by Bodmer et al., 
(1998). Briefly, three primer sets were used to amplify exons 1, 2 and 3 of the VHL gene 
from normal and tumor tissue DNA. PCR products were purified using the QIAquick PCR 
purification kit (QIAgen) and subsequently sequenced using the ABI PRISM BigDye 
Terminator Cycle Sequencing Kit (PE Biosystems). The sequence products were analysed 
using an ABI PRISM 3700 DNA Analyser (PE Biosystems). All mutation analyses were 
performed in duplicate. 
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CGH 
CGH was done as described previously (Jeuken et al., 1999; Simons et al., 2000).  Briefly, 
reference DNA was extracted from peripheral blood lymphocytes as described by Miller et 
al., (1988). Both tumor DNA and normal DNA were extracted from paraffin-embedded 
tissues as described by Jeuken et al., (2000). Reference DNA was labelled through nick-
translation with biotin-dUTP (Roche), and sample DNA was labelled using the ULS 
rhodamine labelling kit (Kreatech Diagnostics). Differentially labelled reference and sample 
DNA were precipitated in the presence of 100x human Cot-1 DNA (Gibco BRL Life 
Technologies) and carrier DNA and hybridized onto normal metaphase spreads using a 
Hybaid hybridization station (Hybaid). After post-hybridization washes, biotinylated DNA was 
detected using streptavidin-FITC. CGH images were analysed using the Quips CGH 
analysis software (Applied Imaging). Detection thresholds were set at 0.8 and 1.2.  
 
Results  
 
Renal cell cancer family and t(3;6)(q12;q15) 
In a previous study, we described a family with 3 cases of RCC and t(3;6)(q12;q15) (Geurts 
van Kessel et al., 1999). Recently, another RCC case was detected in this family. The 
pedigree is shown in Figure 5.1. Karyotyping of peripheral blood lymphocytes showed the 
presence of t(3;6)(q12;q15) in all the RCC patients and in 10 additional family members. The 
carrier status of  members II:1, II:4, and II:6 (Figure 5.1) could be deduced.  
 
 
RCC developed in patient III:2 in 1987 at the age of 59. Complete nephrectomy of the left 
kidney was done. After pathologic examination, the diagnosis of clear cell RCC was 
established. Patient III:3 underwent surgery for RCC in 1990 at the age of 41. Complete 
nephrectomy of the left kidney was done, and the pathologic findings confirmed the 
diagnosis of clear cell RCC. RCC developed in patient III:13 in the right kidney in 1993 at the 
age of 63. Complete nephrectomy of the kidney was performed, and a diagnosis of clear cell 
Figure 5.2 Karyotypes of cultured tumor ( tumor 1) cells of patient III:25. In the tumor cells, loss of der(3), 7, 8, 9, 10
and 22, and gain of 5 and 12 are seen. The der(6) and del(6)(p12) chromosomes are marked by an arrow and an
asterisk, respectively. In addition, two unidentified markers (mar) are present. 
  
 
chapter 5 
67 
RCC was established. In 2000, family member III:25 was diagnosed with RCC, and 
complete nephrectomy of the affected right kidney was carried out. This tumor, too,  was of 
the clear cell type. Fresh peripheral blood, tumor, and normal tissues were collected from 
this patient before treatment. The clinical data of these 4 patients are summarized in Table 
5.1. 
 
Table 5.1 Clinical data of the t(3;6)(q12;q15)-positive RCC patients. 
 
Patient Gender Age at diagnosis Histology Grade* Cancer site 
 
III:2 F 59 Clear cell 1 left 
III:3 F 41 Clear cell 2 left 
III:13 F 63 Clear cell 2 right 
III:25 M 67 Clear cell 2 right 
 
* grade is determined according to nuclear morphology 
 
Cytogenetic characteristics of normal and malignant kidney tissue samples 
Both normal and malignant kidney tissue samples of patient III:25 were subjected to  tissue 
culture and cytogenetic analysis. Normal kidney sample (normal 1) exhibited a 
pseudodiploid karyotype with a balanced t(3;6)(q12;q15) in all 10 cells examined. Two 
different tumor samples were used for karyotyping. Owing to the relatively high proliferation 
rate of the normal kidney cells, several diploid cells with t(3;6)(q12;q15) were encountered in 
both tumor samples. In addition, in tumor 1 loss of chromosomes 7, 8, 9, 10, and 22 and 
gain of chromosomes 5 and 12 were encountered in 5 tumor cells examined. Loss of the 
der(3) also was noted. The der(6) was found to be present. The remaining chromosome 6 
copy showed a short arm deletion and two marker chromosomes were present (Figure 5.2). 
The karyotype reads 44,XY,-3,+5,der(6)t(3;6)(q12;q15),del(6)(p12),-7,-8,-9,add(9)(q34),-
10,+12,-22,+mar1,+mar2 [5]. Subsequent metaphase FISH analysis, using whole 
chromosome 6- (green) and 3p-specific (red) painting probes, confirmed the cytogenetic 
observations, i.e., net loss of der(3) and partial deletion of 6p (Figure 5.3). 
In tumor 2 loss of one copy of the chromosomes 2, 14, 21, and 22, and total loss of the 
chromosomes 13, 17, and Y were noted in 5 cells examined. As in tumor 1, der(3) was lost 
and der(6) was retained. In addition, three marker chromosomes were detected (not shown). 
Figure 5.3 FISH analysis of  tumor sample 1 (patient III:25) using 3p (red) and whole chromosome 6 (green) painting
probes (left panel). A: normal chromosome 3; B: der(6) chromosome; C: del(6)(p12) chromosome. The chromosomes
were counterstained using DAPI. For chromosome identification, a converted DAPI image is shown in the right panel. 
A
B
C A
B
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The karyotype of this tumor reads 39,X,-Y,-2,-3,der(6)t(3;6)(q12;q15),-13,-13,-14,-17,-17,-
21,-22,+mar1,+mar2,+mar3 [5]. Unfortunately, no additional material was available for 
metaphase FISH analysis. Therefore, interphase FISH was undertaken to evaluate the 
chromosome 3 status in the cultured tumor samples 1 and 2. For this analysis, a centromere 
3-specific probe was used in conjunction with the 3p-specific painting probe (Table 5.2). In 
tumor 2, two centromere 3 signals were noted in all (100%) of the interphase nuclei 
examined. Two copies of 3p were encountered in 79% of the interphase nuclei, most likely, 
indicating that both the normal chromosome 3 and the der(3) were retained in a high 
percentage of the cultured cells. Unfortunately we were unable to determine whether 
(centromeric) chromosome 3 sequences were contained in either one of the two marker 
chromosomes. In tumor 1, two centromere 3 signals were found in only 45% of the 
interphase nuclei examined. In addition, a single 3p signal was observed in 70% of the cells, 
which is compatible with loss of the der(3) in a considerable proportion of the cells. 
 
Table 5.2 Interphase FISH analysis of tumor samples 1 and 2 and normal kidney sample 1 of 
patient III:25.  
Probe Chromosome 3p Centromere 3 
 
Number of signals 1 2 3 1 2 3 
 
Tumor 1 389(70%) 164(30%) 0 114(55%) 91(45%) 0 
Tumor 2 70(17%) 337(79%) 17(4%) 0 100(100%) 0 
Normal 1 n.d. n.d. n.d. 17(5%) 285(91%) 13(4%) 
 
n.d. not determined 
 
LOH analysis of primary tumors and cultured cells 
DNA isolated from cultured tumor samples (tumor 1 and tumor 2) and primary tumor 
samples (tumor 3 and tumor 4) from patient III:25 were subjected to LOH analysis. The 
percentages of tumor cells in the primary samples 3 and 4 were 60% and 80%, respectively. 
For this study, six chromosome 3 and six chromosome 6 markers were used. The markers 
and their relative locations on the respective chromosomes are depicted in Figure 5.4. 
Tumor samples 2, 3 and 4 did not show LOH with any of the markers tested, whereas tumor 
sample 1 showed LOH for the markers D3S1560, D3S1286, D3S966, D6S260, D6S300, 
Figure 5.4 Diagram showing chromosome 3 (left) and chromosome 6 (right) markers used for LOH analysis and their
relative positions on both chromosomes. The positions of the translocation breakpoints are marked. 
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D6S262, and D6S305 (Figure 5.5; summarized in 
Table 5.3). The markers showing LOH on 
chromosome 3 are all located above the 
breakpoint, and the markers showing LOH on 
chromosome 6 are all located below the 
breakpoint, except D6S260, which is located 
above the breakpoint on the short arm of 
chromosome 6 (Figure 5.4). These findings are in 
agreement with the cytogenetically observed loss 
of der(3) and partial deletion of 6p in this tumor 
(see previous discussion).  LOH analyses on 
tumor samples from patients III:2, III:3 and III:13 
were not conclusive. 
 
CGH profile and VHL mutation analysis of RCC 
from patient III:3 
CGH analysis, performed on RCC tumor material 
of patient III:3, resulted in an overall normal DNA 
profile (data not shown), except for chromosomes 
3 and 6 (Figure 5.6). Significant loss was observed 
for the 3p and 6q regions, compatible with a net 
loss of the der(3). CGH analysis of normal renal 
tissue showed a normal profile (Figure 5.6). 
Subsequent VHL mutation analysis of this tumor 
showed a deletion of a single nucleotide at 
position 302 (302delT), leading to a frameshift that 
results in an altered amino acid sequence and a 
delayed stop. No VHL gene mutations were found 
in any of the other tumor samples derived from 
patients III:2, III:13, and III:25. 
 
Discussion  
 
We have identified a family with RCC and a 
t(3;6)(q12;q15). In this family, clear cell RCC 
developed in 4 patients. Fresh blood, tumor, and 
normal kidney tissue samples were obtained from one of the patients (III:25). This material 
was processed for cell culture and DNA extraction. One normal sample and two tumor 
samples were karyotyped. Whereas the normal kidney tissue sample showed pseudodiploid 
karyotype with t(3;6)(q12;q15), as expected, the two tumor samples showed several 
aberrations with marked clonal differences. Both tumor samples showed cytogenetic loss of 
the der(3). Interphase FISH and LOH analyses, however, confirmed significant loss of 3p 
material in only one of the two samples. This discrepancy may be explained by the presence 
of different amounts of contaminating normal kidney cells in the samples after cell culture 
and/or the presence of chromosome 3 sequences in either one of the cytogenetically studied 
marker chromosomes. Slight differences in interphase FISH results from the two tumor 
samples using 3p- and centromere 3-specific probes may be explained similarly. In two 
additional primary tumor biopsies from this RCC patient with high percentages of tumor cells 
(60% and 80%, respectively) we failed to obtain any evidence for LOH, using both 
chromosome 3- and chromosome 6-specific sets of polymorphic DNA markers. No VHL 
gene mutations were found in any of these biopsy specimens. 
Figure 5.5 Allele plots of chromosome 3 
marker D3S1560 (see Figure 5.4) derived 
from a normal tissue sample and tumor 
samples 1-4 of patient III:25. LOH is only 
observed in tumor sample 1 (arrow). Allele 
sizes are indicated (247 and 253 nucleotides). 
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Table 5.3  LOH results of tumor samples 1-4 of patient III:25. 
 
Polymorphic markers Renal cell carcinomas 
 
Chromosome 3 sample 1 sample 2 sample 3 sample 4 
D3S1560 + - - - 
D3S1286 + - - - 
D3S966 + - n.d. n.d. 
D3S1303 - - - - 
D3S1290 - - - - 
D3S1614 - - - - 
Chromosome 6 
D6S344 - - - -  
D6S260 + - - - 
D6S271 - - - - 
D6S300 + - - - 
D6S262 + - - - 
D6S305 + - - - 
 
-: LOH negative; +: LOH positive; n.d. not determined 
 
Together, these observations may be explained by the presence of tumor heterogeneity 
and/or by the development of independent neoplasms within one kidney of patient III:25, as 
was observed earlier in another case of familial RCC and a t(2;3)(q35;q21) (Bodmer et al, 
1998). Based on the observed lack of 3p loss in at least a subset of the tumor samples, and 
a similar observation recently made in a case of early nodular RCC in the previously 
reported t(2;3)(q35;q21) family (Bodmer et al., 1998, 2002), we conclude that initial loss of 
the der(3) may not be a universal feature of RCC development in familial translocation 3-
positive cases. In the tumor of patient III:3, loss of the der(3) could be deduced through CGH 
analysis. In addition, a novel VHL gene mutation was found in the remaining allele. 
These observations are in complete agreement with our earlier findings in t(2;3)(q35;q21)-
positive familial RCCs (Bodmer et al., 1998) and our suggestion that VHL gene mutations 
may occur as relatively late events related to tumor outgrowth rather than tumor initiation 
Figure 5.6 CGH results of chromosome 3 and 6 from normal kidney (upper panels) and tumor (lower panels) samples
of patient III:3. Regions of 3p and 6q loss are marked by bars at the left side of the chromosomes. Average
fluorescence ratio profiles of 16 and 12 (chromosome 3) and 13 and 16 (chromosome 6) chromosome copies are
shown, respectively. Lower and upper thresholds are set at  0.8 and 1.2, respectively. 
3-16 6-13
3-12 6-16
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(Geurts van Kessel et al., 1999). The latter notion is supported by the fact that in 43-66% of 
sporadic RCCs, no VHL gene mutations are found (Van den Berg and Buys, 1997). It also is 
consistent with the report of Clifford et al., (1998) that provides evidence for VHL-
independent pathways in the development of clear cell RCC. Taken together, in the familial 
RCC case reported here tumorigenesis may not be initiated by loss of the der(3) but by 
other genetic and/or micro-environmental changes affecting, for example, chromosome 
stability. Gene(s) located at or near the breakpoints may serve as such. At present, we are 
in the process of fine mapping the t(3;6)(q12;q15) breakpoint. 
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Abstract 
 
Previously, we described a family with a significantly increased predisposition for renal cell 
cancer co-segregating with a t(2;3)(q35;q21) chromosomal translocation. Several primary 
tumors of the clear cell type from different family members were analysed at a molecular 
level. Loss of the derivative chromosome 3 was consistently found. In addition, different 
somatic Von Hippel Lindau (VHL) gene mutations were observed in most of the tumors 
analysed, even within the same patient. Based on these results a multistep tumorigenesis 
model was proposed in which (nondisjunctional) loss of the derivative chromosome 3 
represents an early event and somatic mutation of the VHL gene represents a late event 
related to tumor progression. More recently, however, we noted that these two anomalies 
were absent in at least one early-stage tumor sample that we tested. Similar results were 
obtained in another family with renal cell cancer and t(3;6)(q12;q15), thus suggesting that 
another genetic event may precede these two oncogenetic steps. We speculate that 
deregulation of a gene(s) located at or near the translocation breakpoint may act as such. In 
order to identify such genes, a detailed physical map encompassing the 3q21 breakpoint 
region was constructed. Through a subsequent positional cloning effort we found that this 
breakpoint targets an hitherto unidentified gene, designated DIRC2 (disrupted in renal 
cancer 2). Computer predictions of the putative DIRC2 protein showed significant homology 
to different members of the major facilitator superfamily (MFS) of transporters. Based on 
additional DIRC2 expression and mutation analyses, we propose that the observed gene 
disruption may result in haplo-insufficiency and, through this mechanism, in the onset of 
tumor growth. 
 
Introduction 
 
Hereditary renal cell carcinomas (RCC) of the clear cell type mostly occur as a consequence 
of the Von Hippel Lindau (VHL) cancer syndrome in which patients carry a germline 
mutation in one allele of the VHL tumor suppressor gene (Zbar and Lerman, 1998). In 
addition, seven families have thus far been described with constitutional chromosome 3 
translocations and hereditary clear cell RCC (Cohen et al., 1979; Kovacs and Hoene, 1988; 
Kovacs et al., 1989; Koolen et al., 1998; Geurts van Kessel et al., 1999; Zajaczek et al., 
1999; Kanayama et al., 2001). In one of these families, in which a t(2;3)(q35;q21) 
translocation segregates, five RCC cases have thus far been identified in three generations 
(Koolen et al., 1998; Bodmer et al., 1998, 2002). In all instances the patients appeared to be 
translocation carriers. Subsequent molecular studies on eight primary tumors in this family 
showed loss of the derivative chromosome 3 (der(3)), containing the short arm of 
chromosome 3 (3p) in seven of them and different VHL mutations in the remaining 3p allele 
in five of them (Bodmer et al., 1998, 2002). Similar observations were made in some of the 
other chromosome 3 translocation-positive RCC families (Li et al., 1993; Schmidt et al., 
1995; Eleveld et al., 2001; Kanayama et al., 2001). Based on these results a tumorigenesis 
model for the development of familial clear cell RCCs was proposed in which 
(nondisjunctional) loss of the short arm of chromosome 3 and somatic mutation of the 
remaining VHL allele on 3p represent critical steps (Schmidt et al., 1995; Bodmer et al., 
1998). In one early-stage tumor biopsy in this family, however, neither der(3) loss nor VHL 
gene mutations were observed (Bodmer et al., 2002). The same was observed in several 
tumor biopsies in another RCC-family with a t(3;6)(q12;q15) translocation (Eleveld et al., 
2001). These findings led us to assume that the two oncogenetic steps mentioned above 
may be preceded by another genetic event related to tumor initiation (Eleveld et al., 2001; 
Bodmer et al., 2002). Deregulation of a gene(s) located at or near the translocation 
breakpoint(s) may act as such.  
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Previous positional cloning efforts have led to the identification of breakpoint-spanning 
genes in the familial RCC-associated t(3;8)(p14;q24) (Ohta et al., 1996; Gemmill et al., 
1998). At the 3p14 breakpoint the FHIT (fragile histidine triad) gene, which coincides with 
the common fragile site FRA3B, was identified (Ohta et al., 1996). The gene encodes a 
hydrolase with, preferably, Ap3A as substrate (Barnes et al., 1996). Aberrant FHIT 
transcripts and FHIT genomic lesions were frequently observed in a variety of primary 
tumors and tumor derived cell lines (Ohta et al., 1996; Druck et al., 1997; Baffa et al., 1998; 
Sorio et al., 1999). Since similar FHIT alterations were also observed in non-malignant cells 
(Druck et al., 1997; Geurts et al., 1997; Van den Berg et al., 1997; Panagopoulos et al., 
1997), it was suggested that fragility of the locus itself might account for the observed 
anomalies (Van den Berg et al., 1997; Le Beau et al., 1998). FHIT transfection studies, 
however, showed that replacement of FHIT in Fhit deficient cancer cells in nude mice 
suppresses tumorigenicity, indicating that FHIT may function as a tumor suppressor 
(Siprashvili et al., 1997). As mutant FHIT, lacking enzyme activity, can also suppress 
tumorigenicity, it was proposed that another function of this protein, such as the binding to 
Ap3A or other proteins, might be related to tumor development (Siprashvili et al., 1997). 
More recent studies reporting a reduced or even complete absence of FHIT protein 
expression in clear cell RCCs (Hadaczek et al., 1999; Eyzaguirre et al., 1999) are in 
agreement with these latter notions. In addition, the increased incidence of carcinogen-
induced tumor formation in Fhit-deficient mice similar to that observed in the human Muir-
Torre tumor syndrome (MTS) (Fong et al., 2000) supports such a role for FHIT. The 
chromosome 8 breakpoint of the 3;8 translocation also disrupts a gene, TRC8, which shows 
significant homology to the Drosophila patched gene (Gemmill et al., 1998). Interestingly, 
inactivation of the human homologue of this patched gene (PTCH) leads to excessive 
growth, indicating that also this gene most likely functions as a tumor suppressor (Teh et al., 
1999). These observations underline the notion that deregulation of a gene(s) located at or 
near familial RCC associated translocation breakpoints may be related to tumor 
development. More recently, a new gene, DIRC1 (disrupted in renal cancer 1), was 
identified at the chromosome 2q33 breakpoint of a constitutional RCC-related 2;3 
translocation (Druck et al., 2001). The function of this gene is unknown. At the chromosome 
3 breakpoint of this translocation no genes were identified yet. 
Here we report the physical mapping and positional cloning of the t(2;3)(q35;q21) 
chromosomal breakpoint at 3q21 and the subsequent identification of a breakpoint-spanning 
gene, DIRC2, which encodes a novel member of the major facilitator superfamily (MFS) of 
transporters. The putative consequences of this gene disruption for RCC development are 
discussed. 
 
Material and methods  
 
Patient material and cell lines 
From different family members, both carriers and non-carriers of the t(2;3)(q35;q21) 
translocation, Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines were 
established (Bodmer et al., 1998). From one of these cell lines (7127) somatic cell hybrids 
were generated after fusion with thymidine kinase deficient Chinese hamster A3 cells. Four 
hybrids were selected, containing either the normal chromosomes 2 or 3 (A3KE-34B and 
A3KE-1A), the derivative chromosome 2 (A3KE-11C) or the derivative chromosome 3 
(A3KE-1D), as described before (Bodmer et al., 1998). In addition, we used independent 
monochromosomal human-rodent somatic cell hybrids containing the normal chromosomes 
2 or 3 as the only human constituents (Coriell Cell Repositories). Cell lines derived from the 
renal proximal tubules included MDCK2 (dog), LLC-PK1 (pig), and a conditionally 
immortalized cell line derived from a transgenic H-2Kb-ts a58 mouse (Weterman et al., 
2001). Mutation analyses were performed on genomic DNAs from the renal tumors from the 
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family-members II:7 and III:13, which were both t(2;3)(q35;q21) carriers (Koolen et al., 1998; 
Bodmer et al., 1998, 2002). Additionally, mutation analyses were performed on DNAs 
isolated from 10 sporadic RCC-derived cell lines of the clear cell subtype and blood samples 
collected from 42 patients in 31 unrelated families carrying renal tumors with various 
histologies, including renal oncocytomas, unusual papillary RCCs without germline MET 
mutations, and clear cell RCCs without germline VHL mutations. All human samples used 
for this study were obtained with informed consent. 
 
Construction of physical YAC/PAC/BAC/cosmid map 
YAC DNA isolations were performed using Zymolyase (Seikagaku). All YAC inserts were 
characterized using pulsed field gel electrophoresis (CHEF-DR III, Biorad). FISH analysis 
was performed on metaphase spreads from t(2;3)-positive EBV cell lines essentially as 
described before (Eleveld et al., 2001). For the isolation of YAC end-fragments, a DOP-
vector PCR protocol was used (Wu et al., 1996) employing the partially degenerate primer 
6-MW, the left YAC vector primer UL and the right YAC vector primer UR. For nested PCR 
we used the left internal vector primer LS2 and the right internal vector primer RA2. Primer 
sequences are given in Table 6.1. The DOP-vector PCR protocol was also used to isolate 
end-fragments from PACs. The pCYPAC2 specific primers were used as described (Wu et 
al., 1996). A gridded total human PAC library (RPCI-5; BAC_PAC Resources, Roswell Park 
Cancer Institute, Buffalo, NY; Ioannou et al., 1994) and a gridded chromosome 3 specific 
cosmid library (RessourcenZentrum/ PrimärDatenbank, RZPD, Berlin, Germany; Trask et 
al., 1991) were used for the selection of PACs and cosmids. DNA isolations from the 
isolated PACs and cosmids were performed using a plasmid purification kit (QIAgen). For 
Southern blot analysis, genomic DNA was isolated from the different cell lines via standard 
SDS/proteinase K lysis, phenol-chloroform extractions and ethanol precipitations. After size-
selection on agarose gels this DNA was blotted onto Genescreen Plus membranes 
(Dupont). Probes were labelled by random priming with [α32P]dCTP and, after pre-annealing 
with hybridime DNA (HT Biotechnology) for 5 hours, hybridized to the blots overnight at 
65°C in 0.5 M sodium phosphate buffer, 1mM EDTA, 7% SDS. Subsequently, the blots were 
washed stepwise starting with 100 mM sodium phosphate, 0.1% SDS, which was decreased 
to 40 mM, 0.1% SDS. Finally, the blots were exposed to X-ray films at -80ºC using 
intensifying screens. 
 
Long range PCR 
Long range (LR) PCR between cosmid L1951 and PAC 860G10 was performed using the 
primers LT3A-FOR and 860Sp6-REV (Table 6.1). PAC 832H17 was used as a template. 
PCR was carried out in a mixture containing 100 ng DNA, 1 x ExTaq buffer (Takara), 0.2 
mM of each dNTP, 0.2 pmol of each primer, and 2.5 units of ExTaq (Takara) in a final 
volume of 50 µl. PCR cycles included an initial denaturation for 3 min at 94°C, 10 cycles of 
15 sec at 94°C, 15 sec at 64°C (decreasing 1°C per cycle to 54°C), and 15 min at 68°C, 25 
cycles of 15 sec at 94°C, 15 sec at 64°C, and 15 min at 68°C, followed by a final elongation 
step at 72°C for 10 min. 
 
cDNA cloning and sequencing 
For the search of genes in the breakpoint region, two cDNA libraries derived from normal 
human kidney tissue and human kidney tumor tissue that were previously constructed in our 
laboratory (Weterman et al., 1996), were used. These cDNA libraries were screened with 
genomic YAC and PAC clones. Subsequent sequence analyses were performed using a 
Ready Reaction Dye Terminator Cycle sequencing kit (PE Biosystems) and run on a ABI 
3700 automated sequencer (PE biosystems). BlastN searches against nr, dbEST, month 
and HTGS databases were done at the NCBI server (http://www.ncbi.nlm.nih.gov/) (Altschul 
et al., 1990). Sequences of the breakpoint-spanning gene were assembled with those 
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obtained from the EST database using the Staden Genome Assembly Package (Bonfield et 
al., 1995) accessed through the Nijmegen Centre of Molecular and Biomolecular Informatics 
(www.cmbi.nl).  
To extend the 5’ end of the DIRC2 cDNA, 5’ RACE was performed with the Marathon cDNA 
amplification kit (Clontech) using cDNA prepared from human kidney. The cDNAs were 
amplified following the supplier’s manual using gene-specific primers (GSPs) 782-GSP3 and 
754-GSP3N (Table 6.1 and Figure 6.3). For this PCR reaction the AdvanTage cDNA PCR 
kit (Clontech) was used.  
 
Table 6.1 Primers  
 
Name Sequence 5’→3’ Use 
 
6-MW CCGACTCGAGNNNNNNATGTGG DOP-vector PCR 
UL  CACCCGTTCTCGGAGCACTGTCCGACCGC DOP-vector PCR 
UR  ATATAGGCGCCAGCAACCGCACCTGTGGCG DOP-vector PCR 
LS2  TCTCGGTAGCCAAGTTGGTTTAAGG DOP-vector PCR 
RA2  TCGAACGCCCGATCTCAAGATTAC DOP-vector PCR 
LT3A-FOR GTATGGTGGCTCACGCCTGTTATCCTAG LR-15 PCR 
860Sp6-REV CAGCGGACACAACTCCACTTCATGTTAG LR-15 PCR 
782-GSP3 GTGCTGCATTCATTACAGTTGGACCTG 5’RACE 
754-GSP3N CAATCCATTTAACATCTGTCCTCCATG 5’RACE 
primer 1 TCGAATACAGCCTCTCTGGGAGTTT RT-PCR 
primer 2  AGGACTATTCTGCGCTGGGCTAGT RT-PCR 
primer 3 TCGCCATGGGCTCTCGCT RT-PCR 
primer 4  TCCTCTCGCCGGTGTTTCCT RT-PCR 
primer 5  TCCCCCAAGATAACTGAGCATTGA RT-PCR 
primer 6  TCATCTGCAGAAAACCACGTCGTA RT-PCR 
primer 7  AAGGAAGGATGTCAGGAGCACAGTT RT-PCR 
mGAPDHfor  GGTGAAGGTCGGTGTGAACG RT-PCR 
mGAPDHrev  CAAAGTTGTCATGGATGACC RT-PCR 
ex1C  GCGTCGCCATGGGCTCTC RT-PCR  
ex2A GCATATAATGTCAGTATGATTG Mutation analysis 
ex2B ATGACCCTTTACTGATCTTCTTAA  Mutation analysis 
ex3A TGTATACTTATTGCCATAGTTAAA Mutation analysis 
ex3B GCACATGCTCCCCCAAGAT Mutation analysis/RT-PCR 
ex3C GCTATTGCATCAATGCTCAGT Mutation analysis/RT-PCR 
ex3D CTGTTATACAAAAAGTAGAGTG Mutation analysis 
ex4A AACTTTTTGTGTTTCCTGGTTA Mutation analysis 
ex4B GAAGGTGTCAGTCAAAGCCAT Mutation analysis 
ex5A GACATACATTTTTCATGACTAAG Mutation analysis 
ex5B AAGAACACGTAACCAGTATTTAT Mutation analysis 
ex6A TATTGCAGTATGATTGTCTTG Mutation analysis 
ex6B GCTCTGTCCACTCACAAG Mutation analysis 
ex7A AGTGAAAGTGTGTCATTTGCTT Mutation analysis 
ex7B CCTACTGTCAGAGTTATGTAC Mutation analysis 
ex8A AAGAGAACACCCCGAAGATC Mutation analysis 
ex8B AAGTGACAACTCCACAAGTAA Mutation analysis/RT-PCR 
ex8C TGTCTACCCAGTTCCAGAAG Mutation analysis 
ex8D TAGTGACCCAAACTTTTCTTGT Mutation analysis 
ex9A TAATGCAGAGCAGATTCCTTC Mutation analysis 
ex9B GTGTGCAGTATTGATTTCCAG Mutation analysis 
 
To extend the GC-rich first exon, RT-PCR was performed with extra Betaine and DMSO on 
again the Marathon Ready human kidney cDNA (Clontech) with different primers 
corresponding to the 5’ genomic region (primers 1-4) and cDNA specific primers 
corresponding to exons 2 and 3 (primers 5-7). The sequences of these primers and their 
positions within the DIRC2 gene are shown in Table 6.1 and Figure 6.3, respectively. PCR 
reactions were carried out in 25 µl reaction mixtures with 0.5 ng cDNA, 1 x buffer 
(GibcoBRL), 1.5 mM MgCl2 (GibcoBRL), 0.2 mM of each dNTP, 0.2 pmol of each primer, 0.5 
units Taq-polymerase (GibcoBRL), 1M Betaine (Fluka), and 1.3% DMSO (Sigma) under 
standard conditions at an annealing temperature of 58ºC (Henke et al., 1997).  
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Protein analysis  
EST predictions and BlastP searches against the nr, swissprot and month databases were 
done at the NCBI server (Bonfield et al., 1995). Transmembrane segments were identified 
by five different prediction programs: DAS at Stockholm University 
(http://www.sbc.su.se/~miklos/DAS/), TMHMM at the Technical University of Danmark 
(http://www.cbs.dtu.dk/services/TMHMM-1.0/), PHD-htm at European Molecular Biology 
Laboratory (EMBL) (http://www.embl-heidelberg.de/predictprotein/), Tmpred at Swiss 
Institute for Experimental Cancer Research (ISREC) 
(http://ulrec3.unil.ch/software/TMPRED_form.html) and SOSUI at Tokyo University 
(http://sosui.proteome.bio.tuat.ac.jp/sosuiframe0.html). Protein motifs in the predicted amino 
acid sequence were identified by PROSITE at the Expert Protein Analysis System (ExPASy) 
server of the Swiss Institute of Bioinformatics (SIB) (http://ca.expasy.org/tools/scnpsit1.html). 
 
Expression analysis 
For expression analysis RNA was extracted from a t(2;3)-positive EBV lymphoblastoid cell 
line, a t(2;3)-positive primary renal tumor, and a sporadic clear cell renal tumor cell line. RNA 
from the tumors were isolated using LiCl (Sigma) (Auffray and Rougeon, 1980) and RNA 
from the EBV cell line was isolated using RNAzol (Campro Scientific). For Northern blot 
analysis total RNA (10 µg) was denatured using glyoxal (Sigma) during gel electrophoresis 
and blotted onto Hybond N-plus membranes (Amersham). These blots, and Northern blots 
containing poly(A)+ RNAs from multiple normal tissues (Clontech), were hybridized with a 
1.7 kb cDNA clone of DIRC2 (IMAGE:338833) as a probe using conditions as described 
above for Southern blot analysis. 
RT-PCR was performed using 5 µg of total RNA isolated from the different proximal renal 
tubule cell lines (see above), Superscript-II RT (Life Sciences), random hexamer primers, 
and specific primer pairs. The primers ex1C and ex3B amplified the exons 1 to 3 of the 
human DIRC2 gene and the primers ex3C and ex8B amplified the exons 3 to 8. Mouse 
Gapdh was included as a control for the integrity of the mouse RNA. The primers amplifying 
this Gapdh gene were: mGAPDHfor and mGAPDHrev. The PCR reactions were performed 
under standard conditions (see above) at an annealing temperature of 55°C. The primer 
sequences and position of the DIRC2 primers are given in Table 6.1 and Figure 6.3, 
respectively. 
 
Mutation analysis 
Mutation analysis was performed by direct sequencing of PCR products covering DIRC2 
exons 2-9, including the intron-exon boundaries. The exon and intron primers used for PCR 
amplification and direct sequencing are given in Table 6.1. PCR products were purified 
using Multiscreen-PCR plates (Millipore) and sequenced with the Big Dye Terminator kit 
(Perkin-Elmer). Before running the samples on an ABI 3700 automated sequencer (Applied 
Biosystems), they were again purified with spin column plates (EdgeBiosystems). 
 
Results 
 
Construction of a 3q21 breakpoint-spanning contig  
Previously, the t(2;3)-associated breakpoints were cytogenetically assigned to bands 2q35 
and 3q21, respectively (Koolen et al., 1998). CEPH yeast artificial chromosome (YAC) 
clones from the 3q21 region were selected and positioned by fluorescence in situ 
hybridization (FISH) relative to the breakpoint using lymphoblastoid cell line-derived 
metaphase spreads. By doing so, four YACs (957g11, 766d8, 912f12, and 944d9) were 
mapped proximal to the 3q21 breakpoint and two YACs (790d8 and 827d3) were mapped 
distal to the 3q21 breakpoint (Figure 6.1). In addition, three overlapping YACs (944h8, 
959e4, and 822a12) were found to span the breakpoint. In Figure 6.2A a typical FISH 
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experiment, with YAC 944h8 as a probe, is shown. Besides a signal on the normal 
chromosome 3, as expected, a split signal is seen at the breakpoint regions on both 
derivative chromosomes (Figure 6.2A, der(2) and der(3)). In order to confirm the breakpoint-
spanning nature of this YAC, end-fragments were generated by polymerase chain reaction 
(PCR) between a partially-degenerate oligonucleotide primer (DOP) and the vector primer, 
and used as probes on Southern blots containing EcoRI digested DNA extracted from 
translocation carrier-derived somatic cell hybrids (A3KE-11C, A3KE-34B, A3KE-1A, and 
A3KE-1D; Bodmer et al., 1998), independent monochromosomal hybrids containing human 
chromosomes 2 (m2) and 3 (m3), Chinese hamster A3 cells and translocation carrier-
derived lymphocytes (7127). One of the end-fragments (944UL) hybridized to a 5.3 kb EcoRI 
fragment in lymphocytes, both cell hybrids containing chromosome 3 (Figure 6.2B, lanes 
7127, m3, and A3KE-1A), and the der(2) containing hybrid (Figure 6.2B, lane A3KE-11C; 
Figure 6.1 Schematic representation of the 3q21 breakpoint region. Markers are shown in the upper part of the figure
followed by the respective YAC, PAC, and cosmid positions. Breakpoint-spanning YACs, PACs, and cosmids are
indicated by black bars, whereas the breakpoint-flanking YACs, PACs, and cosmids are indicated by grey bars. LR-15
is the breakpoint-spanning genomic fragment that was isolated by long range PCR. The translocation breakpoints that
coincide with a 4 kb deletion are indicated by BP1 and BP2 (arrows) on LR-15. The exons 6 and 7 of the DIRC2 gene
are also positioned within LR-15. The genes in the breakpoint region, their respective transcriptional directions and
relative sizes are shown in the lower part of the figure. 
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arrow). The other end-fragment (944UR) hybridized to a 2.2 kb EcoRI fragment in 
lymphocytes, both cell hybrids containing chromosome 3 (Figure 6.2C, lanes 7127, m3, and 
A3KE-1A), and the der(3) containing hybrid (Figure 6.2C, lane A3KE-1D; arrow). These 
results thus independently confirmed the breakpoint-spanning nature of this YAC. The 
breakpoint could be positioned in between the markers WI-5963 and D3S1760 (Figure 6.1). 
These two markers, and two end-fragments of YACs 944h8 and 912f12, were subsequently 
used as probes to screen a human P1 artificial chromosomes (PAC) library and a human 
chromosome 3-specific cosmid library. Five PACs (832H17, 860G10, 1173P12, 828J14, and 
1040F10) and one cosmid (M1344) were selected. All shared the marker D3S1760 (Figure 
6.1). FISH and Southern blot analyses of the t(2;3)-derived somatic cell hybrid panel 
revealed that four of the selected PACs (860G10, 1173P12, 828J14, 1040F10) and cosmid 
M1344 mapped distal to the 3q21 breakpoint and that PAC 832H17 was breakpoint-
spanning (Figure 6.1). The end-fragments of this latter PAC were again used as probes to 
screen the chromosome 3-specific cosmid library. Two cosmids (L1951 and O156) were 
isolated, of which L1951 mapped proximal and O156 mapped distal to the breakpoint. Thus, 
the breakpoint was narrowed down to the region between cosmid L1951 and PAC 860G10. 
Long range PCR (LR-PCR) between sequences of the respective PAC and cosmid inserts 
produced a fragment of 15 kb (Figure 6.1, LR-15). Southern analysis confirmed that LR-15 
was indeed breakpoint spanning and, additionally, that the breakpoint coincides with a 
deletion of approximately 4 kb (data not shown). Through database searches two 
sequenced bacterial artificial chromosome (BAC) clones, RP11-90F21 and RP11-67L2 
(GenBank accession numbers AC011116 and AC078794, respectively), were identified 
(Figure 6.1). Primer-sets were selected and, using the t(2;3)-derived somatic cell hybrid 
panel, the breakpoint region could be narrowed down to ∼500 bp on both sites of the 
deletion (Figure 6.1; BP1 and BP2).  
 
Figure 6.2 FISH and Southern blot analyses of breakpoint-spanning YAC 944h8. (A) FISH analysis using YAC 944h8
as a probe (green) on t(2;3)-positive metaphase spreads showing a signal on the normal chromosome 3 and a split
signal on both der(2) and der(3) (marked by arrows). The centromere of chromosome 3 is detected in red. (B and C)
Southern blot analyses using YAC end-fragments 944UL (B) and 944 UR (C) as probes. 7127 is a t(2;3)-positive
lymphocytic cell line, m2 and m3 are independent monochromosomal human/rodent somatic cell hybrids containing a
normal chromosome 2 and 3, respectively. A3KE-11C, A3KE-1D, A3KE-34B, and A3KE-1A are t(2;3)(q35;q21)-derived
human/hamster somatic cell hybrids containing der(2), der(3), normal chromosome 2 and normal chromosome 3,
respectively. A3 is the hamster control. DNAs were digested with EcoRI. Fragment sizes are indicated in kilobases
(kb). 
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A novel gene, DIRC2, is disrupted by the 3q21 translocation breakpoint 
To identify genes at/near the 3q21 breakpoint, two kidney related cDNA libraries were 
screened with breakpoint-spanning PAC 832H17 and breakpoint-flanking cosmid L1951. 
Two cDNAs were isolated of which the 3’ends matched with several expressed sequence 
tags (ESTs) from UniGene cluster Hs.11360. Alignment of the isolated cDNAs with the 
different EST sequences from the database revealed a consensus transcript of 1628 bp. 
Rapid amplification of cDNA ends (RACE) and a modified reverse transcriptase (RT)-PCR, 
including Betaine and DMSO (Henke et al., 1997), extended this cDNA sequence at the 5’ 
end with 420 bp (the latter with the primer-sets 2-6 and 2-7; Figure 6.3). Simultaneously, 
database searches revealed a human cDNA for the hypothetical protein FLJ14784 
(GeneBank accession number AK027690) which showed extensive homology (97-100% 
identity) to our transcript and extended the composite consensus sequence with another 58 
bp. Alignment of the in total 2106 bp cDNA sequence with that of the two sequenced 
breakpoint-spanning BACs (RP11-90F21 and RP11-67L2) and other overlapping BAC 
clones in the database, i.e. RP11-396B8, RP11-457E6, and RP11-181G12 (Figure 6.1; 
GenBank accession numbers AC010858, AC048348, and AC069581, respectively), 
revealed the presence of nine exons. The putative exon-intron boundaries and the sizes of 
the exons and introns are listed in Table 6.2. 
 
Table 6.2 Genomic organization of the DIRC2 gene. 
 
Exon Exon 5’splice site Exon 3’splice site Exon Intron 
   size (bp)  size (kb) 
 
1   GACAAGAGAG gtgaggggtc 476 11.343 
2 ttcattttag GTCTCCGGAT TTAAAAGAAG gtaaatcctg 94 20.864 
3 taaattccag ATTAATTCAT TTATATGCAG gtaatttgaa 266 6.254 
4 tttctttcag AATTTGGAGT GATTATTAAG gtaaatatac 130 12.385 
5 tcattcacag CAATTTTCGA TGTCAGCCAA gtaagtattt 109 10.463 
6 ttcttaacag GTAGATGCTG CTATGGCAAG gtgagaatat 68 3.705 
7 ttgtttttag GTTTGCAGAT TTAACCACAG gtgagcatag 128 ? 
8 tttattttag TGACATTGTA TCATACAGAG gtaagaaatt 183 6.674 
9 cttacagag TTGTCTTGGT   650 
 
Uppercase and lowercase letters indicate exon and intron sequences, respectively. The preliminary exon-intron boundaries are based on 
comparison of cDNA sequence to genomic sequences and the consensus splice site sequences. 
 
An open reading frame (ORF) of 1434 bp was predicted of which the putative translation 
initiation codon ATG is embedded in a strong Kozak consensus sequence (Kozak et al., 
1996) within the first exon. (Figure 6.4). The GC-rich first exon and 5’untranslated region (5’ 
Figure 6.3 Schematic representation of the DIRC2 exons 1-9 (intron and exon sizes are not drawn to scale) and the
5’ and 3’UTRs (black boxes). Primers used for 5’RACE and RT-PCR are indicated and positioned (not drawn to
scale). The t(2;3) translocation breakpoints BP1 and BP2 and the G to A polymorphism (-31(G>A)) are both marked in
intron 7. 
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UTR) are indicative of a CpG island. The 3’ UTR is 535 bp long and a highly conserved 
-134 ACCAGGCGCGGTCCGGAGGCCGAGGGCGACCACAGCAGCCTCC
-91 GCCTCCTGCTGCTCCGGACTATTCTGCGCTGGGCTAGTCGGCGGTGACCCGGACTGCGCCCGGCAGTGGCTTCGCGGGCGACGCGTCGCC
1 ATGGGCTCTCGCTGGAGCAGCGAAGAGGAGAGGCAGCCGCTGCTGGGGCCCGGGCTCGGGCCTGGGCTGGGGGCCTCCTGGAGAAGCCGG
1 M G S R W S S E E E R Q P L L G P G L G P G L G A S W R S R
91 GAGGCGGCGGCGGCGGCGCTGCCCGCGGCGGTCCCGGGTCCCGGGCGGGTATACGGGCGCCGCTGGCTGGTGCTGCTGCTCTTCTCGCTG
31 E A A A A A L P A A V P G P G R V Y G R R W L V L L L F S L
TM1
181 CTGGCGTTCGTTCAGGGCCTGGTCTGGAACACCTGGGGTCCCATCCAGAACTCGGCGCGCCAGGCCTACGGCTTCTCCAGCTGGGACATC
61 L A F V Q G L V W N T W G P I Q N S A R Q A Y G F S S W D I
TM2
ex1>2
217 GCGCTGCTCGTGCTGTGGGGGCCCATCGGCTTCCTGCCCTGCTTCGCGTTCATGTGGCTCCTGGACAAGAGAGGTCTCCGGATAACTGTG
91 A L L V L W G P I G F L P C F A F M W L L D K R G L R I T V MFS Motif
TM3
ex2>3
361 CTCCTGACATCCTTCCTTATGGTTTTGGGAACTGGTCTAAGATGCATACCTATATCAGACTTAATCCTTAAAAGAAGATTAATTCATGGA
121 L L T S F L M V L G T G L R C I P I S D L I L K R R L I H G
451 GGACAGATGTTAAATGGATTGGCAGGTCCAACTGTAATGAATGCAGCACCATTTCTCTCTACGACGTGGTTTTCTGCAGATGAAAGGGCC
151 G Q M L N G L A G P T V M N A A P F L S T T W F S A D E R A ACS Motif
TM4
541 ACAGCCACAGCTATTGCATCAATGCTCAGTTATCTTGGGGGAGCATGTGCATTTTTAGTTGGACCACTTGTTGTTCCAGCTCCCAATGGG
181 T A T A I A S M L S Y L G G A C A F L V G P L V V P A P N G
TM5
ex3>4
631 ACATCACCTCTTCTTGCTGCAGAGAGCAGCAGGGCGCATATTAAAGATCGCATAGAGGCTGTGTTATATGCAGAATTTGGAGTTGTCTGC
211 T S P L L A A E S S R A H I K D R I E A V L Y A E F G V V C
TM6
721 TTAATATTTTCTGCAACACTAGCTTATTTCCCACCCCGACCTCCTCTTCCTCCCAGTGTTGCTGCAGCTAGCCAGCGGCTGAGTTATCGG
241 L I F S A T L A Y F P P R P P L P P S V A A A S Q R L S Y R PxxP Motif
ex4>5
811 AGAAGCGTTTGTAGATTATTAAGCAATTTTCGATTTTTGATGATTGCTTTAGCATATGCCATACCACTTGGTGTATTTGCTGGCTGGTCT
271 R S V C R L L S N F R F L M I A L A Y A I P L G V F A G W S
TM7
ex5>6
901 GGAGTTCTGGACTTAATTTTAACACCAGCGCATGTCAGCCAAGTAGATGCTGGCTGGATTGGATTTTGGTCCATAGTTGGAGGCTGTGTT
301 G V L D L I L T P A H V S Q V D A G W I G F W S I V G G C V
TM8
ex6>7
991 GTTGGAATAGCTATGGCAAGGTTTGCAGATTTTATCAGGGGTATGCTGAAACTAATTCTTCTCCTCCTGTTTTCGGGAGCTACACTGTCA
331 V G I A M A R F A D F I R G M L K L I L L L L F S G A T L S
TM9
ex7>8
1081 TCCACGTGGTTCACCCTGACCTGTTTGAACAGCATCACACACCTACCTTTAACCACAGTGACATTGTATGCCTCCTGTATTCTCCTGGGA
361 S T W F T L T C L N S I T H L P L T T V T L Y A S C I L L G
TM10
1171 GTGTTCTTGAATAGCAGCGTGCCTATATTTTTTGAGCTTTTTGTGGAAACTGTCTACCCAGTTCCAGAAGGAATTACTTGTGGAGTTGTC
391 V F L N S S V P I F F E L F V E T V Y P V P E G I T C G V V
TM11
ex8>9
1261 ACTTTTTTAAGTAATATGTTTATGGGAGTACTTTTATTTTTTCTCACATTTTATCATACAGAGTTGTCTTGGTTCAACTGGTGCCTTCCC
421 T F L S N M F M G V L L F F L T F Y H T E L S W F N W C L P
TM12 
1351 GGGTCGTGTTTGCTCAGTCTCCTCCTCATTCTGTGCTTCAGGGAATCCTATGACAGACTCTATCTTGATGTGGTTGTCTCCGTTTAATAG
451 G S C L L S L L L I L C F R E S Y D R L Y L D V V V S V *
1441 CACAGACTTGAAGGAGTTTAAAAGGAGGCTGGAAATCAATACTGCACACTGCACATTTGCTCAGAATTGCACATCTAACAGGAAAAGAGG
1531 GAGAAGAAAGAAACTTCATTCAGAGGTTTTGTTAGGTTACAGATTATCACATTAATTTAATTACTACTAGGTAATAATAATGGGAGACTT
1621 GAGTGATAATAGGGGATTTTAAAACTCTACAGATGGCATACCTGTGCCTGCTTCTGGGGTTGGAAGTGTGACTTCTTACACATAAAGCAC
1711 TACCTAAGTAATTCTCTCTCTGTTTTGTGCCAGTGCTAAACTACTGATTACTTGTAATTATGAAAAGAAATAAAGGGTGTCTATCATATG
1801 AAGATAACGCCTTCCCTAAGTCACATATCAGAATAGGAAGATATGCCACTAACTTCTAAAGAAGTTCAAACCCTGTATCCAATTTTAATG
1891 ATAAAATAGCCAAGAGGTATATCGATGATGGAAATTAGCCACATGTACACTACATTTTTTCTAATAAAGCCATTTCTTATATG 
Figure 6.4 Full-length cDNA and deduced amino acid sequence of the DIRC2 gene (GenBank accession number
AK027690; GenPept accession number BAB55300). The exon-exon boundaries (ex1>2-ex8>9), the putative start
(ATG) and stop codon (TAA) and the polyadenylation signal sequence (AATAAA) are indicated in boldface in the
nucleotide sequence. In the amino acid sequence, the predicted transmembrane segments are underlined (TM1-12)
and the MFS- and ACS-specific motifs are boxed as well as the proline rich region (PxxP motif). Conserved amino
acids within the MFS- and ACS- motifs are in boldface. One putative N-linked glycosylation site is indicated by a grey
arrowhead below the sequence, and three putative phosphorylation sites are indicated by black arrowheads below the
sequence. 
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polyadenylation signal sequence (AATAAA) was observed 15 nucleotides upstream of the 
poly(A) addition site (Figure 6.4).  
LR-15 contains both the exons 6 and 7 of this gene and the translocation breakpoint (BP1) 
was found to map 2 kb downstream from exon 7, thereby indicating that this gene is 
disrupted by the translocation (Figure 6.1). These results were confirmed by Southern blot 
analyses using cDNAs corresponding to this gene as probes on somatic cell hybrid and 
control DNAs (data not shown). This gene turned out to be anonymous and, therefore, we 
have designated it DIRC2 (disrupted in renal cancer 2). 
 
DIRC2 is a member of the MFS superfamily of transporters 
The putative full-length DIRC2 cDNA contains an ORF of 1434 bp encoding a predicted 
protein of 478 amino acids (Figure 6.4). Different web-based protein prediction programs 
defined twelve membrane-spanning domains and cytoplasmic amino- and carboxy-termini 
within the predicted protein (Figure 6.4). Furthermore, one putative N-glycosylation site, two 
putative protein kinase C phosphorylation sites, and one putative casein kinase II 
phosphorylation site could be predicted in different hydrophilic domains (Figure 6.4). A 
proline rich region was observed in the large hydrophilic region between the membrane-
spanning domains 6 and 7. Database searches with the predicted amino acid sequence of 
DIRC2 revealed 100% and 98% identity to the human hypothetical protein FLJ14784 
(GenPept accession number BAB55300) and a predicated protein from Macaca fascilaris 
(GenPept accession number BAB17282), respectively. A significant homology in the amino 
acid region 69-427 (43% similarity) was also found with the human feline leukemia virus type 
C receptor (FLVCR; GenPept accession number AAD45243). This receptor has been 
classified as a member of the ancient major facilitator superfamily (MFS) of transporters, 
which contains carriers that transport small solutes across membranes in response to 
chemical-osmotic gradients (Pao et al., 1998; Tailor et al 1999). The MFS family of proteins 
is characterized by the presence of twelve membrane-spanning domains with a large 
hydrophilic region between the membrane-spanning domains 6 and 7 and a well conserved 
MFS-specific motif between the membrane-spanning domains 2 and 3. DIRC2 exhibits all 
these characteristics (Figure 6.4). Moreover, DIRC2 shows homology to an unknown 
transporter in Leishmania major (44% similarity in amino acids 278-433; GenPept accession 
numbers AAF34284) and a sodium dependent inorganic phosphate cotransporter in 
Arabidopsis thaliana (50% similarity in amino acids 156-215; GenPept accession number 
AAD32766).  
 
DIRC2 is expressed in proximal tubular cells of the kidney 
To determine whether DIRC2 is expressed in a tissue-specific manner, a cDNA probe was 
hybridized to a Northern blot prepared from eight different normal adult human tissues. 
Although DIRC2 expression-levels appeared to be low in general, a 2.2 kb DIRC2 transcript 
could be identified in most of these tissues, including kidney (Figure 6.5A). RT-PCR on RNA 
extracted from proximal epithelial tubule cell lines of different species (dog, pig and mouse) 
was performed since clear cell RCCs are thought to develop from this part of the nephron. 
Since different mouse and pig ESTs showed 85 to 95% homology to the human DIRC2 
sequence, respectively, the primers used were designed from the human sequence. A PCR 
product was readily obtained from the mouse cell line using the first primer set (Figure 6.5B, 
lane3), whereas the second primer set yielded PCR products from the pig and dog cell lines 
(Figure 6.5B, lanes 1,2). Inadequate homology of the primer sequences to the respective 
RNAs may explain the observed absence of signals in some of the cell lines. In addition, 
placenta RNA was included as a positive control for human DIRC2 expression (Figure 6.5A, 
lane 6 and Figure 6.5B, lane p). 
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DIRC2 mutation analysis in patients and tumors 
In order to further elucidate the role of DIRC2 in RCC development, we performed mutation 
analyses on tumors isolated from two affected t(2;3) family members (II:7 and III:13; Koolen 
et al., 1998; Bodmer et al., 1998, 2002). PCR products spanning exons 2 to 8 and the 
coding sequence of exon 9 were analysed by direct sequencing. Reliable sequence data 
could not be obtained from the first exon due to its GC-richness. One G to A sequence 
variant in intron 7 (31 nucleotides upstream from the intron-exon boundary of exon 8) was 
identified in patient III:13, but not in patient II:7 (Figure 6.3). Since patient II:7 is the father of 
patient III:13 (Koolen et al., 1998), the G to A sequence variant must be derived from the 
unaffected mother of III:13 and thus, is unlikely to be linked to RCC development. In 
addition, Northern blot analysis of a renal tumor sample obtained from a t(2;3)-carrier (II:7; 
Koolen et al., 1998; Bodmer et al., 1998, 2002) revealed a normal DIRC2 transcript, which 
was also detected in an unrelated sporadic renal tumor sample, but not in the t(2;3)-positive 
lymphoblastoid cell line tested (Figure 6.5C). No additional aberrant bands were observed in 
the translocation-positive tumor.  
The same G to A sequence variant was also encountered in 2 of 10 unrelated sporadic clear 
cell RCC cell lines and in 3 of the 42 blood samples derived from RCC patients of 31 
unrelated families. No other sequence variants were found in these samples. In addition, 
RT-PCR and Northern blot analyses revealed normal DIRC2 transcripts in all sporadic 
RCCs that we tested (data not shown). 
 
Discussion 
 
Previous molecular studies in translocation chromosome 3-positive RCC families showed 
that loss of the derivative chromosome containing the 3p arm and somatic mutation of the 
VHL gene are important steps in the development of these clear cell renal tumors (Li et al., 
1993; Schmidt et al., 1995; Bodmer et al., 1998, 2002; Kanayama et al., 2001; Eleveld et al., 
Figure 6.5 Expression of the
DIRC2 gene in normal tissues
and tumors. (A) Northern blot
containing mRNAs extracted
from adult human tissues and
placenta (Clontech) hybridized
with a 1.4 kb DIRC2 cDNA
encompassing exon 2 to 9.
Lanes: 1, pancreas; 2, kidney;
3, skeletal muscle; 4, liver; 5,
lung; 6, placenta; 7, brain; 8,
heart. (B) RT-PCR analyses
of mRNAs extracted from
proximal renal tubular cell
lines from dog (lane 1), pig
(lane 2) and mouse (lane 3).
Lane p contains human
placenta RNA (positive
control) and lane mQ water
(negative control). (C)
Northern blot containing RNAs
extracted from a t(2;3)-
positive EBV cell line (lane 1),
a t(2;3)-positive tumor (lane
2), and a sporadic renal clear
cell tumor (lane 3), hybridized
with the same 1.4 kb DIRC2
cDNA as in A. Fragment sizes
are indicated in kilobases (kb).
1 2 3
2.2 
C
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2001). As none of these anomalies were observed in an early stage tumor in this t(2;3)-
positive RCC family (Bodmer et al., 2002) and several tumor samples in another t(3;6)-
positive RCC family (Eleveld et al, 2001), an additional translocation-associated oncogenetic 
event was suggested. Therefore, we set out to analyse the t(2;3)-related 3q21 breakpoint in 
more detail. Through positional cloning of this breakpoint we found that an anonymous 
gene, designated DIRC2, was disrupted. This gene contains 9 exons of which the first exon 
is GC-rich and, thus, indicative of a CpG island. The 3q21 breakpoint maps within intron 7 of 
this gene and coincides with a ∼4 kb genomic deletion. DIRC2 encodes a predicted protein 
of 478 amino acids with an overall significant degree of homology to the feline leukemia 
virus type C receptor and various putative transporters which are all members of the MFS 
superfamily of transporters (Pao et al., 1998; Tailor et al., 1999). The DIRC2 protein has, in 
accordance to the MFS transporters, twelve membrane-spanning domains and a conserved 
MFS-specific signature between the membrane-spanning domains 2 and 3. DIRC2 also 
shows homology to an Arabidopsis thaliana sodium dependent inorganic phosphate 
cotransporter. This latter type of transporter has been categorized to the anion-cation 
symporter (ACS) subfamily of the MFS superfamily (Pao et al., 1998). The ACS subfamily 
encompasses proteins that are widely distributed in both prokaryotic and eukaryotic 
organisms. As a consequence of their ancient divergences, most of the ACS subfamily 
members are distantly related. Only four amino acid residues were found to be conserved in 
all ACS family members and, as such, serve as an ACS signature (Pao et al., 1998). These 
residues were also found to be present in DIRC2 (Figure 6.4) and thus suggest that this 
protein may act as such a symporter. The high degree of homology (>85%) of the DIRC2 
transcript to ESTs and transcripts of different eukaryotic species including monkey, pig, dog 
and mouse, and the significant degree of homology (30-45%) of the predicted DIRC2 protein 
to different predicted proteins in Leishmania major and Arabidopsis thaliana, indicate that 
the gene has been strongly conserved throughout evolution. The hydrophilic regions of the 
predicted DIRC2 protein contain one glycosylation site and several phosphorylation sites 
which may be involved in the interaction of this protein with the extracellular and intracellular 
environments, respectively. A proline-rich region was also observed in the intracellular 
hydrophilic region between membrane-spanning domains 6 and 7. Previous studies have 
shown that Src homology 3 (SH3) domains from several proteins may recognize these 
proline-rich (P-x-x-P) motifs as binding sites (Rickles et al., 1994), thereby mediating critical 
protein-protein interactions involved in responses to extracellular signals. The DIRC2 protein 
may, via this putative protein binding site, also be involved in such cellular signaling 
pathways. Transport systems for organic anions and cations are primarily involved in the 
secretion of drugs in renal tubules and, thus, play a critical role in protecting the organism 
against their potential toxic effects (Inui et al., 2000). Disruption of such a transporter, as is 
the case in the t(2;3) family, may impose stress conditions onto renal epithelial cells 
resulting in dysplasia and/or genomic instability. Teleologically, such a condition may result 
in loss of the der(3) chromosome and, thus, trigger the oncogenetic process. According to 
the previously proposed multi-step model (Bodmer et al., 1998), subsequent VHL gene 
mutations may lead to full-blown tumor development. 
To substantiate a role for DIRC2 in proximal renal tubular epithelial cells, various expression 
studies and mutation analyses were performed. Multiple tissue Northern blot analysis 
showed that the DIRC2 gene is expressed in several tissues, among which the kidney. 
Subsequent RT-PCR analyses on RNAs extracted from epithelial cells derived from the 
proximal kidney tubule demonstrated that this gene is also expressed in this part of the 
kidney. Northern blot analysis of t(2;3)-positive tumor cells revealed normal DIRC2 
transcripts, indicating that the remaining intact chromosome 3 allele is normally transcribed. 
Since no additional abnormal transcripts were detected, we conclude that truncated and/or 
fusion transcripts are absent or expressed at very low levels. Subsequent mutation analysis 
on the remaining DIRC2 allele (>80% of the gene) revealed one G to A sequence variant in 
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intron 7. As we could deduce that this variant must be derived from an unaffected family 
member, we conclude that it is not disease-linked. The DIRC2 gene was also normally 
expressed in several sporadic RCCs. Additional mutation analyses of these RCCs and blood 
samples of a series of unrelated RCC patients revealed, besides the G to A variant, no 
further mutations. As yet mutations in the first exon cannot be excluded and, therefore, this 
option remains to be tested. The apparent hemizygous state of DIRC2 in t(2;3)-positive 
tumor cells leads us to suggest that, if disruption of the DIRC2 gene contributes to tumor 
development, it must be through a haplo-insufficiency scenario. Currently, we are 
investigating this option in further detail. 
At this stage it can not be excluded that RCC initiation is caused by a position effect, 
whereby the translocation breakpoint deregulates another gene located upstream or 
downstream from DIRC2 (Kleinjan and Van Heyningen, 1998). Directly proximal to the first 
exon of DIRC2, and thus ∼80 kb proximal to the translocation breakpoint BP1, the first exon 
of a predicted gene was identified. In the database, several matching ESTs were found for 
this gene and the corresponding cDNA predicts a putative ORF encoding a protein of 484 
amino acids. Subsequent database searches revealed 73% homology to PASS1 (Figure 
6.1), a rat protein that was previously found to be associated with the small stress protein 
hsp27 (GenPept accession number AAD48846; Liu et al., 2000). Small stress or heat shock 
proteins are thought to play critical roles in cellular stress responses and to render cells 
stress-resistant. PASS1 is most abundantly expressed in kidney and testis. In addition, two 
different PASS1 transcripts were encountered in kidney cells and alternative splicing has 
been suggested as a causative mechanism (Liu et al., 2000). Another interesting 
observation is that PASS1 expression affects the ability of hsp27 to protect cells against 
shock. This, and the finding that hsp27 levels are elevated in renal tumors as compared to 
normal kidney tissues (Takashi et al., 1997, 1998), turns PASS1 into another interesting 
RCC candidate gene. Another gene of interest is SEMA5B, which is located ~20 kb distal to 
DIRC2 exon 9 (GenBank accession number AK001234; Figure 6.1). Interestingly, two other 
human semaphorin genes, SEMA3F and SEMA3B, map in one of the so called tumor 
suppressor regions on the short arm of chromosome 3 (Roche et al., 1996; Xiang et al., 
1996; Sekido et al., 1996; Van den Berg and Buys, 1997). As such, they have been 
considered as candidate genes involved in tumor development. SEMA5B contains, besides 
the Sema domain (pfam01403) a plexin repeat domain (pfam01437) and four 
thrombospondin type 1 domains (pfam00090). These latter domains are known to bind the 
protein thrombospondin-1 (TSP-1) to transforming growth factor (TGF)β1 (Schultz-Cherry et 
al., 1994; Crawford et al., 1998). A role for TGFβ1 in kidney cancer is suggested since 
elevated levels of TGFβ1 have been observed in patients with renal cell cancer (Wunderlich 
et al., 1998; Junker et al., 2000) and an altered TGFβ1 signaling pathway has been 
observed in kidney tumors (Cardillo et al., 2001). The possible involvement of SEMA5B and 
PASS1 in RCC development through breakpoint related position effects remains to be 
investigated.  
Although the translocation breakpoints of the seven RCC families with constitutional 
chromosome 3 translocations affect different genes, these may affect the same genetic 
pathway to RCC development. From these results, however, no obvious overlap in function 
or genetic pathway could be made between the DIRC2 gene and/or one of its neighbouring 
genes and the other breakpoint genes, such as FHIT, TRC8, or DIRC1. Finally, it also 
remains to be investigated whether additional candidate genes are located in the 2q35 
breakpoint region and whether deregulation of one or more of these genes contributes to 
RCC development. 
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Abstract  
 
Previously, we identified a novel family with renal cell cancer and a t(2;3)(q35;q21). 
Positional cloning of the chromosome 3 breakpoint led to the identification of a novel gene, 
DIRC2, that spans this breakpoint. Here we have characterized the chromosome 2 
breakpoint in detail and found that another novel gene, DIRC3, spans this breakpoint. In 
addition, we found that the first two exons of this gene splice to the second exon of PASS1, 
a gene that maps proximal to DIRC2 on chromosome 3. Fusion transcripts were detected in 
t(2;3)-positive cells. We propose that these fusion transcripts may affect normal PASS1 
expression and concomitant stress response and chromatin remodelling events in kidney 
cells and, as a consequence, contribute to familial renal cancer development. 
 
Introduction  
 
Up till now constitutional chromosome 3 translocations have been described in seven 
familial renal cell carcinoma (RCC) cases in which the translocation and RCC segregated 
concordantly (Cohen et al., 1979; Kovacs et al., 1989; Koolen et al., 1998; Geurts van 
Kessel et al., 1999; Zjaczek et al., 1999; Kanayama et al., 2001). Previous cytogenetic and 
molecular studies on primary conventional RCCs in these families revealed that loss of the 
derivative chromosome containing the short arm of chromosome 3 and somatic mutations in 
the Von Hippel Lindau (VHL) gene are critical steps in RCC development (Li et al., 1993; 
Schmidt et al., 1995; Bodmer et al., 1998; Kanayama et al., 2001; Eleveld et al., 2001; 
Bodmer et al., 2002 a). Recently, however, we detected tumors in RCC families with a 
t(2;3)(q35;q21) translocation and a t(3;6)(q12;q15) translocation in which none of these 
molecular abnormalities were present (Eleveld et al., 2001; Bodmer et al., 2002 a). In order 
to analyse the role of these chromosome 3 translocations in RCC development in further 
detail, the identification of genes at or near the chromosomal breakpoints was initiated by 
several groups. As a result of these efforts, the fragile histidine triad gene (FHIT) and the 
TRC8 gene were found at the chromosome 3 and 8 breakpoints of the t(3;8)(p14;q24) 
translocation, respectively (Ohta et al., 1996; Gemmill et al., 1998). The FHIT gene encodes 
a diadenosine-5’5’’’-P1,P3-triphosphate hydrolase and is interrupted by the translocation 
breakpoint in its 5’ untranslated region. As its complete coding sequence is located at the 
derivative chromosome that is lost in the tumors, normal transcripts are only transcribed 
from the remaining normal chromosome 3 allele (Ohta et al., 1996). TRC8 is related to the 
Drosophila segment polarity gene patched, which encodes a receptor for sonic hedgehog. 
This similarity involves a putative sterol-sensing domain and a second extracellular loop that 
participates in the binding of sonic hedgehog (Gemmill et al., 1998). Several studies 
demonstrated that the patched gene is involved in both hereditary and sporadic basal cell 
carcinomas and medulloblastomas (Hahn et al., 1996; Johnson et al., 1996; Goodrich et al., 
1997). TRC8 is disrupted by the translocation in its sterol-sensing domain. FHIT-TRC8 
fusion transcripts were expressed in translocation-positive lymphoblastoid cells (Gemmill et 
al., 1998). Whether these fusion transcripts also lead to the production of chimeric proteins 
has not been demonstrated yet. Different mechanisms by which these breakpoint-spanning 
genes affect renal cells and, ultimately, lead to tumor development may be at work, 
including: (1) altered expression of FHIT as a result of promoter swapping or position effects 
brought about by the translocation, (2) the formation of fusion protein(s) with transforming 
capacities and (3) haplo-insufficiency resulting from disruption and/or loss of transcription of 
TRC8. More recently, a novel gene, DIRC1 (disrupted in renal cancer 1), was identified at 
the chromosome 2q33 breakpoint of a RCC-related t(2;3)(q33;q21) translocation that was 
found in a Polish family (Druck et al., 2001). The function of this gene is unknown. At the 
chromosome 3 breakpoint of this translocation no genes were identified yet. In the 
constitutional t(2;3)(q35;q21) translocation (Bodmer et al., 1998). Another novel gene, 
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DIRC2, was identified at the 3q21 breakpoint (Bodmer et al., 2002 b). This gene encodes a 
membrane-bound protein that represents a novel member of the major facilitator superfamily 
(MFS) of transporters.  
In our search for fusion genes and transcripts related to the RCC-associated t(2;3)(q35;q21) 
translocation, genomic sequences and gene(s) at the chromosome 2 breakpoint were 
identified. We have used the vectorette polymerase chain reaction (PCR) technique to 
isolate genomic fragments encompassing the 2q35 breakpoint. Subsequent sequence 
analysis of these fragments revealed a novel gene, DIRC3, which is disrupted by the 
breakpoint. In addition, using reverse transcriptase (RT)-PCR and rapid amplification of 
cDNA end (RACE) techniques, we found that this gene fuses to a gene on chromosome 3, 
located proximal to the previously identified chromosome 3 breakpoint gene DIRC2, and to 
different cryptic exons in the breakpoint regions on both chromosomes 2 and 3. Finally, in 
order to determine whether differences in chromosomal breakpoint regions may have 
contributed to the differences in clinical manifestations observed within this family, such as a 
wide range in the age of RCC onset and the development of bladder cancer instead of 
kidney cancer in one of the translocation carriers, we compared the sequences of the 
chimeric breakpoint fragments from several family members. 
 
Material and methods  
 
Patient material and cell lines 
From several family members, both carriers and non-carriers of the t(2;3)(q35;q21) 
translocation, Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines were 
established (Bodmer et al., 1998). From one of these cell lines somatic cell hybrids were 
generated after fusion with thymidine kinase deficient Chinese hamster A3 cells. Four 
hybrids were selected, containing either the normal chromosomes 2 or 3 (A3KE-34B and 
A3KE-1A, respectively), the derivative chromosome 2 (A3KE-11C) or the derivative 
chromosome 3 (A3KE-1D), as described before (Bodmer et al., 1998). In addition, we used 
independent monochromosomal human-rodent somatic cell hybrids containing the normal 
chromosomes 2 or 3 as the only human constituents (Coriell Cell Repositories). DNA and 
RNA were extracted from EBV-cell lines, somatic cell hybrids, and fresh tumor material. 
Informed consent from family members was obtained for inclusion of the materials in this 
study 
 
Vectorette PCR 
After closing in on the chromosome 3 breakpoints (BP1 and BP2) (Bodmer et al., 2002 b) 
genomic walking experiments were performed using the Universal Vectorette System 
(Sigma-Genosys). Genomic DNA of t(2;3)-derived somatic cell hybrids containing the 
derivative chromosome 3 (A3KE-1D) and derivative chromosome 2 (A3KE-11C) were used 
as template. Based on restriction analyses of both breakpoint-regions, suitable restriction 
enzymes were selected. After digestion of 1 µg DNA from somatic cell hybrids A3KE-1D and 
A3KE-11C with these enzymes (Figure 7.1, Sau3AI and PvuII for A3KE-1D, and TaqI for 
A3KE-11C), the resulting DNA fragments were ligated to matching vectorette units for 4 
hours at 16°C. Vectorette libraries obtained from the derivative chromosome 3 were 
amplified using vectorette primers and the following sequence specific primers Vectorette5O 
(5’ GTT CAG AGA AGT TCC CAG TTT CAG C 3’) and Vectorette5N (5’ AGT GTG GAA 
CAC AAA ATG AGG GTG G 3’) (Figure 7.1, primers 1 and 2, respectively), in which the 
latter was used for the nested reaction. For the vectorette library obtained from the 
derivative chromosome 2, the sequence specific primers Vectorette3O (5’ GAA AGT TAG 
CTG GGC ATG GTG GC 3’) and Vectorette3N (5’ GCT GTG AGC CAA GGT CGC ACC A 
3’) (Figure 7.1, primers 8 and 7, respectively) were used. All PCRs were carried out with the 
AdvanTage cDNA PCR kit (Clontech). As a control the A3KE-1A cell line, containing the 
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normal chromosome 3 was included. The different PCR fragments that were obtained were 
cloned and sequenced as described below.  
 
Genomic PCR and sequence analysis 
Genomic PCRs of chimeric translocation breakpoints on both the derivative chromosomes 2 
and 3 (Figure 7.1, BP2,3 and BP1,4, respectively) were performed on DNA isolated from the 
respective somatic cell hybrid cell lines and 2;3 translocation-positive EBV cell lines from 
several carriers in the RCC-family using the primers der(2) for (5’ GAT TTG AAG AGA CCT 
GCT CAT G 3’) and der(2)rev2 (5’ CAG GTG ATG TCT TCT CTT GTG GG 3’) for BP2,3 
(Figure 7.1, primers 5 and 6 respectively), and (2;3)for (5’ GCA GAC ATC TCA TCA ATA 
AG 3’) and (2;3)rev2 (5’ CCA AAC TGC CCA TAT ATA AC 3’) for BP1,4 (Figure 7.1, primers 
3 and 4 respectively). The PCR fragments of the different translocation carriers were cloned 
and sequenced using a Ready Reaction Dye Terminator Cycle sequencing kit (PE 
Biosytems) and an ABI 3700 automated sequencer (PE Biosystems) and, subsequently, 
compared with each other. 
 
RACE and RT-PCR 
To ensure the presence of presumed stop codons in the DIRC3 sequence, RT-PCR was 
performed from exon 10 to 12 on normal placenta-derived cDNA. The primers used in the 
PCR reaction were TTRC2for (5’ GGA CAC CCA CAC AGA TTC AC 3’) in exon 9 and 
TTRC2rev (5’ GAC TTG GTC CAT TGA TTT GTT C 3’) in exon 12. The PCR included 35 
Figure 7.1 Schematic overview of the genomic organization of the translocation breakpoint regions on both
chromosomes 2 and 3 and the derivative chromosomes (der(3) and der(2)). The translocation breakpoints on
chromosome 3 (BP1 and BP2) are located in intron 7 of DIRC2 and coincide with a 3464 kb deletion. The translocation
breakpoints on chromosome 2 (BP3 and BP4) are located in intron 2 of DIRC3 and coincide with a 34 bp deletion. On
the derivative chromosomes the primers are indicated that were used for vectorette PCR (primers 1 and 2 on the
der(3) and primers 7 and 8 on the der(2)) and for analysis of the chimeric breakpoints (primers 3 and 4 on the der(3)
and primers 5 and 6 on the der(2)). BP1,4 fuses the proximal part of the 3q arm to the distal part of the 2q arm on
der(3) and BP2,3 fuses the distal part of the 3q arm to the proximal part of the 2q arm on der(2). The centromeric (cen)
and telomeric (tel) directions are indicated. 
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cycles of 30 sec at 94°C, 30 sec at 55°C, and 3 min at 72°C. The PCR products were 
separated by gel-electrophoresis, isolated, cloned and sequenced as described above.  
3’ RACE products for both DIRC2 and DIRC3 were generated from translocation-positive 
EBV cells, translocation-positive tumor tissue (Bodmer et al., 1998), and translocation-
negative normal kidney tissue (Clontech). The reverse transcriptase reaction was performed 
using 5 µg of RNA, Superscript-II (Life Sciences), and the primer AP2 (5’ AAG GAT CCG 
TCG ACA TCT TTT TTT TTT TTT TTT T 3’). The primers used for the subsequent PCR 
reaction, in combination with AP2, were D2for1 (5’ TTC GTT CAG GGC CTG GT 3’) and 
D2for2 (5’ TGG AGC AGC GAA GAG GA 3’) for the DIRC2 gene and D3for1 (5’ AGT CCC 
TGT CAG CAG CA 3’) and D3for2 (5’ TTC CAG GGA GGC TTA CGA 3’) for the DIRC3 
gene. To increase the specificity of the product, a second nested PCR was performed with 
the UAP2 primer (5’ CUA CUA CUA CUA AAG GAT CCG TCG ACA TC 3’) and the D2forN 
(5’ ACA TCG CGC TGC TCG T 3’) for the DIRC2 gene and the D3forN primer (5’ TCT GGG 
TGC TGA GCT G 3’) for the DIRC3 gene. The PCR reactions were performed under 
standard conditions (see above) using an annealing temperature of 55°C. 
To reveal whether the disrupted DIRC3 gene on chromosome 2 fuses to the PASS1 gene, 
that is located proximal to the breakpoint gene DIRC2 on chromosome 3 and has the same 
transcription orientation on the translocation derivative chromosome 3 as DIRC3, RT-PCR 
was performed on RNA extracted from, again, translocation-positive EBV cells, 
translocation-positive tumor tissue, and translocation-negative normal kidney tissue 
(Clontech). In the first PCR round, the forward primer in the first exon of the DIRC3 gene, 
FTPex1F (5’ ATG ATG GTG ATG GAA GGA GTC T 3’), was used in combination with a 
reverse primer in the third exon of the PASS1 gene, FTPex3R (5’ AGT CAG CAT AAG CCC 
AGA ACT T 3’). In the second nested PCR reaction, the forward primer in the second exon 
of the DIRC3 gene, FTPex2F (5’ ATG GAA ATA TCA GTG GGC TGG A 3’), was used in 
combination with the reverse primer in the second exon of the PASS1 gene, FTPex2R (5’ 
AAT CGT ATC TGC TTG CCA TGA A 3’). 
 
Results 
 
Isolation of chimeric 2;3 translocation breakpoint fragments 
In a previous study we reported the isolation of the chromosome 3 breakpoint of the familial 
(2;3)(q35;q21) translocation and the identification of a gene that is disrupted by this 
breakpoint, DIRC2 (Bodmer et al., 2002 b; GenBank accession number AK027690). The 
chromosome 3 breakpoint maps in between exons 7 and 8 of DIRC2 and coincides with a 
~4 kb intronic deletion (Figure 7.1, BP1 and BP2). To evaluate whether the chromosome 2 
breakpoint also disrupts a gene, we set out to identify the genomic sequence of this 
chromosomal region using vectorette-PCR. For this purpose, two primer-sets were selected 
at ~500 bp up- and downstream of both chromosome 3 breakpoints (Figure 7.1, primers 1 
and 2 at BP1 and primers 7 and 8 at BP2). Several amplified fragments were obtained from 
somatic cell hybrids containing both derivative chromosomes (A3KE-11C and A3KE-1D, 
respectively) and compared with fragments similarly obtained from a normal chromosome 3-
containing somatic cell hybrid (A3KE-1A). Bands that were generated from the derivative 
chromosomes but not from the normal chromosome 3 were isolated, cloned and sequenced. 
Subsequent database searches and sequence comparisons revealed a 800 bp Sau3AI 
fragment that was unique for the derivative chromosome 3 (Figure 7.1, BP1,4). About 300 
bp from this fragment was recognized as a sequence derived from the chromosome 3 
breakpoint region. The other ∼500 bp showed homology to sequence stretches present in 
two sequenced bacterial artificial chromosome (BAC) clones RP1124P2 (GenBank 
accession number AC022195) and RP11295A19 (GenBank accession number AC011235) 
located at 2q35. PCR on DNA extracted from lymphocytes of a translocation carrier (t(2;3)+) 
and a non-translocation carrier (t(2;3)-), two independent monochromosomal somatic cell 
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hybrids containing the human chromosomes 2 (m2) and 3 (m3) as the only human 
constituents, the translocation-derived somatic cell hybrid panel (A3KE-34B, A3KE-1A, 
A3KE-1D, and A3KE-11C), and Chinese hamster A3 cells with primers corresponding to 
both sites of the chromosomal breakpoints (Figure 7.1, primer 3 and 4 for BP1,4 and primers 
5 and 6 for BP2,3) confirmed that these chromosome 2 BACs were breakpoint-spanning. As 
shown in Figure 7.2, a ~1.2 kb fragment could be generated with one primer-set (primers 5 
and 6) from lymphocytes of a translocation-carrier (t(2;3)+) and the derivative chromosome 
2-positive hybrid (A3KE-11C), but not from the other cell lines, indicating that this product 
must indeed be the 2;3 chimeric fragment present on the derivative chromosome 2 (Figure 
7.1, BP2,3). With the second primer-set (primers 3 and 4) a ~500 bp fragment was 
generated from lymphocytes of a translocation-carrier (t(2;3)+) and the derivative 
chromosome 3-positive hybrid (A3KE-1D), but not from the other cell lines, indicating that 
this product must be the 2;3 chimeric fragment present on the derivative chromosome 3 
(Figure 7.1, BP1,4). Sequence analysis of both chimeric breakpoint fragments confirmed 
these assumptions and, in addition, revealed that the exact size of the chromosome 3 
deletion that we observed previously and estimated to be about 4 kb (Bodmer et al., 2002 
b), exactly measures 3464 bp (Figure 7.1, between BP1 to BP2). In addition, these analyses 
revealed that the breakpoint on chromosome 2 coincides with a deletion of 34 bp (Figure 
7.1, between BP3 to BP 4). 
 
Disruption of a novel gene, DIRC3, by the chromosome 2 breakpoint 
The Human Genome Project Working Draft (UCSC) was used to identify expressed 
sequence tags (ESTs) and predicted genes within the breakpoint-spanning BAC clones 
RP1124P2 and RP11295A19 on chromosome 2. One full-length cDNA FLJ14199 (GenBank 
accession number AK024261) was found encompassing 12 exons, of which the putative 
boundaries are depicted in Table 7.1. The breakpoint was found to map in between the 
exons 2 and 3 and, therefore, to disrupt this gene (Figure 7.1). Database searches revealed 
several matching ESTs from UniGene cluster Hs. 14479 to the 3’end of the cDNA. From the 
5’end, two matching ESTs were found (GenBank accession numbers AU131516 and 
Figure 7.2 PCR analyses of the chimeric breakpoint fragments (BP1,4 and BP2,3) in the t(2;3)(q35;q21)-derived panel
of somatic cell hybrids and controls. The lanes marked by t(2;3)+ and t(2;3)- contain translocation-positive and –
negative lymphocytes, respectively. M2 and m3 represent independent monochromosomal human/rodent somatic cell
hybrids containing a normal chromosome 2 and 3, respectively. A3KE-34B, A3KE-1A, A3KE-1D, and A3KE-11C are
translocation-derived human/hamster somatic cell hybrids containing the normal chromosome 2, normal chromosome
3, der(3), and der(2), respectively. A3 is a hamster control. The sizes of the fragments are indicated in kilobases (kb).  
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BG562780). The total length of the predicted transcript is 3071 bp. The last exon contains a 
consensus polyadenylation signal sequence (AGTAAA) at 20 nucleotides upstream of the 
poly(A) addition site. Striking is the high density of stop codons in all three reading frames of 
this cDNA (Figure 7.3). To check whether the presumed stop codons might be due 
sequence errors in the database we amplified 1 kb of the 3’-end of this gene, including the 
exons 10 to 12, from normal placenta-derived RNA by RT-PCR and compared this 
sequence with database sequences. However, no sequence differences were observed 
indicating that from this gene, most likely, a noncoding RNA is transcribed. This gene is 
novel and, therefore, designated DIRC3 (disrupted in renal cancer 3).  
 
Table 7.1 Genomic organization of the DIRC3 gene. 
 
Exon Exon 5’splice site Exon 3’splice site Exon Intron 
  size (bp)  size (kb) 
 
1   CATGGACCTG gtgaggag 320 121.054 
2 ttgcaag GAGAGAAAAC AATTTGACGA gtaagtta 178 44.284 
3 ccttctag TCCTCTATTC CAAAGTGGAG gtgacaga 359 0.735 
4 ctttctag ATGGTTGTCC AAAACACCTG gtgagttc 99 5.449 
5 tatggcag CCAAGACCC TGTCACATCAG gtaaggag 83 0.604 
6 cttcctag AATCTGAAGG CATTTTACAG gtatgaaa 196 1.070 
7 gtttttag ATTGTCTTCT AACCACCCAG gtaagata 221 97.159 
8 taatgcag GTTAATGTGG AGTCAAGAAG gtaatgta 156 2.026 
9 tttcacag GAGTCTTGTA GAAAAATAAG gtatggtg 125 6.668 
10 acttttag GTGCATACGC ACACTTTGCG gtatgtga 258 718 
11 tatataag GCTCTATCTT CAGTCTTCAG gtgagaaa 236 33.102 
12 tttttcag AAATTAAGAA   839 
 
Uppercase and lowercase letters indicate exon and intron sequences, respectively. The preliminary exon-intron boundaries are based on 
comparison of cDNA sequence to genomic sequences and the consensus splice site sequences. 
 
Different gene segments were predicted within the intronic sequences of DIRC3 and directly 
up- and downstream from this gene. Till now, however, no ESTs or predicted proteins 
homologies were found in the respective databases. Furthermore, several unspliced single 
ESTs were found in different introns of DIRC3. However, most of them contain repeats and, 
most likely, represents genomic contaminants in the EST database. Known genes that 
directly flank DIRC3 are the Transition Protein 1 (TNP1) at the proximal site and Tensin 
(TNS) at the distal site. TNP1 maps at approximately ∼400 bp distance and TNS at ∼300 bp 
distance from DIRC3 (Figure 7.4A).  
 
 
 
Figure 7.3 Reading frame analysis of the DIRC3 cDNA. Open triangles and vertical lines indicate the relative positions
of the translocation initiation and termination codons (TGA, TAA, and TAG), respectively, for each of the three reading
frames (+1, +2, +3). At the bottom of the figure the positions of the exons 1-12 are indicated, schematically.  
+1
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Expression of DIRC3-PASS1 fusion transcripts  
The breakpoint-spanning genes, DIRC2 and DIRC3, are transcribed in opposite directions 
(Figure 7.4) and, therefore, no functional fusion transcripts are predicted from these genes. 
3’ RACE experiments on both translocation-positive tumor material and lymphoblastoid cells 
generated different PCR products using DIRC3-specific primers. Sequence analyses of 
these PCR products revealed three different DIRC3 gene fusion products, among which 
aberrantly spliced RNA products between different cryptic gene fragments located in the 
intronic sequences of the DIRC3 gene on chromosome 2 and the DIRC2 gene on 
chromosome 3. A gene located directly upstream from DIRC2 is the human homologue of 
PASS1 (Figure 7.4B; Bodmer et al., 2002 b). The PASS1 gene contains 9 exons of which 
the putative boundaries are depicted in Table 7.2 (GenBank accession number BC011897). 
This gene encodes a predicted peptide of 488 amino acids (GenPept accession number 
AAH11897) that is most abundantly expressed in the kidney (Liu et al., 2000). As PASS1 
and DIRC3 are transcribed in the same direction from the same DNA strand on the 
derivative chromosome 3, we reasoned that a fusion transcript might be formed. To test this 
option, forward primers were generated within the first two exons of DIRC3 (FTPex1for and 
FTPex2for) and reverse primers within the second and third exon of PASS1 (FTPex2rev and 
FTPex3rev). RT-PCR was performed on RNA isolated from normal kidney tissue and a 
t(2;3)-positive lymphoblastoid cell line. One RT-PCR product of ~300 bp was generated with 
the primer-set FTPex2for-FTPex2rev from the t(2;3)-positive lymphoblastoid cell line, 
whereas no such products were generated from the normal kidney tissue. Subsequent 
cloning and sequencing of this RT-PCR fragment showed the predicted fusion between 
DIRC3 and PASS1, in which the first coding exon of the PASS1 gene is replaced by the first 
two exons of the DIRC3 gene (Figure 7.5A). When using the first ATG initiation codon 
(nucleotide 243 of GenBank accession number BC011897), a truncated PASS1 protein of 
451 amino acids lacking the first 37 amino acids could be translated from this chimeric 
transcript (Figure 7.5B). This truncated protein still retains the PASS1 JmJC domain and 
Hsp27 interacting region (HIR), which are considered to be crucial for its function (Liu et al., 
2000).  
Figure 7.4 Diagram showing the relative positions in kilobase (kb) and transcriptional directions of the genes at/near
the chromosome 2 and 3 (A and B, respectively) breakpoints (BP3,4 and BP1,2, respectively). The breakpoint-
spanning genes DIRC2 and DIRC3 are indicated in dark grey, whereas its neighbouring genes are indicated in light
grey. 
A. Genes at/near the breakpoint on chromosome 2
B. Genes at/near the breakpoint on chromosome 3
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Identical translocation breakpoints in different translocation carriers of the RCC 
family 
In the family that we studied, a wide range in the age of RCC onset was observed among 
the translocation carriers (from 30 years in patient III:13 to 68 years in patient II:1; Koolen et 
al., 1998; Bodmer et al., 2001). In addition, one family member that carries the translocation 
developed bladder cancer (II:5, Koolen et al., 1998). One explanation for these phenotypic 
differences could be the occurrence of minor differences in chromosomal breakpoints 
resulting from erroneous meiotic recombination events. Therefore, the translocation 
breakpoints (BP1,4 and BP2,3) were analysed in lymphocytes of nine different translocation 
carriers in this family (Koolen et al., 1998). Two of these carriers developed renal cancer, 
one developed bladder cancer, and six did not develop any cancer yet. In all cases the 
chromosome 3 breakpoints coincided with the previously observed 3464 bp deletion and the 
chromosome 2 breakpoints with the 34 bp deletion. No differences could be detected by 
sequence analyses in any of these breakpoint fragments.  
 
Table 7.2 Genomic organization of the human PASS1 gene. 
  
Exon Exon 5’splice site Exon 3’splice site Exon Intron 
  size (bp)  size (kb) 
 
1    GGGGAGGAAG gtaggtgc  182 15.717 
2  ctttctag GTGAACATGT ATGAGCACAG gtatgact 186 8.848 
3  cattgcag TTCCTCAGTT TCTTTTCCAG gtaagtca 182 9.346 
4  caaaacag GATGTGAAAT TACAAGGAAG gtaatgtg 137 ? 
5  ? GAAACGATGG ATCCAACTAG ? 54 ? 
6  ? AATCCCTTAT CCCAGGACAG gtaatagg 118 2.586 
7  g/tttttcag GTTCTCTTTG GATTGAACTG gtactttt 84 ? 
8  taattcag GAAGAGGATC CCCCACTGAG gtaggcgg 111 127 
9  tcccttag GTTGAGGAAA   612  
 
Uppercase and lowercase letters indicate exon and intron sequences, respectively. The preliminary exon-intron boundaries are based on 
comparison of cDNA sequence to genomic sequences and the consensus splice site sequences. 
 
Discussion  
 
A constitutional translocation was identified between the chromosomes 2 and 3 in a family 
with RCC. Cytogenetic and molecular investigation of renal tumors isolated from different 
members of this family revealed that genetic alterations related to this translocation may 
play important roles in RCC development (Bodmer et al., 1998; Bodmer et al., 2002 a). 
Previously, we have identified a novel gene, DIRC2, that is disrupted by the 3q21 breakpoint 
and which encodes a new member of the MFS superfamily of transporters (Bodmer et al., 
2002 b). It was suggested that disruption of this gene might lead to haplo-insufficiency and, 
as such, to a stress condition in proximal renal epithelial cells resulting in dysplasia and/or 
genomic instability. We also suggested that other translocation-related mechanisms may be 
at work, such as the formation of fusion transcripts. Therefore, we set out to analyse the 
translocation breakpoint at 2q35 in detail. Via vectorette-PCR we were able to isolate a 
chimeric 2;3 translocation fragment present on the derivative chromosome 3. Analysis of this 
fragment revealed that a novel gene, designated DIRC3, is disrupted by the 2q35 
breakpoint. This gene contains 12 exons and the breakpoint maps between the exons 2 and 
3. The full- length cDNA sequence revealed a high density of stop codons and an extensive 
open reading frame could not be predicted. The gene transcribes a spliced and 
polyadenylated RNA molecule (GenBank accession number AK024261). The most likely 
option is that this gene product functions as a noncoding RNA. Other genes known to 
express noncoding RNAs include H19, Xist, His-1, bic, BORG, SRA and DD3 (Brannan et 
al., 1990; Brockhoff et al., 1992; Askew et al., 1994; Velleca et al., 1994; Tam et al., 1997; 
Takeda et al., 1998; Lanz et al., 1999; Bussemakers et al., 1999). Some of these genes 
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have been implicated in tumor development. DD3, for example, is a gene that is highly 
expressed in prostate cancer and, therefore, suggested to play a role in tumor development 
(Bussemakers et al., 1999). H19 is thought to have tumor suppressor activity (Hao et al., 
1993). Also His-1 and bic, both cloned from a common retroviral insertion site in murine 
leukemia virus-induced myeloid leukemia and in avian leukosis virus-induced B-cell 
lymphoma, respectively, have been implicated in growth control and oncogenesis (Askew et 
al., 1994; Tam et al., 1997). Similarly, a role for DIRC3 in tumor development may be 
suggested. We were able to detect DIRC3 expression in placenta by RT-PCR, but no 
signals were observed on Northern blots containing RNA from multiple adult and embryonic 
tissues (data not shown), which conforms to the presence of only a few corresponding ESTs 
in public databases.  
Subsequent 3’RACE and RT-PCR analyses revealed the presence of four DIRC3 gene 
fusions, among which three representing aberrant splicings to different cryptic gene 
segments located in the intronic sequences of the DIRC3 gene on chromosome 2 and the 
DIRC2 gene on chromosome 3. In addition, a fusion between DIRC3 and PASS1, a kidney-
related gene located ~80 kb proximal to the 3q21 breakpoint (Bodmer et al., 2002 b), was 
found. As the first coding exon of PASS1 is replaced by the first two exons of DIRC3, the 
DIRC3-PASS1 fusion transcript most likely encodes a truncated PASS1 protein starting from 
an internal translation initiation site embedded in a strong Kozak consensus sequence in the 
PASS1 sequence (Figure 7.5B). The JmjC and HIR domains are retained in this putative 
truncated protein. JmjC domains have been found in metalloenzymes, which adopt the cupin 
fold and are thought to be involved in the regulation of chromatin remodelling 
(SMART00558). The HIR domain acts as a region that may interact with the heat-shock 
Figure 7.5 Diagram showing the PASS1 and DIRC3 (fusion) genes (A) and predicted proteins (B). In the DIRC3-
PASS1 fusion transcript the first exon of the PASS1 gene is replaced by the first two exons of the DIRC3 gene. This
fusion transcript may encode a truncated PASS1 protein that, like the normal PASS1 protein, contains the JmjC and
Hsp27 interacting region (HIR) domains, which are thought to be critical for PASS1 function. 
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protein Hsp27 (Liu et al., 2000). Further In vitro transcription and translation studies are 
required to reveal the exact nature of the PASS1 protein resulting from this gene fusion. 
Kidney cells normally expresses two different PASS1 transcripts of 1.8 and 1.4 kb, 
respectively, of which the latter appears to be kidney-specific. The presence of this smaller 
transcript suggests kidney-related alternative splicing (Liu et al., 2000). The DIRC3-PASS1 
fusion gene is transcribed from the derivative chromosome 3, which gets lost in most of the 
tumors that we studied (Bodmer et al., 1998; Bodmer et al., 2002 a). Interestingly, the FHIT-
TRC8 transcript that results from the RCC-associated 3;8 translocation is also transcribed 
from the derivative chromosome that, later on, is lost in the tumors. It may, therefore, be 
suggested that the expression of these fusion transcripts may affect renal cells in early 
stages of tumor development, possibly, in a dominant-negative fashion. Expression of 
DIRC3-PASS1, for example, may distort the ratio between the two normal PASS1 
transcripts in renal cells and thus affect its kidney-related function. Monitoring of putative 
differences in expression between the two alternative PASS1 transcripts in both normal 
kidney tissue and tumor tissue of a translocation carrier in this RCC family may underscore 
this notion. Finally, RACE experiments failed to reveal fusion transcripts from the DIRC2 
gene. This result is in agreement with the previously observed lack of such transcripts 
through Northern blot analysis of translocation-positive EBV cell lines and tumor tissues 
(Bodmer et al., 2002 b). 
Other neighbouring genes within 1 Mb distance from DIRC3 are TNP1 and TNS (Figure 
7.4A). The most interesting one of these two genes is TNS, located at ~400 kb distal from 
the breakpoint. This gene is expressed at high levels in the kidney and studies in Tns-null 
mice revealed multiple cysts in their kidneys. These cysts lead to kidney degeneration and 
renal failure, indicating that the TNS gene is critical for a normal kidney function (Lo et al., 
1997). TNS is a focal adhesion molecule that binds to actin filaments and interacts with 
phosphotyrosine-containing proteins. It includes a region that is also encountered in the 
tumor suppressor PTEN (Chen et al., 2000). A role for the TNS gene in tumor development 
was also suggested, as a reduced expression has been observed in prostate and breast 
cancer cell lines (Chen et al., 2000). To evaluate whether any of these genes, or the 
neighbouring genes identified in the chromosome 3 breakpoint region (Bodmer et al.,2002 
b), contribute to the development of RCCs expression studies in renal tumors and normal 
kidney tissues are currently in progress.  
Finally, we also analysed the genomic translocation breakpoints from different translocation 
carriers in this RCC family. The rationale therefore was that subtle genomic differences 
might explain the phenotypic differences that were observed between the different 
translocation carriers in this RCC family, such as the wide range in age of onset and the 
development bladder cancer in one patient (Koolen et al., 1998; Bodmer et al., 2002 a). Also 
in other RCC families with chromosome 3 translocations such phenotypic differences were 
noted. Non-RCC malignancies were also observed in two translocation carriers of the RCC 
family with the constitutional t(3;8)(p14;q24) translocation and in two family members of the 
RCC family with the constitutional t(1;3)(q32;q13.3) translocation, although it is not known 
whether these latter patients were also translocation carriers (Li et al., 1993; Kanayama et 
al., 2001). Phenotypic differences between translocation carriers could be caused by 
deletions and/or duplications generated by incomplete pairing and unequal crossing over of 
the respective derivative chromosomes at the breakpoints during meiotic division (Smeets et 
al., 1992). Molecular cloning and characterization revealed that the breakpoints on the 
chromosomes 2 and 3 of the 2;3 translocation coincided with deletions of 34 bp and 3464 
bp, respectively.  Analyses of the chimeric breakpoint fragments of different translocation 
carriers in this RCC family, however, revealed that they were all identical.  
Taken together, we have isolated the chromosome 2 breakpoint of a familial translocation 
that is associated with the development of RCCs and found that a novel gene, DIRC3, is 
disrupted by the translocation. In addition, we found that the first two exons of DIRC3 form 
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fusion transcripts with PASS1, a gene implicated in kidney function (Liu et al., 2000). We 
speculate that, next to the previously suggested haplo-insufficiency of DIRC2, DIRC3-
PASS1 fusion transcripts may contribute to familial RCC development via dominant-negative 
effects on PASS1 expression and concomitant cellular stress response and/or chromatin 
remodelling events. Currently, we are investigating these options in further detail. 
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Abstract 
 
Recently, we described several relatives within one renal cell cancer (RCC) family sharing a 
constitutional t(2;3)(q35;q21) chromosomal translocation. Based on molecular studies on 
several independent primary tumors in this family, a causative role for this translocation in 
tumor development was suggested. Subsequent positional cloning of the 3q21 chromosomal 
breakpoint revealed that this breakpoint disrupts a novel gene, DIRC2 (disrupted in renal 
Cancer 2). This gene encodes an evolutionary conserved transmembrane protein and 
represents a novel member of the MFS superfamily of transporters. To evaluate whether 
DIRC2, is also targeted in sporadic RCC cases with cytogenetically defined 3q21 
breakpoints, fluorescence in situ hybridization (FISH) analysis was performed on metaphase 
spreads and/or interphase nuclei of 12 primary sporadic RCCs using genomic clones from a 
3q21 breakpoint-spanning contig as probes. Three breakpoints were mapped proximal to 
the familial breakpoint and nine breakpoints were mapped distal to this breakpoint. Two of 
the latter breakpoints were mapped in the contig within 1 Mb distance from the familial 
breakpoint. Since these clustered 3q21 breakpoints do not coincide with the familial 3q21 
breakpoint they, most likely, affect gene(s) distinct from DIRC2. 
 
Introduction  
 
Previously, we identified a family with an increased incidence in the development of clear 
cell renal cell cancer (RCC) and a constitutional chromosomal translocation t(2;3)(q35;q21) 
(Koolen et al., 1998). All RCC patients in this family were carriers of the translocation, thus 
suggesting a causal relationship. Subsequent cytogenetic and molecular studies of primary 
tumors in this family showed that loss of the derivative chromosome 3, containing the short 
arm of chromosome 3, and somatic mutations in the remaining Von Hippel-Lindau (VHL) 
allele are critical steps in the development of these tumors (Bodmer et al., 1998). However, 
in a recent study we found that none of these molecular abnormalities were present in at 
least one early stage tumor in this family. A similar observation was made in several tumor 
biopsies in another RCC-family with a t(3;6)(q12;q15) translocation (Eleveld et al., 2001). 
These findings led to the conclusion that another initiating event may precede the two critical 
steps mentioned above, and that direct deregulation or disruption of a gene(s) at/near the 
translocation breakpoint could act as such (Eleveld et al., 2001; Bodmer et al., 2002 a). 
Through positional cloning of the 3q21 breakpoint a novel gene, DIRC2, was recently 
identified. This gene consists of 9 exons, codes for a 2.1 kb mRNA and is expressed in 
proximal cells of the nephron, the site from which clear cell RCCs are thought to originate 
(Bodmer et al., 2002 b). The first seven exons of this gene were located proximal to the 
translocation breakpoint and the remaining two exons were located distal to this breakpoint. 
DIRC2 is predicted to encode a multimembrane-spanning protein that represents a new 
member of the major facilitator superfamily (MFS) of transporters. Since we were unable to 
detect any fusion and/or truncated forms of DIRC2, we speculated that disruption of this 
transporter leads to haplo-insufficiency and, as such, may result in dysplasia as a first step 
in the process of malignant transformation (Bodmer et al., 2002 b). Additional genes with a 
possible functional relevance in the context of renal cell cancer development were also 
identified near this 3q21 breakpoint (Bodmer et al., 2002 b). Deregulation of one or more of 
these genes by a position effect of the breakpoint could also play a role in tumor 
development (Kleinjan and van Heyningen, 1998).  
Loss of heterozygosity (LOH) of sequences derived from the short arm of chromosome 3 is 
a frequent molecular event occurring in clear cell/nonpapillary RCCs. Three regions on the 
short arm of chromosome 3 (3p25, 3p21.3, and 3p12-p14) are affected most frequently 
(Kovacs, 1993; Van den Berg et al., 1997; Kok et al., 1997). LOH of these regions has also 
been noted in several other tumor types including lung, bladder, cervix, head and neck, 
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breast and ovary (Kok et al., 1997; Todd et al., 1997) and supports the hypothesis that these 
regions may harbour tumor suppressor genes. The identification of the VHL tumor 
suppressor gene at 3p25 (Latif et al., 1993) and the fact that this gene was frequently 
mutated in sporadic RCCs, is in good agreement with the observed tumor-related LOH at 
3p25. Different candidate tumor suppressor genes have also been identified in the other 3p 
regions, but their exact role(s) in cancer development remains to be established. The long 
arm of chromosome 3 is less frequently involved in RCC related chromosomal 
abnormalities. Of all the translocation/inversion breakpoints encountered in sporadic RCCs 
and described in the fifth edition of the ‘Catalogue of chromosome aberrations in cancer’ 
(Mitelman, 1994), 23% occurred in the 3q arm with a clustering in two defined regions, 3q13-
21 and 3q11-12 (Van den Berg et al., 1993; Balzarini et al., 1998 and references therein; 
Dijkhuizen et al., 1998). In addition, besides the t(2;3)-positive family mentioned above, 
three other familial RCC cases have been reported with chromosome 3 translocation 
breakpoints located within these 3q cluster regions (Zajaczek et al., 1999; Geurts van 
Kessel et al., 1999; Kanayama et al., 2001). Other tumor types with recurring chromosomal 
abnormalities in these regions include various leukemias (Rynditch et al., 1997) and lung 
cancers (Dennis et al., 1999). Together, these observations support the suggestion that 
these chromosomal regions may harbour genes that are associated with tumor 
development.  
Here we describe the mapping of chromosome breakpoints at 3q13-q22 in 12 sporadic clear 
cell RCCs relative to the familial t(2;3)-associated breakpoint in 3q21 by fluorescence in situ 
hybridization (FISH) using genomic clones from this region as probes. 
 
Table 8.1 Karyotypes of 12 sporadic renal cell carcinomas with breakpoints in the 3q13-22 region 
 
Tumor  Karyotype* Reference 
 
1 43~44,XY,-3,-6,del(10)(q22-q26),der(22)t(3;22)(q13;p13) Van den Berg et al. 1993 
2 47,XY,der(2)t(2;3)(q32;q22),-3,+7,+13 Van den Berg et al. 1993 
3 41~44,X,-X,del(1)(p34),+del(1)(p13),der(2)t(2;3)(q32;q21),-3,-8,-14,  Van den Berg et al. 1993 
 -18,mar1  
4 42~47,XX,+der(2)t(2;3)(q35;q21),-3,-14,+16 Dijkhuizen et al. 1998 
5 48,XX,-3,+5,der(10)t(3;10)(q21;q22),+21,+mar Balzarini et al. 1998 
6 45,XY,-3,der(16)t(3;16)(q21;q24) Balzarini et al. 1998 
7 46,XY,der(3)?del(3)(q21) Balzarini et al. 1998 
8 44,X,-Y,der(2)t(2;3)(q35;q21),-3 unpublished 
9 45,XX,-3,der(5)t(3;5)(q13;p15) unpublished 
10 46,XX,der(3)del(3)(p14)t(3;5)(q21;q22) unpublished 
11 46,XY,t(3;7;14)(q13;q31;q34) unpublished 
12 49,X,-Y,+7,+7,der(11)t(3;11)(q21;p15),+16,+17 unpublished 
 
*chromosome 3 breakpoints are marked in boldface  
 
Material and methods  
 
Tumor samples, tissue cultures and chromosome preparations 
The RCC samples used in this study were collected at the Centre for Human Genetics in 
Leuven and the Department of Medical Genetics in Groningen. Histologically all tumors, 
except one, were classified as belonging to the non-papillary/clear cell subtype. 
Chromosome preparations were obtained after short term culture of the primary RCCs in 
RPMI-1640 medium supplemented with fetal calf serum and antibiotics. Cytogenetic 
analysis was carried out using standard procedures and the resulting karyotypes were 
described according to the International System for Cytogenetic Nomenclature (ISCN, 
1995). 
 
FISH analysis 
For mapping of the chromosome 3 breakpoints in sporadic RCCs relative to the familial 
RCC-associated breakpoint at 3q21, we used two cosmids (L1951 and O156) and one YAC 
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Figure 8.1 Schematic representation of the 3q21breakpoint-
region and the relative positions of cosmids L1951 and O156 
and YAC 790d8 with respect to the familial t(2;3)(q35;q21) and 
sporadic renal cancer associated breakpoints (1-12) within this 
region. The genes in the breakpoint region and their respective 
transcriptional directions are also schematically shown (left). 
Cen
Tel
L1951
O156
790d8
t(2;3) Breakpoint familial 
RCC case
Breakpoints sporadic renal 
tumours
11 
1, 6
2, 3
4, 7, 8, 12
5, 9, 10
YAC/cosmids/genes in 
3q21 contig
SEMA5B
(KIAA1445)
PASS1
DIRC2
(CEPH 790d8) derived from a genomic contig spanning the familial translocation breakpoint 
(Bodmer et al., 2002 b) as probes. A centromere 3-specific probe was co-hybridized as a 
reference. The experimental procedures used for FISH were essentially as described before 
(Eleveld et al., 2001; Suijkerbuijk et al., 1994). Briefly, the cosmid and YAC probes were 
labelled with Cy3dCTP (Amersham) and the centromere probe with SpectrumGreen (Vysis) 
using a nick translation kit (GibcoBRL). Before hybridization, the probes were denatured and 
competed with a 40-fold excess of Cot-1 DNA (GibcoBRL) to block repeat sequences 
present in these genomic fragments. Metaphase spreads were denatured in 70% 
formamide/2 x SSC at 72°C for 2 minutes and, subsequently, hybridized overnight at 37°C in 
a Hybaid hybridization station (Hybaid). SpectrumGreen and Cy3 signals were detected 
directly after post hybridization washings for 1 minute in 0.4 x SSC/0.05% Tween-20 at 68ºC 
and mounting of the slides in vectashield medium containing 1.5 µg/ml 4,6-diamino-2-
phenylindole (DAPI, Vector Laboratories). The slides were analysed using the Oncor 
Imaging software package (Oncor Imaging). 
 
Results 
 
Through a positional cloning effort, the 
familial t(2;3)(q35;q21)-associated 
breakpoint 3q21 was isolated and a 
novel gene, DIRC2, spanning this 
breakpoint was identified (Bodmer et 
al., 2002 b). To evaluate whether this 
same gene is also targeted in sporadic 
RCCs with cytogenetically defined 
breakpoints in the 3q21 region, we set 
out to analyse 12 such tumors. The 
karyotypes of these tumors are listed in 
Table 8.1. All tumors were of the clear 
cell subtype with the exception of one 
(tumor 12) which was of the papillary 
subtype. Most of the tumors contained 
unbalanced chromosome 3 
translocations in which the derivative 
chromosome 3, which contains the 
short arm of chromosome 3, was lost. 
Although the familial translocation 
breakpoint was cytogenetically defined 
in 3q21, four tumors with their 
chromosome 3 breakpoints assigned to 
3q13 (tumors 1, 9, and 11) or 3q22 
(tumor 2) were also included in this 
study since the quality of tumor-derived 
metaphase spreads does not always 
allow for precise breakpoint 
determinations. 
For positional cloning of the familial 
t(2;3) translocation a breakpoint 
spanning YAC/PAC/cosmid contig was 
established (Bodmer et al., 2002 b). 
Two cosmids, L1951 and O156, and 
one YAC, 790d8 from this contig were 
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selected for this study (Figure 8.1). The two cosmids flank a breakpoint-spanning PAC 
832H17 (L1951 proximal and O156 distal) thus defining a region of approximately 200 kb 
around the familial t(2;3) breakpoint. YAC 790d8 is located approximately 1 Mb distal from 
the breakpoint on 3q (Figure 8.1). FISH analyses were performed on metaphase spreads or 
interphase nuclei derived from short-term cultures of the primary sporadic RCCs. The 
cosmid/YAC probes were visualized in red 
and, concomitantly, the chromosome 3 
centromere in green (Figure 8.2). The most 
distant cosmid L1951 and YAC 790d8 probes 
were tested on all tumor samples. Cosmid 
O156 was only tested on tumors of which the 
breakpoint was found to be mapping in 
between L1951 and 790d8. In Figure 8.2A-C, a 
typical example of a FISH experiment (on 
tumor sample 2) is shown with both cosmids 
and the YAC as probes. Only one signal was 
observed for both L1951 and O156 together 
with a centromere 3 signal on the normal 
chromosome 3 (Figure 8.2A and 8.2B, 
respectively). A second signal was not 
detected for these cosmids and, hence, must 
be located on the derivative chromosome 3 
that is lost in the tumor (see Table 8.1, 
karyotype), indicating that the breakpoint of 
this tumor is located distal from O156 (Figure 
8.1 and Table 8.2). For YAC 790d8, two 
signals were observed on both the normal 
chromosome 3 (together with the centromere 3 
probe) and the derivative chromosome 2 
(Figure 8.2C). Thus, the breakpoint mapped 
proximal from this YAC (Figure 8.1 and Table 
8.2). Another interpretation may be that the 
breakpoint of this tumor maps within the YAC, 
but that a split signal was not observed due to 
loss of the derivative chromosome 3 (see 
above). Most of the tumors tested exhibited 
unbalanced chromosome 3 translocations 
(Table 8.1) and were analysed and interpreted 
similar to tumor 2. Tumor 7 did not exhibit an 
unbalanced translocation but, instead, a 
chromosome 3 deletion including a breakpoint 
at 3q21. The region distal to this breakpoint 
was lost. Summarized, three breakpoints 
(tumors 1, 6, 11) mapped proximal to the 
familial breakpoint and nine breakpoints 
(tumors 2, 3, 4, 5, 7, 8, 9, 10, 12) mapped 
distal to the familial breakpoint (Figure 8.1 and 
Table 8.2). The breakpoints of tumors 2 and 3 
were mapped in between cosmid O156 and 
YAC 790d8 and, thus, within 1 Mb distance 
from the familial breakpoint (Figure 8.1). In 
tumors 8 and 12 more centromere 3 signals 
Figure 8.2 FISH-analysis using cosmid L1951 (A),
cosmid O156 (B), and YAC 790d8 (C) on metaphase
spreads derived from sporadic tumor case 2. The
centromere 3 probe is detected in green and the
cosmids and YAC signals are detected in red. The
cosmid and YAC signals on chromosome 3 and the
derivative chromosome 2 are indicated by arrows. 
A
B
C
3
3
3
der(2)
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were observed than expected as based on their karyotypes (2 versus 1 in tumor 8, and 3 
versus 2 in tumor 12). In both cases FISH analyses revealed that the translocation 
chromosomes are dicentric, in which the short arm of chromosome 3 and the chromosome 3 
centromere were retained. Signals of both cosmid L1951 and YAC 790d8 were observed 
next to the centromere 3 signal on these dicentric chromosomes, which indicates that their 
translocation breakpoints must be located more than 1 Mb distal to the familial breakpoint 
(Figure 8.1 and Table 8.2). The third centromere 3 signal in tumor 12 suggests a (partial) 
trisomy for chromosome 3, which is in accordance with earlier findings in papillary RCCs 
(Balzarini et al., 1998). Based on these results, the karyotype of tumor 8 reads: 44,X,-
Y,der(2)t(2;3)(q35;q21),-3.ish dic(2;3)(q35;q21)(cen3++, L1951++, 790d8++) and of tumor 
12: 49,X,-Y,+7,+7,der(11)t(3;11)(q21;p15),+16,+17.ish +3 dic(3;11)(q21;p15)(cen3+++, 
L1951+++, 790d8+++). 
 
Table 8.2 Translocation breakpoint mapping in the 3q13-21 region in 12 sporadic renal cell 
carcinomas by FISH. 
 
Tumor Breakpoint Probes proximal/distal to familial breakpoint 
  Cen3* L1951** O156** 790_d_8**  
 
1 3q13 1x der(22) n.d. der(22) proximal (possibly within L1951) 
2 3q22 1x der(3) der(3) der(2) distal (within contig) 
3 3q21 1x der(3) der(3) der(2) distal (within contig) 
4 3q21 1x der(3) n.d. der(3) distal (possibly within 790d8) 
5 3q21 1x der(3) n.d. der(3) distal  
6 3q21 1x der(16) n.d. der(16) proximal (possibly within L1951) 
7 3q21 2x n.d. n.d. der(3) distal (possibly within 790d8) 
8 3q21 2x dic(2;3) n.d. dic(2;3) distal (possibly within 790d8) 
9 3q13 1x der(3) n.d. der(3) distal 
10 3q21 2x der(3) n.d. der(3) distal 
11 3q13 2x der(7) n.d. der(7) proximal 
12 3q21 3x dic(3;11) n.d. dic(3;11) distal (possibly within 790d8) 
 
*number of signals observed 
**location of signal(s) on derivative chromosomes 
n.d.: not determined 
 
Discussion 
 
In this study, FISH analysis revealed that the clustered breakpoints at 3q21 of twelve 
different sporadic RCCs do not coincide with the familial t(2;3) translocation breakpoint at 
this locus. The breakpoints of two tumors mapped in the genomic contig within 1 Mb 
distance from the familial breakpoint. As yet, it cannot be excluded that these breakpoints do 
affect DIRC2 by a more distant position effect. Alternatively, they may also affect the gene 
mapped directly distal to DIRC2, the human homologue of semaphorin 5B (SEMA5B or 
KIAA1445) (Figure 8.1). In the tumors with unbalanced chromosome 3 translocations, lack 
of derivative chromosome 3 signals leaves the option that the breakpoints map within the 
probes used and, thus, within the familial translocation breakpoint-spanning contig. 
Therefore, we cannot exclude that the breakpoints of tumors 1 and 6, that were located 
proximal to the familial translocation breakpoint, still map within L1951 and, thus, directly 
affect DIRC2 and/or its neighbouring gene the human homologue of PASS1 (protein 
associated with the small stress protein hsp27) (Liu et al., 2000; Bodmer et al., 2002 b). 
Neither can it be excluded that the breakpoints of tumors 4, 7, 8 and 12, that were located 
distal to the familial translocation breakpoint, map within YAC 790d8 at 1 Mb distance from 
the familial breakpoint. Deregulation of the DIRC2 gene and/or other genes in this 
breakpoint region by these breakpoints is only possible by a distant position effect (Figure 
8.1). The breakpoint of tumor 11 mapped proximal from cosmid L1951 and its distance to 
the familial breakpoint can vary from approximately 50 kb (directly located proximal from 
cosmid L1951), at which it can affect directly DIRC2 or PASS1, to a few Mb (as breakpoint 
was cytogenetically mapped at 3q13). The breakpoints of the tumors 5, 9, and 10 mapped at 
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more than 1 Mb distance from the familial breakpoint and, therefore, are unlikely to directly 
affect one of the genes at/near the familial translocation breakpoint (Figure 8.1). 
The fact that chromosome 3 translocations and derivative chromosome 3 losses occur as 
sole abnormalities in at least part of the sporadic primary RCCs, together with the finding 
that similar anomalies are also seen in primary familial RCCs, add to the idea that these 
translocations may be causally related to RCC development. The question remains whether 
breakpoints in the 3q21 region occur randomly and whether loss of the short arm of 
chromosome 3 in general confers an increased proliferative potential to renal epithelial cells 
(Dos Santos et al., 1999) or that the 3q21 breakpoints occur non-randomly and directly or 
indirectly affect a gene(s) in the region. Loss of the short arm of chromosome 3 has been 
frequently found in sporadic RCCs and supports the idea that genes critical for RCC 
development must be located on this arm. However, in two clear cell tumors in our panel of 
sporadic RCCs no 3p loss was observed. The dicentric chromosome that was found in 
tumor 8 included this part of chromosome 3. Tumor 11 appeared to contain a balanced 
three-way translocation between the chromosomes 3, 7 and 14 and, thus, also to retain the 
3p arm. Besides these sporadic RCC cases, similar observations were made in early-stage 
tumors in the family with t(2;3)(q35;q21) (Bodmer et al., 2002 a) and in different tumor 
biopsies in the family with t(3;6)(q12;q15) (Eleveld et al., 2001). These observations, and the 
finding that the chromosome 3 breakpoints in sporadic RCCs are clustered within certain 
peri-centromeric regions (3p21-3q21), support a concept of non-random breakage. 
However, the mechanism by which these non-random breaks occur is not clear yet, nor are 
the consequences of these breakages. Here we show that cytogenetically clustered 
breakpoints map at different positions within these clustered regions and that the distances 
between these positions can vary by a few Mb. These findings lead us to conclude that 
these breaks can only affect the same gene(s) through position effects.  
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General discussion and future prospects 
 
Cancer may be regarded as a genetic disease, in which the accumulation of mutations and 
chromosomal alterations accompany clonal selection and outgrowth of cells. Familial and 
inherited forms of cancer have provided important insights into the molecular mechanisms 
underlying tumor development. Different forms of genetic predisposition have been 
described for different subtypes of renal cell carcinomas (RCCs). The development of the 
conventional RCC subtype is most commonly associated with the Von Hippel Lindau (VHL) 
cancer syndrome, in which patients carry germline mutations in the VHL gene. Also, familial 
RCC cases have been described exhibiting constitutional chromosome 3 translocations. As 
conventional RCCs only developed in the translocation carriers in these families, the 
question arose whether these translocations predispose to RCC development. In this thesis, 
two novel RCC families with chromosome 3 translocations have been described. Molecular 
genetic analyses of these two families have contributed to our understanding of the genetic 
epidemiology and the molecular origin of this type of inherited cancer. Our results will be 
discussed together with those obtained in two families that were published previously (see 
Chapter 1) and three additional families that were published more recently. 
In the first part of this chapter, the clinical features and family histories of these seven RCC 
families will be discussed with special emphasis on the genetic epidemiology of the disease. 
In the second part of this chapter, the various molecular analyses that were performed on 
the tumors in these families will be discussed and a general RCC oncogenesis model will be 
proposed. The positional cloning of chromosomal breakpoint genes and their possible 
role(s) in RCC development will be discussed in the third part of this chapter. 
 
Chromosome 3 translocations as risk factors 
At the start of our study, two RCC families with constitutional chromosome 3 translocations 
were described (Chapter 1). In the first family, a constitutional t(3;8)(p14;q24) was found in 
several family members, including ten RCC patients (Cohen et al., 1979). Six of these 
patients developed bilateral RCC and two of them developed thyroid carcinoma. The age of 
RCC onset varied between 37 and 59 years, and in one family member a benign renal cyst 
was diagnosed at the age of 32. In the second family, several siblings carried a 
constitutional t(3;6)(p13;q25) of which the only member of the family over 50 years of age 
carrying the translocation developed multiple bilateral RCCs (Kovacs et al., 1989). In this 
thesis two novel RCC families are described. In the first family, five members over three 
generations carrying a constitutional t(2;3)(q35;21) developed RCCs (Chapters 2 and 4). 
Three patients developed multiple tumors, two of them in both kidneys. The age of diagnosis 
varied between 40 and 68 years in four patients. One patient was diagnosed through a 
screening program at the age of 30 years (Chapter 4). At that time he showed no overt RCC 
symptoms. In this patient multiple small cystic and solid tumors, so called early stage 
neoplasms, were found in both kidneys. One additional translocation carrier in this family 
developed bladder cancer at the age of 66 years. In the second family a t(3;6)(q12;q15) 
translocation was transmitted and four patients with conventional RCC were diagnosed. The 
age of onset in this family varied between 41 and 67 years and no bilateral RCCs were 
observed (Chapter 5). An additional third RCC family was identified by us but not described 
in detail yet (Geurts van Kessel et al., 1999). Within this family a t(3;4)(p13;p16) was found 
in three generations. One translocation carrier developed RCC at the age of 52 years. 
Finally, two RCC families with constitutional chromosome 3 translocations were reported 
more recently by others. Seven RCC patients over three generations were encountered in a 
Polish family with a constitutional t(2;3)(q33;q21) (Zajaczek et al., 1999). Further clinical 
details about these patients were not published. In a Japanese family with a constitutional 
t(1;3)(q32;q13.3), four RCC patients over four generations were encountered (Kanayama et 
al., 2001). The age of onset varied between 56 and 79 years. All patients were diagnosed 
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after the manifestation of RCC-associated symptoms. Two other family members died of 
gastric cancer and exocrine pancreatic cancer, respectively. It is not known to us whether 
these latter two patients also carried the translocation.  
 
Table 9.1 General features of the seven RCC families with constitutional chromosome 3 
translocations. 
 
Kindred Translocation Number of  Generations  Mean Reference 
  RCC cases involved age*  
 
A t(3;8)(p14;q24) 11 3 44* Cohen et al., 1979 
B t(3;6)(p13;q25.1) 1 3 50** Kovacs et al., 1989 
C t(2;3)(q35;q21) 5 3 47* Koolen et al., 1998  
D t(3;6)(q12;q15) 4 4 57.5** Geurts van Kessel et al., 1999  
E t(3;4)(p13;p16) 1 3 52** Geurts van Kessel et al., 1999 
F t(2;3)(q33;q21) 7 3 n.i. Zajaczek et al.,1999  
G t(1;3)(q32;q13.3) 4 4 66.7** Kanayama et al., 2001 
 
* age at diagnosis through clinical symptoms and through a screening program 
** age at diagnosis through clinical symptoms 
n.i. no information 
 
Some general features of the seven different kindreds (A-G) are summarized in Table 9.1. 
Five of these familial RCC cases (A, C, D, F, and G) represent more than two first degree 
RCC relatives in three or more generations and, thus, may be informative for studying the 
epidemiology of this type of familial RCC. The most important criteria for inherited 
predisposition versus sporadic RCC are the early age of onset and the multifocal and/or 
bilateral character of the cancer (Maher and Yates, 1991; Woodward et al., 2000). These 
latter characteristics were observed in the families mentioned and, thus, support inherited 
predisposition. The age of diagnosis for hereditary RCC lies between the third and fifth 
decades. The mean age of RCC onset in families with the VHL disease is 44.8 years, 
whereas in sporadic RCC cases this is 61.8 years (Woodward et al., 2000). The mean age 
of onset in four of the five informative families (with more than two first degree RCC relatives 
in three or more generations) with constitutional chromosome 3 translocations is 51.2 years 
(calculated by dividing the total age of all RCC patients in these four families through the 
number of patients) and, thus, is intermediate between those seen in VHL disease and 
sporadic RCC. Notable are the relatively late ages at diagnosis in kindreds D and G. These 
ages are similar to the mean age at diagnosis in sporadic RCC cases. It may also be noted 
that the mean ages of onset in families A and C are relatively low. These families, however, 
include several young asymptomatic patients (ages 30-40 years) that were diagnosed 
through screening programs. When these patients are excluded from the calculated mean 
ages at diagnosis, the respective mean ages become 46 years for family A and 51 years for 
family C, which are still below those calculated in the families D and G. In addition, two 
translocation carriers in family G reached ages over 80 years without overt RCC symptoms. 
Similar observations were made in families C and D. Taken together, it can be concluded 
that the RCC inheritance patterns in these kindreds conform to autosomal dominant 
transmissions with median to low penetrances.  
Two of the RCC families listed in Table 9.1 (D and E) were identified in a series of ten 
families with constitutional chromosome 3 translocations that were filed in our department 
for other disorders than RCC (Figure 9.1; Geurts van Kessel et al., 1999). Evaluation of 
these families was performed by written questionnaires and oral interviews in order to define 
the extent of constitutional chromosome 3 translocations as risk factors for RCC 
development. The detection of two RCC families among these ten families with in total five 
affected RCC patients is significantly higher than the (sporadic) RCC incidence in the overall 
Dutch population. This observation, in addition to the already published families, supported 
the notion that germline chromosome 3 translocations may act as predisposing factors in the 
development of RCC. Reasons why in the other eight families no RCCs were detected 
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include the small sizes of several of these families with only few translocation carriers at 
relatively young ages. Another option is that the position of the breakpoint on chromosome 3 
may play a critical role in RCC predisposition. Although the positions of the breakpoints vary 
between the seven RCC families, they all map in the proximal p- and q-arm regions of 
chromosome 3. This observation is illustrated in Figure 9.1 and is in full agreement with the 
observations made in sporadic RCCs (Kovacs and Kung. 1991; Meloni et al., 1992). The 
black bars (Figure 9.1, right) represent the breakpoint frequencies of 157 sporadic RCC-
associated chromosome 3 translocations that are listed in the ‘Mitelman Database of 
Chromosome Aberrations in Cancer’ (http://cgap.nci.nih.gov/Chromosomes/CytList). This 
breakpoint position-related phenomenon may explain the variation in penetrances and other 
phenotypic differences (i.e., the severity of the disease and the development of non-RCC 
malignancies) between the seven RCC families. In addition, specific genes at or near these 
breakpoints may play (a) critical role(s) in RCC development (see below). These notions 
may have consequences for the identification of persons at risk, the development of genetic 
counselling strategies and (clinical) patient management. Periodic echoscopic screening and 
counselling are already actively pursued in the ‘at risk’ families that we have identified so far, 
thereby allowing early RCC detection and surgical intervention. By doing so three novel 
tumors were detected in family C (Chapter 4). To evaluate the consequences of 
chromosome 3 translocations on RCC development and whether familial translocations ‘at 
risk’ indeed exhibit pericentromeric breakpoints on chromosome 3, an inventory was initiated 
Figure 9.1: Diagram showing human chromosome 3 with on the left side the seven RCC-associated constitutional
chromosome 3 translocations and their respective breakpoint positions. On the right side, breakpoint frequencies in
germline chromosome 3 translocations in 93 Dutch families (grey bars) and in somatic chromosome 3 translocations in
157 sporadic RCCs (black bars) are shown. The breakpoint frequencies are indicated in percentages. 
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of families with germline chromosome 3 translocations known at the different Clinical 
Genetic Centres in the Netherlands. This inventory yielded 93 such families. The grey bars 
in Figure 9.1 represent the positions and breakpoint frequencies of these translocations. It 
appears that the breakpoints in these constitutional translocations are more or less randomly 
spread over chromosome 3 and, therefore, the corresponding families represent a suitable 
cohort for RCC risk assessment purposes. 
 
Table 9.2 Molecular features of the seven RCC families with constitutional chromosome 3 
translocations. 
 
Kindred Translocation Number of  Number of  Loss 3p** VHL  
  RCC cases tumors* mutations** 
 
A t(3;8)(p14;q24) 11 6(4) 5/5 2/2 
B t(3;6)(p13;q25.1) 1 6(1) 5/5 n.d. 
C t(2;3)(q35;q21) 5 8(4) 7/8 5/7 
D t(3;6)(q12;q15) 4 7(4) 2/5 1/7 
E t(3;4)(p13;p16) 1 n.d. n.d n.d. 
F t(2;3)(q33;q21) 7 2(?) 2/2 n.d. 
G t(1;3)(q32;q13.3) 4 4(3) 4/4 2/4 
 
* The number of tumors that were analysed in these families; the numbers between brackets are the numbers of affected RCC patients 
in the families from which the independent tumors were isolated. 
** The number of tumors in which loss of 3p or VHL mutations were observed, respectively; the numbers behind the slashes are the 
numbers of tumors which were informative for these analyses. 
n.d. not deternined 
 
A three step model for familial RCCs  
Detailed loss of heterozygosity (LOH) and VHL mutation analyses were performed in the 
RCC families with t(2;3)(q35;q21) and t(3;6)(q12;q15), respectively (Chapter 3, 4 and 5; 
kindreds C and D). In most LOH analyses, allele patterns of chromosome 2 and 3 
microsatellite markers were compared between tumor tissues, normal control tissues, and 
somatic cell hybrids containing either the derivative chromosomes 2 or 3 or their normal 
counterparts. Other techniques that we used included ‘classical’ karyotyping, fluorescence in 
situ hybridization (FISH) and comparative genome hybridization (CGH). The results obtained 
through these studies revealed loss of the derivative chromosome 3 and, thus one 3p copy, 
in almost all (7 out of 8) of the tumor samples analysed in family C and in 2 (out of 5) tumor 
samples analysed in family D (Table 9.2). These results support a crucial role for 3p loss in 
tumor development in these familial RCC cases. However, the observed lack of 3p loss in 
some of the tumors, including one early stage tumor that was diagnosed via a screening 
program in family C, implies that another genetic alteration may precede 3p loss during 
tumor formation (see below). Subsequent VHL gene analyses revealed 6 novel mutations in 
14 tumors analysed. From our results we conclude that, most likely, loss of the derivative 
chromosome 3 occurred before the somatic VHL mutations (Chapter 3). The detection of 
different mutations, even in 4 tumor biopsies isolated from one patient, implied that these 
tumors developed independently and not as metastases of one primary tumor. Besides that, 
our molecular studies also indicated the occurrence of tumor heterogeneity (Chapter 5). 
Similar observations have been reported in the other RCC families with constitutional 
chromosome 3 translocations (Table 9.2; Kovacs et al., 1989; Li et al., 1993; Schmidt et al., 
1995; Zajaczek et al., 1999; Kanayama et al., 2001). Based on these combined findings, an 
alternative three step model for RCC development is proposed which is schematically 
illustrated in Figure 9.2. In this model the first hit is not a germline mutation in a tumor 
suppressor gene but, instead, a germline reciprocal translocation involving chromosome 3. 
This idea was first put forward by Kovacs and Kung (1991) and was based on the observed 
presence of unbalanced translocations involving the chromosome 3p region in both 
hereditary and sporadic RCCs. These translocations are thought to result from 
nonhomologous chromatid exchanges. The exact mechanism behind the recombination 
process in these germline translocations, however, is not known yet. Short tandemly 
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repeated DNA sequences or fragile sites, such as FRA3B in the RCC-associated 
t(3;8)(p14;q24), have been implicated to serve as sites of recombination (Kovacs, 1993; 
Ohta et al., 1996). Nondisjunctional loss of the derivative chromosome that carries the 3p 
segment on which RCC-related genes such as VHL are located, is the second step in the 
alternative three step model for RCC development. Initially, we suggested that these losses 
may occur at any stage in (embryonic) kidney development, and that the risk of developing 
RCC in translocation carriers may be correlated with the extent of somatic mosaicism in 3p 
loss (Chapter 3). Subsequently, this hypothesis was tested by culturing normal kidney cells 
of translocation carriers in family C, but could not be confirmed (data not shown). The third 
step in our model represents a somatic mutation in the remaining allele of (a) RCC-related 
tumor suppressor gene(s) on 3p. The VHL gene is such a gene and was found to be 
mutated at least in a subset of the tumors tested in these families. The observed lack of VHL 
gene mutations in the other tumors may be attributed to silencing of the gene by promoter 
hypermethylation or other (epi-) genetic alterations such as intrachromosomal deletions or 
mutations in the VHL regulatory region. These latter options were not tested in the RCC 
families described here. An alternative option is that (an)other, yet unidentified, RCC-related 
tumor suppressor gene(s) on 3p is involved. This latter notion is supported by the fact that in 
40-60% of sporadic RCCs no VHL gene mutations are found. The presence of a VHL-
independent pathway, next to a VHL-dependent pathway, was therefore suggested (Van 
den Berg and Buys, 1997; Clifford et al., 1998). Interestingly, tumor suppressor genes may 
act through both recessive and haplo-insufficiency mechanisms (Chapter 1). Till now, 
however, no genes for RCC fulfilling these criteria have been identified on 3p. The lack of 3p 
loss observed in a few tumors in the families C and D led us to assume that another (epi-) 
genetic event may precede 3p loss in the genetic cascade leading to RCC development. As 
the translocation is the only apparent genetic alteration in these cells, a role for a gene(s) 
located at or near the translocation breakpoint(s) was suggested. This idea was supported 
by similar findings in sporadic RCC cases in which balanced chromosome 3 translocations 
were detected as the only karyotypic change (Mitelman 1994). The alternate three step 
model proposed here for this form of hereditary RCC may explain the reduced penetrance 
compared to that in the VHL disease, i.e., an extra step is required in this tumorigenesis 
model (versus two hits in the VHL disease). 
Besides kidney cancer, also other types of cancer were diagnosed in some of the RCC 
families, i.e., thyroid cancer in family A, bladder cancer in family C, and pancreatic cancer 
and gastric cancer in family F. In the first two families, these patients are known to be 
translocation carriers. Genetic alterations affecting 3p have been reported for the sporadic 
Figure 9.2: Schematic illustration of the alternative three step tumorigenesis model in hereditary RCCs with 
constitutional chromosome 3 translocations (adapted from Kovacs, 1993 and Kanayama et al., 2001).  
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forms of each of these different tumor types, as well as in tumors from other organs (Panani 
et al., 1995; Schneider et al., 1995; Reznikoff et al., 1996; Grebe et al., 1997; Yu et al., 
2001; Barghorn et al., 2001). Thus, the first two steps for hereditary RCC may also affect 
other tissues and organs. Further cytogenetic and molecular analyses of these non-RCC 
malignancies in these families are required to reveal whether 3p loss and VHL (or other 3p 
derived) gene mutations also play a role in these tumors. The question remains why the 
frequencies of tumor formation in these families are highest in the kidney. The kidney plays 
a pivotal role in the elimination of numerous xenobiotics, such as drugs, toxins, and 
endogenous metabolites. As such, kidney cells may be more severely exposed to potentially 
toxic metabolites than other tissues, leading to transformation of these cells into tumor 
precursor cells. The translocation and subsequent nondisjunctional loss of 3p may confer a 
selective growth advantage onto these precursor cells. To test this hypothesis, one might 
study 3p losses in association with transforming capacities in cultured normal kidney cells 
with and without the constitutional translocation after exposure to metabolites that are known 
to be specifically adsorbed from the blood into kidney cells. Evaluation of environmental 
conditions and lifestyle (such as tobacco and diet) of different translocation carriers within 
these RCC families may add to this idea.  
Until now, no direct associations were found between chromosome 3 translocations and 
nondisjunctional losses of the derivative chromosome 3 containing the 3p arm (Figure 9.2, 
step 2). One might suggest that these translocations cause overall chromosomal or mitotic 
instability, thus leading to nondisjunctional loss. CGH and cytogenetic analyses of some of 
the kidney tumors reported here indeed showed additional chromosomal abnormalities 
which have also been implicated in conventional RCCs (Chapter 1), i.e., duplication of 
chromosome 5 and loss of chromosomes 8, 9 and 14 (Chapter 4; Kovacs et al., 1989; 
Kanayama et al., 2001). However, no extreme aneuploidies were observed in most of these 
tumors, indicating that chromosomal instability is not dramatically increased (Chapters 3 and 
4). In addition, no microsatellite instability was observed in the tumor DNAs, thereby 
excluding this type of genetic instability. A bleomycine sensitivity test, which measures cell 
cycle defects in the G2-phase, was performed on immortalized lymphoblastoid cell lines 
derived from both translocation-carriers and non-carriers in families B and C. No obvious 
differences were observed and, therefore, this type of genetic instability could also be 
excluded (Chapter 3; Kovacs et al., 1989).  
As mentioned before, the breakpoints in the different familial constitutional translocations are 
nonrandomly distributed over chromosome 3 (peri-centromerically). It remains to be 
established why breakpoints in this peri-centromeric region may preferentially lead to RCC. 
One option could be that those breakpoints located more distal on 3p lead to somatic loss of 
relatively small parts of the 3p arm, not containing important RCC-related genes. 
Breakpoints more distal on 3q would lead to somatic loss of the major part of chromosome 
3, which may not be compatible with survival of renal epithelial cells. This latter notion is in 
full agreement with observations in sporadic RCC cases: as yet, no RCCs have been 
described with 3q22-3qtel deletions (Mitelman Database of Chromosome Aberrations in 
Cancer; http://cgap.nci.nih.gov/Chromosomes/CytList). An alternate option is that the genes 
located at or near the translocation breakpoints play pivotal roles in especially kidney cells 
and that disruption or deregulation may contribute to RCC development. 
 
Breakpoint genes and their possible role(s) in tumor development  
To determine whether the breakpoints, especially those on chromosome 3, play a role in 
RCC tumorigenesis the isolation and identification of breakpoint-associated genes was 
initiated. In this thesis we describe the positional cloning of the breakpoints of the familial 2;3 
translocation (Chapters 6 and 7). Cytogenetically the breakpoint on chromosome 3 was 
mapped within band 3q21. Subsequent positional cloning efforts revealed that this 
breakpoint disrupts a novel gene DIRC2 (disrupted in renal cancer 2) (Chapter 6). This gene 
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encodes a predicted multimembrane protein of 478 amino acids, which represents a new 
member of the major facilitator superfamily (MFS) of transporters. Most likely, this protein 
acts as an anion-cation transporter. Besides several phosphorylation sites and a 
glycosylation site, the protein also contains a proline rich motif in one of its intracellular 
hydrophobic regions. SH3 domains known to be present in messenger proteins acting in 
signal transduction pathways can recognise proline rich motifs. Thus, DIRC2 may play a role 
in intracellular signaling. RNA studies revealed that the DIRC2 gene is expressed in several 
tissues and, importantly, also in the proximal tubules of the nephron. Mutation analysis of 
the remaining allele in different translocation carriers within the 2;3 family revealed, besides 
a non-RCC linked polymorphism, no genetic changes. Also in a panel of sporadic RCCs and 
blood samples from different non-VHL and non-MET hereditary RCC cases, no mutations 
could be detected. Nevertheless, it should be noted that the first exon of this gene was not 
included in these studies and that mutations in this exon can, therefore, not be excluded yet. 
In addition, DIRC2 contains a CpG island at its 5’ end and gene expression may thus be 
silenced by promoter hypermethylation. Both options remain to be tested. The lack of 
aberrant DIRC2 transcripts in translocation-positive tumor and lymphocytic cells, led us to 
assume that DIRC2-derived fusion transcripts were not present or expressed at 
undetectable levels. Therefore, we also set out to analyse the translocation breakpoint at 
2q35 (Chapter 7). By doing so, we found that this breakpoint disrupts another novel gene, 
DIRC3. No open reading frame could be identified in the 12 exons of this gene and, 
therefore, we suggest that a noncoding RNA is transcribed from this gene. Further analysis 
of the genomic breakpoint fragments indicated that transcription of chimeric DIRC2-DIRC3 
mRNA is unlikely since these genes are positioned in opposite 3’-5’ directions from each 
other. Using RT-PCR, however, we were able to demonstrate that through the 2;3 
translocation the first two exons of DIRC3 are spliced to the second exon of the PASS1 
gene, which is located directly proximal from DIRC2 on chromosome 3 and has the same 
transcriptional orientation as DIRC3. It is not clear yet whether this fusion transcript encodes 
a transforming protein. One scenario may be that the fusion transcript codes for a truncated 
PASS1 protein from an internal translation initiation site in the PASS1 sequence (Chapter 7). 
Additional in vitro transcription and translation experiments are needed to clarify these latter 
issues.  
The PASS1 gene is abundantly expressed in kidney as compared to other tissues (Liu et al., 
2000). In addition, two different PASS1 transcripts were encountered in kidney cells, of 
which the shorter one is kidney-specific. The causative mechanism for the presence of this 
additional PASS1 transcript is not known, but alternative splicing has been suggested (Liu et 
al., 2001). The PASS1 gene encodes a protein that is known to be associated with the small 
stress protein Hsp27 (Liu et al., 2001). Small stress or heat-shock proteins are thought to 
play critical roles in cellular stress responses in order to render cells stress-resistant. The 
observations that Hsp27 expression is elevated in renal tumors as compared to normal 
kidney tissue and that PASS1 has been demonstrated to affect Hsp27’s ability to protect 
cells against shock, turn PASS1 into an interesting RCC-related candidate gene. Another 
interesting feature of PASS1 is its putative ability to regulate chromatin remodelling via its 
JmjC domain (SMART00558; Clissold and Ponting, 2001). A stress situation in the cell may 
change the ratio of the PASS1 transcripts. Consequently, PASS1 may function as ‘stress 
sensor’. A function for the putative DIRC2 encoded transporter in RCC development may lie 
in the fact that transporters are known to execute important functions in the kidney, i.e., to 
prevent urinary loss of filtered nutrients and electrolytes and, simultaneously, to facilitate 
secretion of a variety of potentially toxic metabolic waste products and xenobiotics. In 
general, anion-cation transporters are known to be primarily involved in the secretion of 
xenobiotics (Inui et al., 2000). Disruption of one DIRC2 allele, as we have shown in the 
familial 2;3 translocation (Chapter 6), may therefore result in reduced or defective transit of 
these molecules across the renal proximal tubular epithelium and, consequently, in 
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accumulation within the cells. As some of these molecules may be toxic, an increased 
exposure of these renal cells to these molecules may impose stress conditions upon these 
cells. 
Taken together, there may be two mechanisms by which these breakpoint (fusion) genes 
can lead to tumor development: (1) by haplo-insufficiency effects of DIRC2 and DIRC3 
and/or (2) by altered expression of PASS1 (fusion) transcripts and a change in the ratio 
between these transcripts in kidney cells. It is important to note here that several studies 
have demonstrated that a combination of genetic changes may be critical to the 
development of malignancies (Largaespada, 2001). This was best demonstrated in 
transgenic mice in which the role of the 15;17 translocation was studied in the development 
of acute promyelocytic leukemia (APL) (Rego et al., 2001). In this model, a reduced dosage 
of one of the breakpoint-related genes resulted in an increased penetrance of t(15;17)-
positive acute leukemia, thus demonstrating that haplo-insufficiency of a breakpoint-related 
gene acts in conjunction with fusion transcripts in the pathogenesis of leukemia. Such a 
transgenic mouse model may also be suitable to study the role of the 2;3 translocation in 
RCC development, as such genetic changes may be correlated to the age of onset 
(penetrance) and other tumor-associated phenotypic characteristics (see above). Besides 
these obvious possibilities, a third alternative mechanism may be proposed in which RCC 
development may be triggered by position effects of the translocation, i.e., the breakpoints 
may deregulate the expression of (a) gene(s) located upstream or downstream from DIRC2 
or DIRC3, respectively (Chapters 6 and 7). Such position effects have been demonstrated to 
play a role in several human diseases and are suggested to be caused by alterations in 
promoter or enhancer/silencer elements of genes or by changes in the local chromatin 
organization (heterochromatic versus euchromatic state) and, thus, the accessibility of 
genes to the transcription apparatus (Kleinjan and van Heyningen, 1998). The most 
interesting genes near the translocation breakpoints on chromosome 2 and 3 in relation to 
RCC development are semaphorin 5B (SEMA5B) and tensin (TNS). The SEMA5B gene is 
located in the chromosome 3 breakpoint region at ~20 kb distal from the DIRC2 gene, 
whereas the TNS gene is located in the chromosome 2 breakpoint region ~400kb distal from 
the DIRC3 gene. The SEMA5B gene is related to two other semaphorin genes (SEMA3F 
and SEMA3B) which are both located in one of the putative tumor suppressor regions on the 
short arm of chromosome 3 (3p21). Several studies, among which silencing by promoter 
hypermethylation and transfection, have demonstrated a tumor suppressor function for the 
SEMA3B gene (Sekido et al., 1996; Xiang et al., 1996; Tomizawa et al., 2001). Tensin may 
also serve as a candidate gene for RCC development as it is highly expressed in the kidney. 
Studies in Tns-null mice revealed multiple cysts in the kidneys that subsequently led to 
kidney degeneration and renal failure, thus indicating that this gene is necessary for normal 
kidney function (Lo et al., 1997). Gene deregulation by position effect of the translocation 
breakpoint may also be suggested by our last study (Chapter 8), in which we demonstrated 
that cytogenetically clustered 3q21 breakpoints in sporadic RCCs map at different locations 
at the molecular level. In order to reveal the mechanism(s) that underlie RCC development 
in the t(2;3)-positive family, expression studies of breakpoint genes and their ‘neighbouring’ 
genes in translocation-positive kidney cells versus translocation-negative kidney cells may 
provide relevant clues. Other studies may include mRNA in situ hybridization (to 
demonstrate expression in the relevant part of the proximal tubule), mutation and protein 
analysis in other hereditary and sporadic RCCs, transfection studies and soft agar assays 
(Weterman et al., 2001).  
Although the 2;3 translocation seemed balanced at the cytogenetic level, positional cloning 
and sequence analysis revealed that both breakpoints on chromosome 2 and 3 coincided 
with deletions of 34 bp and 3464 bp, respectively. Thus, at the molecular level, the 
translocation was not balanced (Chapter 7). To reveal whether phenotypic differences 
between RCC family members with this translocation (such as the wide range in the age of 
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onset and the development of bladder cancer in one translocation carrier) were associated 
with additional genetic alterations at the translocation breakpoints due to meiotic 
recombination events, we sequenced and compared the chimeric breakpoint fragments of 
different translocation carriers in this family (Chapter 7). However, no such alterations were 
observed and we conclude that the phenotypic differences mentioned must be related to 
other variations within this family. Another option may be a variation in the expression of 
DIRC3-PASS1 and/or one of its ‘neighbouring’ genes. Also, as suggested earlier in this 
chapter, variations in environment and lifestyle (e.g. exposure to carcinogens) may act as 
such.  
 
Table 9.3 Breakpoint genes identified in seven familial RCC cases.  
 
Kindred Translocation Breakpoint genes Gene description  
 
A t(3;8)(p14;q24) FHIT and TRC8 FHIT: Ap3A hydrolase 
   TRC8: homology to tumor suppressor gene patched 
B t(3;6)(p13;q25.1) unknown - 
C t(2;3)(q35;q21) DIRC2 and DIRC3 DIRC2: anion-cation transporter  
   DIRC3: noncoding RNA 
D t(3;6)(q12;q15) in progress - 
E t(3;4)(p13;p16) unknown - 
G t(2;3)(q33;q21) DIRC1 DIRC1: function unknown 
   no gene disrupted by the chromosome 3 breakpoint 
F t(1;3)(q32;q13.3) in progress - 
 
 
As shown in Table 9.3, additional breakpoint genes have been identified in some of the 
other chromosome 3 translocation-positive RCC families, among which the FHIT and TRC8 
genes in family A (Ohta et al., 1996; Gemmill et al., 1998), which have already been 
discussed in Chapter 1. Several reports supported a tumor suppressor function for these 
genes, but insufficient evidence has been generated to definitively prove such a function. In 
the Polish RCC family (G), the DIRC1 gene was found to be disrupted by the breakpoint on 
chromosome 2 (Druck et al., 2001). This gene consists of three exons and encodes a 
predicted protein of 104 amino acids that does not share any homology with other known 
proteins. RNA studies revealed that this gene is ubiquitously expressed at a low level, also 
in the kidney. The chromosome 3 breakpoint in this family was cytogenetically mapped to 
3q21 and molecular analysis revealed that this breakpoint maps between two microsatellite 
markers at about 15 Mb distance from the breakpoint in family C. No genes were identified 
yet at this breakpoint (Druck et al., 2001). In family F the identification of gene(s) at/near the 
translocation breakpoints is still in progress (Kanayama et al., 2001). Using positional 
cloning, the chromosome 3 breakpoint at 3q13.3 was refined to a 5 cM region between two 
BAC clones. The distance between one of these BAC clones (AC020650) and the 
chromosome 3 breakpoint in family C was estimated to be 5 Mb and thus, most likely, these 
breakpoints do not deregulate the same gene(s). Although the translocation breakpoints in 
these seven families appear to affect different genes, they may be involved in related 
genetic pathways leading to RCC development. Interesting in this respect is the putative 
functional overlap between FHIT (family A) and PASS1 (family C). Both genes are thought 
to be involved in stress signaling and may act as ‘stress sensors’ (Figure 9.3). From both 
genes fusion transcripts are formed as a result of the respective familial translocations. 
These fusion transcripts may affect normal PASS1 and FHIT transcription regulation and, 
thus, stress signaling pathways as outlined in Figure 9.3. Both fusion genes are transcribed 
from the derivative chromosome that is lost during the course of tumor development. It may, 
therefore, be suggested that this loss results from selective pressure onto the cells to restore 
normal stress signaling. In order to carry this latter hypothesis further, it might be worth while 
to perform profiling experiments in which gene expression patterns of normal kidney tissues 
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are compared to those from translocation-positive RCC family members, with special 
emphasis on stress-related pathways and their corresponding genes.  
Taken together, our findings strongly indicate a significant increase in the risk for RCC 
development in carriers of reciprocal chromosome 3 translocations, in particular when the 
translocation breakpoints are located peri-centromerically. It is suggested that deregulation 
of genes located at/near the chromosome 3 breakpoints affect epithelial renal cells of the 
proximal tubule. This deregulation may, directly or indirectly (modifying effect), lead to RCC 
development.  
 
 
 
Figure 9.3: Schematic overview of the possible roles of PASS1 and FHIT in stress signaling in epithelial cells of the
kidney. In (A) the ’no stress’ situation is shown in which FHIT and PASS1 are normally transcribed. HSP27 is not
transcribed. The FHIT protein interacts with its substrate Ap3A. Two PASS1 transcripts are transcribed and, possibly,
translated into two distinct PASS1 proteins (PASS1A and PASS1B). In (B) the hypothetical situation in stress induced
kidney cells is shown. Stress can affect cells in different ways. One option is altering protein activities or inactivating
proteins by affecting protein conformations (Jolly and Morimoto, 2000). This option may also apply to PASS1 and
change the ratio between the two derived proteins (1). The PASS1 proteins are suggested to affect chromatin
remodelling via their JmjC domain. A change in expression may, therefore, affect this remodelling potential and, thus,
transcription regulation, DNA repair, DNA replication and/or chromosome segregation events (2). The accumulation of
misfolded proteins is known to activate the heat shock transcription factor which, in turn, activates the transcription of
the Hsp genes (Morito, 1998). The accumulation of misfolded PASS1 proteins may specifically induce the transcription
of Hsp27 (3, 4). It is also possible that the chromatin remodelling events induce stress signaling pathways that,
eventually, result in the induction of Hsp27 expression (5). By binding to Hsp27, PASS1 is protected from further
misfolding (6) and it can, thus, restore its chromatin remodelling function. Another pathway by which stress signaling
may be induced is via FRA3B and the FHIT gene (pathway A-F). Stress may cause FRA3B instability (A) and, as a
consequence, reduce FHIT expression and/or induce alternative FHIT splicing (B). As a result, Ap3A binding to FHIT
may be impaired. Ap3A is thought to affect the regulation of DNA replication and, possibly, cause late replication (C;
Plateau and Blanquet, 1994). Ap3A is also suggested to induce intracellular signaling in response to stress (D; Plateau
and Blanquet, 1994). It is not known whether this stress signaling pathway also induces Hsp expression (E). However,
Hsp proteins can modulate the half-life time of proteins by modulating ubiquitination and targeted degradation (Jolly
and Morimoto, 2000). Thus, it is possible that Ap3A is sequestered by Hsp proteins (F) and that, consequently, the
DNA replication rate is restored. Solid arrows = published data, dotted arrows = suggested links. 
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Summary  
 
Renal cell carcinomas (RCC) represent 85% of all renal neoplasms. This group of RCCs 
constitutes different histological subtypes with distinct genetic profiles. Usually RCCs occur 
as sporadic tumors. To date, however, a number of familial RCC cases have also been 
reported, including some renal tumor related syndromes such as the Von Hippel Lindau 
(VHL) syndrome and the Birt-Hogg-Dubé syndrome. In recent years, hereditary cancer 
syndromes have been instrumental in the identification of cancer related genes, allowing 
accurate diagnosis and genetic counselling within families. In this thesis we focused on 
familial RCC cases with constitutional chromosome 3 translocations.  
Two such families are described in this work (Chapters 2, 3 and 5). In the first family a 
t(2;3)(q35;q21) translocation was found in several family members, including 5 RCC 
patients. In the second family a t(3;6)(q12;q15) was found in three consecutive generations, 
including 4 RCC patients. All the patients developed RCCs of the conventional subtype. 
Cytogenetic and molecular analyses were performed on a number of the tumors in both 
families and revealed, besides the chromosome 3 translocation, loss of the derivative 
chromosome carrying the 3p segment. In several of these tumors mutations in the RCC-
related VHL tumor suppressor gene, which is located on the 3p arm, were detected 
(Chapters 3 and 5).  Based on these findings, and on similar findings in two other RCC 
families with constitutional t(3;8)(p14;q24) and t(3;6)(p13;q25.1) translocations, a three step 
tumorigenesis model was suggested (Chapters 3 and 9). In this model the constitutional 
chromosome 3 translocation may act as a primary oncogenetic event followed by somatic 
loss of de 3p-containing derivative chromosome. The suggested sequence of these events 
was supported by the analysis of small early stage tumors in the family with the 2;3 
translocation and different tumor biopsies in the family with the 3;6 translocation (Chapters 4 
and 5). Inactivation of (a) tumor suppressor gene(s) on the remaining 3p arm, such as VHL, 
may act as a relatively late event in RCC development. Recently, this model has been 
confirmed by cytogenetic and molecular analyses of RCCs in two other families with 
t(2;3)(q33;q21) and t(1;3)(q32;q13.3) translocations,  respectively (Chapter 9). 
To unravel the pivotal role of chromosome 3 translocations in RCC development, we 
positionally cloned the t(2;3) breakpoint regions and identified two novel breakpoint-
spanning genes. The breakpoint-spanning  gene on chromosome 3, named DIRC2, 
encodes a putative multimembrane protein (Chapter 6). Homology searches revealed that 
this protein may represent a new member of the major facilitator superfamily (MFS) of 
transporters and that it most likely acts as an anion-cation transporter. Mutation analyses 
were performed in both sporadic and familial RCCs, but no pathogenic mutations were 
found. We hypothesize that this gene may contribute to RCC development in an haplo-
insufficient manner by deregulating the filtrating function of epithelial kidney cells. As a 
consequence, stress conditions may be imposed upon these cells (Chapters 6 and 9). The 
gene disrupted by the breakpoint on chromosome 2 was named DIRC3 (Chapter 7). We 
suggest that this gene may produce a noncoding RNA, as no open reading frames were 
found. Further analysis revealed that the first two exons of this gene fuse to exon 2 to 9 of 
the PASS1 gene, which is located directly proximal from the DIRC2 gene on chromosome 3 
(Chapter 7). The PASS1 gene is an interesting candidate for RCC development: its 
expression is high in kidney as compared to other tissues, and an alternative kidney-specific 
transcript is formed. The gene encodes a protein that is suggested to be involved in cellular 
stress responses, since it interacts with the small stress protein Hsp27.  
The familial RCC related chromosome 3 translocations differ from each other in 
chromosomal partners as well as in chromosomal breakpoints, indicating that they may 
affect different genes. It is, therefore, of paramount importance to investigate whether the 
breakpoint genes involved act in similar or related genetic pathways leading to RCC 
development. In Chapter 9 we note that such an overlap may indeed exist. Interestingly, we 
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found similarities in function between the PASS1 and FHIT (fragile histidine triad) proteins. 
The latter is encoded by the chromosome 3 breakpoint gene FHIT identified in an RCC 
family with a t(3;8)(p14;q24) translocation. Both proteins are thought to be involved in stress 
signaling and to act as ‘stress sensors’. We hypothesize that deregulation of their 
expression, due to the respective familial translocations, disturbs normal stress signaling 
pathways, leading to genomic instability and the onset of RCC.  
In total seven RCC families with constitutional chromosome 3 translocations have now been 
identified, among which the two described in this thesis. This finding supports the notion that 
germline chromosome 3 translocations may act as predisposing factors in the development 
of RCC. The RCC inheritance patterns in these families conform to autosomal dominant 
transmissions with median to low penetrances. Although at much lower frequencies, other 
malignancies have also been encountered in these families, including thyroid cancer, 
bladder cancer, pancreatic cancer, and gastric cancer. We hypothesize that the 
chromosome 3 breakpoint positions (and thus the breakpoint genes) determine the 
occurrence of other malignancies and the variation in RCC penetrances in these families. 
The remarkable observation that the chromosome 3 breakpoints in these RCC-associated 
translocations all map in the proximal p- and q-arm regions of chromosome 3 may have 
additional etiologic consequences. Identification of the corresponding RCC-related genes 
and genetic pathways may further contribute to our understanding of this clinical subtype of 
RCC and, finally, in the development of refined genetic counselling and patient management 
strategies. 
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Samenvatting 
 
Ongeveer 85% van alle voorkomende vormen van nierkanker behoren tot de zogenaamde 
niercelcarcinomen. Binnen deze groep van niertumoren kunnen verschillende histologische 
subtypes worden onderscheiden, die tevens gekarakteriseerd worden door verschillende 
genetische afwijkingen. Niercelcarcinomen komen meestal voor in een sporadische vorm. Er 
zijn echter ook erfelijke vormen van dit type nierkanker beschreven. Enkele erfelijke 
syndromen waarbij niercelcarcinomen voorkomen zijn het Von Hippel Lindau syndroom en 
het Birt-Hogg-Dubé syndroom. Erfelijke tumor syndromen hebben in de afgelopen jaren een 
belangrijke bijdrage geleverd aan de identificatie van kanker-gerelateerde genen, en op die 
manier aan correcte diagnosestelling en genetische voorlichting binnen families. In dit 
proefschrift staat een familiaire vorm van nierkanker, waarbij constitutionele chromosoom 3 
translocaties voorkomen, centraal. 
Twee van deze families zijn beschreven in dit werk (Hoofdstukken 2, 3, en 5). In de eerste 
familie werd een t(2;3)(q35;q21) translocatie gevonden in verschillende familieleden, 
waaronder 5 nierkanker patiënten. In de tweede familie werd een t(3;6)(q12;q15) gevonden 
in drie opeenvolgende generaties, inclusief 4 nierkanker patiënten. Al de patiënten in deze 
families ontwikkelden hetzelfde histologische conventionele subtype nierkanker. Een aantal 
van deze tumoren werden cytogenetisch en moleculair genetisch onderzocht. Het bleek dat 
in de meeste tumoren, naast de aanwezigheid van een chromosoom 3 translocatie, één van 
de derivaat chromosomen verloren was gegaan. In alle gevallen was dit het derivaat 
chromosoom met daarop de korte arm van chromosoom 3 (3p-arm). In verschillende van 
deze tumoren werden ook mutaties gevonden in een bekend nierkanker-gerelateerd gen, 
VHL, dat ook op de korte arm van chromosoom 3 ligt (Hoofdstukken 3 en 5). Deze 
bevindingen, en overeenkomstige resultaten in twee andere nierkanker families met 
constitutionele t(3;8)(p14;q24) en t(3;6)(p13;q25.1) translocaties, leidde tot een drie-staps 
tumorigenese model (Hoofdstukken 3 en 9). In dit model fungeert de constitionele 
chromosoom 3 translocatie als de primaire oncogenetische afwijking die gevolgd wordt door 
somatisch verlies van het 3p-bevattende derivaat chromosoom. Deze voorgestelde volgorde 
van deze genetische stappen werd ondersteund door bevindingen in kleine tumoren in een 
vroeg stadium van ontwikkeling in de familie met de 2;3 translocatie en verschillende tumor 
biopten in de familie met de 3;6 translocatie (Hoofdstukken 4 en 5). Inactivatie van (een) 
tumor suppressor gen op de overgebleven 3p arm, zoals het VHL gen, speelt een rol tijdens 
de verdere ontwikkeling van de tumor en is dus een relatief late gebeurtenis in de 
ontwikkeling van niercelcarcinomen. Dit drie-staps model werd recentelijk bevestigd door 
cytogenetische en moleculair genetische studies in twee andere nierkanker families met 
t(2;3)(q33;q21) en t(1;3)(q32;q13.3) translocaties (Hoofdstuk 9). 
Om de centrale rol van de chromosoom 3 translocaties in de ontwikkeling van 
niercelcarcinomen beter te begrijpen hebben we de breukpunten van deze 2;3 translocatie 
moleculair gekloneerd en twee genen geïdentificeerd die door deze breukpunten worden 
onderbroken. Het breukpuntgen op chromosoom 3 werd DIRC2 genoemd en codeert 
waarschijnlijk voor een multimembraan eiwit (Hoofdstuk 6). Uit homologie onderzoek bleek 
verder dat dit eiwit een nieuw lid is van de "major facilitator" superfamilie (MFS) van 
transporters en mogelijk fungeert als anion-kation transporter. Met behulp van mutatie 
analyses werd gezocht naar pathogene gen afwijkingen in zowel sporadische als familiaire 
niercelcarcinomen, maar deze werden niet gevonden. We postuleren dat, als dit gen 
bijdraagt aan de vorming van nierkanker, dit gebeurt via een haplo-insufficiëntie 
mechanisme. Een optie is dat een defect transportergen, zoals bij de 2;3 translocatie, de 
filterfunctie van epitheliale niercellen verstoort en dat er op die manier een stress situatie 
word gecreëerd in deze cellen (Hoofdstuk 6 en 9). Het breukpuntgen op chromosoom 2 
werd DIRC3 genoemd (Hoofdstuk 7). Omdat er geen open leesraam kon worden gevonden 
in dit gen, gaan we ervan uit dat van dit gen geen coderend RNA wordt afgelezen. Verder 
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vonden we dat door de translocatie de eerste twee exonen van dit gen fuseren met de 
exonen 2 tot en met 9 van het PASS1 gen, dat proximaal ligt ten opzichte van het DIRC2 
gen op chromosoom 3 (Hoofdstuk 7). Het PASS1 gen is een interessant kandidaat gen voor 
de ontwikkeling van niercelcarcinomen omdat het in niercellen hoog tot expressie komt 
(vergeleken met andere weefsels) en omdat er een alternatief nier-specifiek transcript wordt 
gevormd. Het gen codeert voor een eiwit dat een interactie aangaat met het stress eiwit 
Hsp27, en zou dus betrokken kunnen zijn bij cellulaire stress reacties van de cel. 
Chromosoom 3 translocaties die gerelateerd zijn aan erfelijke vormen van nierkanker 
verschillen van elkaar in chromosoom partners en chromosomale breukpunten, wat 
impliceert dat ze effect kunnen hebben op verschillende genen. Het is daarom ook van het 
grootste belang om na te gaan of de verschillende breukpuntgenen onderdeel uitmaken van 
dezelfde of overlappende genetische routes die, wanneer verstoord, tot nierkanker kunnen 
leiden. In Hoofdstuk 9 hebben we zo'n overlap beschreven tussen de eiwitten PASS1 en 
FHIT (fragile-histidine triad), waarvan het laatste eiwit wordt gecodeerd door het 
breukpuntgen van de t(3;8)(p14;q24) translocatie in één van de bekende nierkanker 
families. Van beide eiwitten wordt gedacht dat ze betrokken zijn bij stress geïnduceerde 
signaal transductie routes waarbij ze mogelijk de rol spelen van 'stress sensors'. Onze 
hypothese is dat door deregulatie van de expressie van deze eiwitten, als gevolg van de 
translocaties, de stress geïnduceerde signaal transductie routes verstoord worden hetgeen 
uiteindelijk leidt tot genomische instabiliteit en het ontstaan van niercelcarcinomen.  
Zeven nierkanker families met constitutionele chromosoom 3 translocaties zijn tot nu toe 
geïdentificeerd, waaronder de twee die in dit proefschrift zijn beschreven. Deze bevindingen 
ondersteunen het idee dat kiembaan chromosoom 3 translocaties bijdragen tot de 
ontwikkeling van nierkanker. De overerving binnen deze families gebeurt op een autosomaal 
dominante manier met een relatief lage penetrantie. Andere maligniteiten, waaronder 
schildklierkanker, blaaskanker, alvleesklierkanker, en maagkanker, komen ook voor in deze 
families, hoewel in lagere frequenties dan nierkanker. Wij veronderstellen dat de 
chromosoom 3 breukpuntposities (en dus de breukpuntgenen) de variatie in penetrantie en 
het voorkomen van andere maligniteiten in de verschillende families bepalen. Opvallend 
hierbij is dat de chromosoom 3 breukpunten in deze nierkanker-gerelateerde translocaties 
allen gelokaliseerd zijn in de proximale p- en q-arm regio’s van chromosoom 3. De verdere 
identificatie van translocatie-geassocieerde genen en de identificatie van genetische routes 
waarin zij een rol spelen zullen een bijdrage gaan leveren aan het verder begrijpen van het 
ontstaan van deze vorm van niercelcarcinomen en, uiteindelijk, bijdragen tot betere 
erfelijkheidsvoorlichting en behandeling van patiënten.  
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Dankwoord 
 
Tot slot rest mij nog een aantal mensen te bedanken, die ieder op een eigen manier een 
bijdrage hebben geleverd bij het tot stand komen van dit boekje. Allereerst natuurlijk mijn 
promotor, Ad Geurts van Kessel, die mij de gelegenheid heeft gegeven dit werk te beginnen 
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Ik mocht een paar keer mee op pad en dat werden erg waardevolle ervaringen die mij 
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ervaringen en voor mij bij jullie werkzaamheden te betrekken. Ook wil ik Han en Hans 
bedanken. Jullie hebben mij (zonder dat jullie het waarschijnlijk in de gaten hadden) een 
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gespeeld in dit onderzoek en de meeste staan in de artikelen vernoemd als coauteur of in 
de acknowledgements. Een paar wil ik toch bij naam vermelden en bedanken voor hun 
inzet: Eva van den Berg, Trijnie Dijkhuizen, Maria Debiec-Rychter, Jacqueline Cloos, Peter 
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